Methods and compositions for predicting cancer survival and CAR T cell toxicity
Specific therapeutic bacteria are used to predict and mitigate toxicity in CAR T cell therapy, enhancing cancer survival by modulating the gut microbiome and improving treatment outcomes.
Patent Information
- Application Number
- JP2024526839
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-01-26
- Filing Date
- 2022-11-07
- Publication Date
- 2024-11-06
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current CAR T cell therapies for cancer treatment face challenges such as lack of long-term survival, T cell depletion, target antigen loss, and severe toxicity issues like CRS and ICANS, which are difficult to predict and manage, affecting patient outcomes.
The use of specific therapeutic bacteria, including Ruminococcus gnavus, Blautia schinkii, and others, to predict cancer survival and reduce CAR T cell-related toxicity through pharmaceutical compositions that modulate the gut microbiome.
These bacterial compositions help identify subjects at risk for reduced survival or toxicity, allowing targeted interventions to enhance cancer survival and mitigate severe side effects of CAR T cell therapy.
Smart Images

Figure 2024541067000001_ABST
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Application No. 63 / 276,450, filed November 5, 2021, and U.S. Provisional Application No. 63 / 303,461, filed January 26, 2022, the contents of each of which are incorporated by reference in their entirety herein.
[0002] Statement of Government Interests This invention was made with Government support under Grant Nos. K08CA194256, 1K99CA212302, R00CA212302, 1R01CA219871-01A1, 1P01CA214278, R01CA226983, P01 CA23766, P30 CA008748, K08HL143189, R01-CA228358, R01-CA228308, R01-HL147584, P01-CA023766, R01-HL125571, R01-HL123340 and P01-AG052359 awarded by the National Institutes of Health. The Government has certain rights in this invention.
[0003] The present disclosure relates to compositions and methods for predicting cancer survival or toxicity in subjects receiving chimeric antigen receptor (CAR) T-cell therapy. The present disclosure further discloses compositions, e.g., pharmaceutical compositions, and methods for treating the subjects. [Background technology]
[0004] CD19-targeted chimeric antigen receptor (CAR) T cells have transformed the treatment of patients with relapsed or refractory CD19-positive hematologic malignancies 1~4 Four CAR T cell therapies have been approved by the Food and Drug Administration for the treatment of CD19-positive hematologic malignancies. 4~9Despite the encouraging results, most patients experience lack of response or disease relapse, which may be due to lack of long-term survival of CAR T cells, T cell exhaustion or loss of target antigen due to deletions spanning the CD19 locus, CAR masking or alternative splicing. 8、10~13 Additionally, patients may develop unique CAR-mediated toxicity that manifests either as a systemic inflammatory cytokine release syndrome (CRS) or as a neurological event termed immune effector cell-associated neurotoxicity syndrome (ICANS). 14 .
[0005] CRS is the most frequent toxicity after CAR T-cell therapy and is attributed to the activation and proliferation of CAR T cells upon recognition of their target antigen, followed by the release of pro-inflammatory cytokines that trigger the activation of monocytes and macrophages with further cytokine release. 4~6、9 The pathogenesis of ICANS is poorly understood, but it is associated with dysfunction of the blood-brain barrier, and little is known about its exact etiology. 15~17 ICANS occurs most frequently after CRS, with incidence rates ranging up to 87%. 4~6、16 ICANS can be very difficult to treat and are a cause of severe morbidity and mortality in CAR T cell therapy patients. Overall, different CAR costimulatory domains, such as CD28 or 4-1BB, are associated with different frequencies and intensities of toxicity, with CARs bearing CD28 having a higher incidence of severe CRS and neurotoxicity. 18 Several other factors are associated with CAR T cell-specific toxicity. Tumor burden, intensity of lymphodepletion, serum cytokine concentrations, CAR T cell dose, and CAR T cell proliferation are correlated with CRS, whereas serum cytokine concentrations, young patient age, B-cell ALL diagnosis, high bone marrow disease burden, high CAR T cell dose, and pre-existing neurological comorbidities are associated with neurotoxicity. 5、16、19~21 However, these risk factors cannot accurately predict which patients will develop toxicity and to what extent, raising the possibility that other variables contribute to the function of CAR T cells in vivo, both in terms of their antitumor function and their propensity to induce toxicity.
[0006] Thus, there is a need in the art for methods to predict cancer survival or CAR T cell-associated toxicity in subjects undergoing CAR T cell therapy. Summary of the Invention
[0007] The present disclosure provides methods for determining whether a subject with cancer has a likelihood of exhibiting increased or decreased cancer survival following CAR T cell therapy. In certain embodiments, the present disclosure provides methods for determining whether a subject with cancer has a likelihood of exhibiting increased or decreased CAR T cell associated toxicity. The present disclosure further provides therapeutic bacteria and pharmaceutical compositions thereof for treating subjects identified as having a decreased likelihood of cancer survival and / or increased likelihood of CAR T cell associated toxicity.
[0008] In certain embodiments, the present disclosure provides a pharmaceutical composition comprising an effective amount of a therapeutic bacteria. In certain embodiments, the pharmaceutical compositions of the present disclosure may comprise an effective amount of a therapeutic bacterium or spores thereof selected from the group consisting of Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Clostridium methoxybenzovorans, Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, Lactobacillus salivarius, Schaalia odontolytica, Longicatena caecimuris, Bifidobacterium breve, Ruminococcus bromii, Blautia luti, Faecalibacterium prausnitzii, and combinations thereof.Alternatively or additionally, the pharmaceutical composition of the present disclosure may comprise an effective amount of a 16S 16S bacterium of Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Clostridium methoxybenzovorans, Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, Lactobacillus salivarius, Schaalia odontolytica, Longicatena caecimuris, Bifidobacterium breve, Ruminococcus bromii, Blautia luti, Faecalibacterium prausnitzii, or a combination thereof. The bacterium or spore thereof may comprise a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the rRNA gene sequence.
[0009] In certain embodiments, the pharmaceutical composition may comprise a therapeutic bacterium or spore thereof selected from the group consisting of Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Clostridium methoxybenzovorans, Ruminococcus bromii, Longicatena caecimuris, Bifidobacterium breve, Blautia luti, Faecalibacterium prausnitzii, and combinations thereof. In certain embodiments, the pharmaceutical composition may comprise a bacterium or spore thereof comprising a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity with the 16S rRNA gene sequence of Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Clostridium methoxybenzovorans, Ruminococcus bromii, Longicatena caecimuris, Bifidobacterium breve, Blautia luti, Faecalibacterium prausnitzii, or a combination thereof. In certain embodiments, an effective amount of the bacterium or spore thereof increases the chance of cancer survival in a subject administered the pharmaceutical composition.
[0010] In certain embodiments, the pharmaceutical composition comprises a therapeutic bacterium or spore thereof selected from the group consisting of Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Clostridium methoxybenzovorans, or a combination thereof, and / or a 16S spore of Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Clostridium methoxybenzovorans, or a combination thereof. The bacterium or spore thereof may comprise a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the rRNA gene sequence.
[0011] In certain embodiments, the pharmaceutical composition may comprise a therapeutic bacterium or a spore thereof selected from the group consisting of Ruminococcus bromii, Longicatena caecimuris, Bifidobacterium breve, Blautia luti, Faecalibacterium prausnitzii, or a combination thereof, and / or a bacterium or a spore thereof that comprises a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Ruminococcus bromii, Longicatena caecimuris, Bifidobacterium breve, Blautia luti, Faecalibacterium prausnitzii, or a combination thereof.
[0012] In certain embodiments, the pharmaceutical composition may comprise a therapeutic bacterium or spore thereof selected from the group consisting of Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, Lactobacillus salivarius, Blautia luti, Faecalibacterium prausnitzii, and combinations thereof. In certain embodiments, the pharmaceutical composition may comprise a bacterium or spore thereof comprising a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, Lactobacillus salivarius, Blautia luti, Faecalibacterium prausnitzii, or combinations thereof. In certain embodiments, an effective amount of the bacteria or spores thereof reduces the likelihood of CAR T cell-associated toxicity in a subject administered the pharmaceutical composition.
[0013] In certain embodiments, the pharmaceutical composition may comprise a therapeutic bacterium or spore thereof selected from the group consisting of Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, Lactobacillus salivarius, Schaalia odontolytica, or a combination thereof, and / or a bacterium or spore thereof that comprises a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, Lactobacillus salivarius, Schaalia odontolytica, or a combination thereof.
[0014] In certain embodiments, the pharmaceutical composition may comprise a therapeutic bacterium or spore thereof selected from the group consisting of Blautia luti, Faecalibacterium prausnitzii, or a combination thereof, and / or a bacterium or spore thereof comprising a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Blautia luti, Faecalibacterium prausnitzii, or a combination thereof.
[0015] In certain embodiments, the pharmaceutical composition may further comprise a biocompatible pharmaceutical carrier. In certain embodiments, the pharmaceutical composition may further comprise a probiotic bacteria, a probiotic yeast, a prebiotic, a postbiotic, an antibiotic, or a combination thereof. In certain embodiments, the pharmaceutical composition is formulated for oral, nasogastric, rectal, transdermal, or gastrointestinal administration. In certain embodiments, the pharmaceutical composition is in the form of a liquid, a suspension, a dry powder, a tablet, a capsule, a food product, or a combination thereof. In certain embodiments, the therapeutic bacterium is a recombinant bacterium or a progeny thereof.
[0016] The present disclosure further provides a method for identifying a subject as having a decreased likelihood of cancer survival following CAR T cell therapy. In certain embodiments, the method may include: (a) determining a level of the bacteria or spores thereof in a sample from the subject; (b) comparing the level of the bacteria or spores thereof to a reference level of the bacteria or spores thereof, the reference level being the level of the bacteria or spores thereof in a patient not exhibiting cancer survival; and (c) identifying the subject as having a decreased likelihood of cancer survival if the level of the bacteria or spores thereof is higher than the reference level. In certain embodiments, the bacterium or spores thereof are selected from the group consisting of Hungatella effluvii, Coprobacillus cateniformis, Atopobium parvulum, Faecalicoccus acidiformans, Lactococcus lactis, Anaerobacterium chartisolvens, Atopobiaceae Clostridium innocuum, Bacteroides thetaiotaomicron, species of the family Veillonellaceae, and combinations thereof, or the bacterium or spores are selected from the group consisting of 16S Hungatella effluvii, Coprobacillus cateniformis, Atopobium parvulum, Faecalicoccus acidiformans, Lactococcus lactis, Anaerobacterium chartisolvens, Atopobiaceae Clostridium innocuum, Bacteroides thetaiotaomicron, species of the family Veillonellaceae, and combinations thereof. The 16S rRNA gene sequence has at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the rRNA gene sequence.In certain embodiments, the bacterium or a spore thereof is a species of the family Veillonellaceae or is a bacterium or a spore thereof that comprises a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to a 16S rRNA gene sequence of a species of the family Veillonellaceae.
[0017] The disclosure further provides a method for identifying a subject having a likelihood of exhibiting increased CAR T cell-associated toxicity. In certain embodiments, the method may include: (a) determining a level of bacteria or spores thereof in a sample from the subject; (b) comparing the level of bacteria or spores thereof to a reference level of bacteria or spores thereof, the reference level being the level of bacteria or spores thereof in a patient exhibiting CAR T cell-associated toxicity; and (c) identifying the subject as having a likelihood of exhibiting increased CAR T cell-associated toxicity if the level of bacteria or spores thereof is higher than the reference level. In certain embodiments, the bacterium or spore thereof is selected from the group consisting of Streptococcus salivarius, Oscillibacter ruminantium, Eubacterium ramulus, Streptococcus gordonii, Caprocicproducens galactitolivorans, Clostridium hylemonae, and spores thereof, or the bacterium or spore thereof comprises a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Streptococcus salivarius, Oscillibacter ruminantium, Eubacterium ramulus, Streptococcus gordonii, Caprocicproducens galactitolivorans, Clostridium hylemonae, and combinations thereof.
[0018] The disclosure further provides a method for identifying a subject as having an increased likelihood of cancer survival following CAR T cell therapy. In certain embodiments, the method for identifying a subject having cancer as having an increased likelihood of cancer survival following CAR T cell therapy comprises: (a) determining the level of the bacterium or spores thereof in a sample from the subject; (b) comparing the level of the bacterium or spores thereof to a reference level of the bacterium or spores thereof, the reference level being the level of the bacterium or spores thereof in patients who have demonstrated cancer survival; and (c) identifying the subject as having an increased likelihood of cancer survival if the level of the diagnostic bacterium or spores thereof is higher than the reference level.In certain embodiments, the bacteria or spores thereof are selected from the group consisting of Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Longicatena caecimuris, Bifidobacterium breve, Escherichia coli, Clostridium methoxybenzovorans, Ruminococcus bromii, Blautia luti, Faecalibacterium prausnitzii, and combinations thereof, or the bacteria or spores thereof are selected from the group consisting of Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Longicatena caecimuris, Bifidobacterium breve, Escherichia coli, Clostridium methoxybenzovorans, Ruminococcus bromii, Blautia luti, Faecalibacterium prausnitzii, or a combination thereof.
[0019] The disclosure further provides a method for identifying a subject having a potential for exhibiting reduced CAR T cell-associated toxicity. In certain embodiments, the method may include: (a) determining a level of bacteria or spores thereof in a sample from the subject; (b) comparing the level of bacteria or spores thereof to a reference level of bacteria or spores thereof, the reference level being the level of bacteria or spores thereof in a patient who did not exhibit CAR T cell-associated toxicity; and (c) identifying the subject as having a potential for exhibiting reduced CAR T cell-associated toxicity if the level of bacteria or spores thereof is higher than the reference level. In certain embodiments, the bacterium or spore thereof is selected from the group consisting of Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, Lactobacillus salivarius, Schaalia odontolytica, Blautia luti, Faecalibacterium prausnitzii, and combinations thereof, or the bacterium or spore thereof comprises a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, Lactobacillus salivarius, Schaalia odontolytica, Blautia luti, Faecalibacterium prausnitzii, and combinations thereof. In certain embodiments, the bacterium or spore thereof is selected from the group consisting of Blautia luti, Faecalibacterium prausnitzii, and combinations thereof, or the bacterium or spore thereof comprises a 16S rRNA having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Blautia luti, Faecalibacterium prausnitzii, and combinations thereof.In certain embodiments, the bacterium or spore thereof is selected from the group consisting of Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, Lactobacillus salivarius, Schaalia odontolytica, and combinations thereof, or the bacterium or spore thereof comprises a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, Lactobacillus salivarius, Schaalia odontolytica, and combinations thereof.
[0020] In certain embodiments, a method for identifying a subject having cancer as having a likelihood of exhibiting increased cancer survival may include: (a) determining a level of a bacterial gene in a sample from the subject; (b) comparing the level of the bacterial gene to a reference bacterial gene level, the reference level being the level of the bacterial gene in patients who have exhibited cancer survival; and (c) identifying the subject as having a likelihood of exhibiting increased cancer survival if the level of the bacterial gene is higher than the reference bacterial gene level. In certain embodiments, the bacterial gene is a gene involved in aromatic amino acid biosynthesis and / or peptidoglycan biosynthesis.
[0021] In certain embodiments, a method for identifying a subject having cancer as having a likelihood of exhibiting decreased cancer survival and / or increased CAR T cell-associated toxicity may include (a) determining whether the subject is receiving an antibiotic, and (b) identifying the subject as having a likelihood of increased CAR T cell-associated toxicity and / or decreased cancer survival if the subject is receiving piperacillin-tazobactam, imipenem-cilastatin, meropenem, or a combination thereof. In certain embodiments, the antibiotic is administered less than about 4 weeks prior to initiation of CAR T cell therapy.
[0022] In certain embodiments, any one of the methods disclosed herein may include treating a subject identified as having a decreased likelihood of cancer survival or as having an increased likelihood of exhibiting CAR T cell-associated toxicity with a pharmaceutical composition disclosed herein. In certain embodiments, any one of the methods disclosed herein may include treating the subject with a CAR T cell therapy.
[0023] The present disclosure further provides a method for treating a subject having cancer with CAR T cell therapy. In certain embodiments, the method may include: (a) determining a level of the bacteria or spores thereof in a sample from the subject; (b) comparing the level of the bacteria or spores thereof to a reference level of the bacteria or spores thereof, the reference level being the level of the bacteria or spores thereof in a subject that has demonstrated cancer survival; (c) identifying the subject as having an increased likelihood of cancer survival if the level of the bacteria or spores thereof is higher than the reference level; and (d) treating the subject identified as having an increased likelihood of cancer survival with CAR T cell therapy.In certain embodiments, the bacteria or spores thereof are selected from the group consisting of Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Clostridium methoxybenzovorans, Ruminococcus bromii, Blautia luti, Longicatena caecimuris, Bifidobacterium breve, Faecalibacterium prausnitzii, and combinations thereof, or the bacteria or spores thereof are selected from the group consisting of Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Clostridium methoxybenzovorans, Ruminococcus bromii, Blautia luti, Longicatena caecimuris, Bifidobacterium breve and / or Faecalibacterium prausnitzii.
[0024] In certain embodiments, a method for treating a subject having cancer with CAR T cell therapy may include: (a) determining the level of the bacteria or spores thereof in a sample from the subject; (b) comparing the level of the bacteria or spores thereof to a reference level of the bacteria or spores thereof, the reference level being the level of the bacteria or spores thereof in a subject who has not demonstrated cancer survival; (c) identifying the subject as having a decreased likelihood of cancer survival if the level of the bacteria or spores thereof is higher than the reference level; and (d) treating the subject identified as having a decreased likelihood of cancer survival with a pharmaceutical composition comprising one or more therapeutic bacteria and CAR T cell therapy. In certain embodiments, the bacterium or spores thereof are selected from the group consisting of Hungatella effluvii, Coprobacillus cateniformis, Atopobium parvulum, Faecalicoccus acidiformans, Lactococcus lactis, Anaerobacterium chartisolvens, Clostridium innocuum, Bacteroides thetaiotaomicron, species of the family Veillonellaceae, and combinations thereof, or the bacterium or spores are selected from the group consisting of 16S strains of Hungatella effluvii, Coprobacillus cateniformis, Atopobium parvulum, Faecalicoccus acidiformans, Lactococcus lactis, Anaerobacterium chartisolvens, Clostridium innocuum, Bacteroides thetaiotaomicron, species of the family Veillonellaceae, and combinations thereof. The 16S rRNA gene sequence has at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the rRNA gene sequence.In certain embodiments, the therapeutic bacteria is one or more of Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Clostridium methoxybenzovorans, Ruminococcus bromii, Longicatena caecimuris, Bifidobacterium breve, Blautia luti, Faecalibacterium prausnitzii, or one or more of Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus The present invention also includes bacteria containing a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Clostridium senegalensis, Clostridium methoxybenzovorans, Ruminococcus bromii, Longicatena caecimuris, Bifidobacterium breve, Blautia luti, and / or Faecalibacterium prausnitzii.
[0025] In certain embodiments, a method for treating a subject having cancer with CAR T cell therapy may include: (a) determining a level of the bacteria or spores thereof in a sample from the subject; (b) comparing the level of the bacteria or spores thereof to a reference level of the bacteria or spores thereof, the reference level being the level of the bacteria or spores thereof in a subject that did not exhibit CAR T cell-associated toxicity; (c) identifying the subject as having a potential for exhibiting reduced CAR T cell-associated toxicity if the level of the bacteria or spores thereof is higher than the reference level; and (d) treating the subject identified as having a potential for exhibiting reduced CAR T cell-associated toxicity with CAR T cell therapy. In certain embodiments, the bacterium or spore thereof is selected from the group consisting of Streptococcus oralis, Lutispora thermophila, Schaalia odontolytica, Agathobaculum butyriciproducens, Lactobacillus salivarius, Blautia luti, Faecalibacterium prausnitzii, and combinations thereof, or the bacterium or spore thereof comprises a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Streptococcus oralis, Lutispora thermophila, Schaalia odontolytica, Agathobaculum butyriciproducens, Lactobacillus salivarius, Blautia luti, and / or Faecalibacterium prausnitzii.
[0026] In certain embodiments, a method for treating a subject having cancer with CAR T cell therapy may include: (a) determining the level of the bacteria or spores thereof in a sample from the subject; (b) comparing the level of the bacteria or spores thereof to a reference level of the bacteria or spores thereof, the reference level being the level of the bacteria or spores thereof in a subject that has exhibited CAR T cell-associated toxicity; (c) identifying the subject as having a likelihood of exhibiting increased CAR T cell-associated toxicity if the level of the bacteria or spores thereof is higher than the reference level; and (d) treating the subject identified as having a likelihood of exhibiting increased CAR T cell-associated toxicity with a pharmaceutical composition comprising one or more therapeutic bacteria and CAR T cell therapy. In certain embodiments, the bacterium or spore thereof is selected from the group consisting of Streptococcus salivarius, Oscillibacter ruminantium, Eubacterium ramulus, Streptococcus gordonii, Caprocicproducens galactitolivorans, Clostridium hylemonae, and combinations thereof, or the bacterium or spore thereof comprises a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Streptococcus salivarius, Oscillibacter ruminantium, Eubacterium ramulus, Streptococcus gordonii, Caprocicproducens galactitolivorans, Clostridium hylemonae, or combinations thereof.In certain embodiments, the therapeutic bacteria comprises one or more of Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, and / or Lactobacillus salivarius, Schaalia odontolytica, Blautia luti, Faecalibacterium prausnitzii, or a bacterium comprising a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, Lactobacillus salivarius, Schaalia odontolytica, Blautia luti, Faecalibacterium prausnitzii, or a combination thereof.
[0027] In certain embodiments, any one of the methods disclosed herein may include administering to the subject a CAR T cell therapy. In certain embodiments, any one of the methods disclosed herein may include administering to the subject a chemotherapy, an immunotherapy, a stem cell therapy, a cell therapy, a probiotic bacteria, a probiotic yeast, a prebiotic, a postbiotic, an antibiotic, or a combination thereof. In certain embodiments, the cancer survival is the survival of the subject at least about 100 days after the CAR T cell therapy. In certain embodiments, the CAR T cell-associated toxicity is cytokine release syndrome (CRS) and / or immune effector cell-associated neurotoxicity syndrome (ICANS). In certain embodiments, the sample is a fecal sample or a gut content sample of the subject. In certain embodiments, the cancer is selected from the group consisting of acute lymphoblastic leukemia (ALL), chronic lymphoblastic leukemia (CLL), or non-Hodgkin's lymphoma (NHL). In certain embodiments, the CAR T cell therapy comprises CAR T cells that target mucin 16 (MUC16), B-cell maturation antigen (BCMA), and / or CD19.
[0028] The present disclosure further provides a kit comprising any one of the disclosed therapeutic bacteria or pharmaceutical compositions thereof.The present disclosure further provides a kit for carrying out any one of the disclosed methods. For example, without limitation, the kit may contain a variety of plants that contain Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Clostridium methoxybenzovorans, Hungatella effluvii, Coprobacillus cateniformis, Atopobium parvulum, Faecalicoccus acidiformans, Lactococcus lactis, Anaerobacterium chartisolvens, Atopobiaceae, Clostridium innocuum, Bacteroides thetaiotamicron, Streptococcus salivarius, Oscillibacter ruminantium, Eubacterium ramulus, Streptococcus gordonii, Caprocicproducens In one embodiment, the method may include a means for identifying a bacterium or spore thereof selected from the group consisting of Lactobacillus galactitolivorans, Clostridium hylemonae, Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, Schaalia odontolytica, Lactobacillus salivarius, Ruminococcus bromii, Bifidobacterium breve, Longicatena caecimuris, Escherichia coli, Blautia luti, Faecalibacterium prausnitzii, and combinations thereof.
[0029] In certain embodiments, the kit of the present disclosure may further include instructions for treating a subject having cancer. In certain embodiments, the kit may include instructions for identifying a subject as having a likelihood of exhibiting increased cancer survival or a likelihood of exhibiting decreased cancer survival. In certain embodiments, the instructions include (a) determining a level of bacteria or spores thereof in a sample of the subject, (b) comparing the level of bacteria or spores thereof to a reference level of bacteria or spores thereof, and (c) identifying the subject as having a likelihood of exhibiting increased cancer survival or a likelihood of exhibiting decreased cancer survival based on the comparison. In certain embodiments, the kit may include instructions for identifying a subject as having a likelihood of increased CAR T cell-associated toxicity or a likelihood of decreased CAR T cell-associated toxicity. In certain embodiments, the instructions include (a) determining a level of bacteria or spores thereof in a sample of the subject, (b) comparing the level of bacteria or spores thereof to a reference level of bacteria or spores thereof, and (c) identifying the subject as having a likelihood of increased CAR T cell-associated toxicity or a likelihood of decreased CAR T cytotoxicity based on the comparison.
[0030] The present disclosure further provides the use of the pharmaceutical composition of the present disclosure. In certain embodiments, the present disclosure provides the use of the pharmaceutical composition disclosed herein for treating a subject having cancer. In certain embodiments, the present disclosure provides the use of the pharmaceutical composition disclosed herein for increasing the likelihood of cancer survival in a subject. In certain embodiments, the present disclosure provides the use of the pharmaceutical composition disclosed herein for decreasing the likelihood of CAR T cell-related toxicity in a subject. In certain embodiments, the cancer and / or subject is being treated with CAR T cell therapy or will be treated with CAR T cell therapy. [Brief description of the drawings]
[0031] [Figure 1-1]Impact of antibiotic exposure in patients with hematological malignancies treated with anti-CD19 CAR T cell therapy. (A) The antibiotic cohort (left panel) consists of CD19 CAR T cell recipients from MSK (n=127) and Penn (n=101) evaluated in a retrospective observational study of antibiotic exposure (N=228). Frequency of antibiotic exposure (right panel) 4 weeks prior to CAR T cell infusion in patients with NHL and ALL (N=228). Percent frequency of exposure to piperacillin / tazobactam, imipenem / cilastatin, and meropenem is highlighted in yellow and indicates the antibiotics that make up the PIMs (also shown in yellow). Percent frequency of exposure to cefepime is shown in green. The blue graph indicates cumulative exposure to any antibiotic. "Other" includes all antibiotics administered to only one patient each (clindamycin, cephalexin, tobramycin, cefpodoxime, atovaquone, ampicillin / sulbactam, cefuroxime, cefazolin). (B) Kaplan-Meier overall survival curves by log-rank test in ALL and NHL populations by exposure to any antibiotic within 4 weeks prior to CD19 CAR T-cell infusion (N=228). Grey lines indicate patients not exposed to antibiotic treatment, and yellow lines indicate patients exposed to antibiotic treatment. (C, D, E) Kaplan-Meier curves of progression-free survival (PFS) and overall survival (OS) by log-rank test by exposure to PIM antibiotic within 4 weeks prior to CD19 CAR T-cell infusion in patients with ALL and NHL (OS only, N=228), NHL (n=137), and ALL (n=91), respectively. Grey lines indicate patients with no exposure to PIM antibiotics, and yellow lines indicate patients with exposure to PIM antibiotics. For Kaplan-Meier analysis, points represent data censored at the last time point when the patient was known to be alive and progression-free. Shading indicates 95% confidence intervals, and checkmarks indicate censored events.(F, G, H) Histograms of the frequency of any grade of CRS and ICANS by Wilcoxon rank sum test according to exposure to PIM antibiotics within 4 weeks prior to CD19 CAR T cell infusion in patients with ALL and NHL (n=228), NHL (n=137), and ALL (n=91), respectively. Blue indicates the absence of any grade of CRS or ICANS, and red indicates the presence of any grade of CRS or ICANS. Abbreviations: Trimeth. / Sulfameth.: trimethoprim / sulfamethoxazole, IV: intravenous, NHL: non-Hodgkin's lymphoma, unexposed: patients with no PIM exposure and patients who did not receive any antibiotics within 4 weeks prior to CD19 CAR T-cell infusion, ALL: acute lymphoblastic leukemia, p: p-value, PIM: exposure to either piperacillin / tazobactam, imipenem / cilastatin, or meropenem within 4 weeks prior to CD19 CAR T-cell infusion, CRS: cytokine release syndrome, ICANS: immune effector cell-associated neurotoxicity. [Figure 1-2]Impact of antibiotic exposure in patients with hematological malignancies treated with anti-CD19 CAR T cell therapy. (A) The antibiotic cohort (left panel) consists of CD19 CAR T cell recipients from MSK (n=127) and Penn (n=101) evaluated in a retrospective observational study of antibiotic exposure (N=228). Frequency of antibiotic exposure (right panel) 4 weeks prior to CAR T cell infusion in patients with NHL and ALL (N=228). Percent frequency of exposure to piperacillin / tazobactam, imipenem / cilastatin, and meropenem is highlighted in yellow and indicates the antibiotics that make up the PIMs (also shown in yellow). Percent frequency of exposure to cefepime is shown in green. The blue graph indicates cumulative exposure to any antibiotic. "Other" includes all antibiotics administered to only one patient each (clindamycin, cephalexin, tobramycin, cefpodoxime, atovaquone, ampicillin / sulbactam, cefuroxime, cefazolin). (B) Kaplan-Meier overall survival curves by log-rank test in ALL and NHL populations by exposure to any antibiotic within 4 weeks prior to CD19 CAR T-cell infusion (N=228). Grey lines indicate patients not exposed to antibiotic treatment, and yellow lines indicate patients exposed to antibiotic treatment. (C, D, E) Kaplan-Meier curves of progression-free survival (PFS) and overall survival (OS) by log-rank test by exposure to PIM antibiotic within 4 weeks prior to CD19 CAR T-cell infusion in patients with ALL and NHL (OS only, N=228), NHL (n=137), and ALL (n=91), respectively. Grey lines indicate patients with no exposure to PIM antibiotics, and yellow lines indicate patients with exposure to PIM antibiotics. For Kaplan-Meier analysis, points represent data censored at the last time point when the patient was known to be alive and progression-free. Shading indicates 95% confidence intervals, and checkmarks indicate censored events.(F, G, H) Histograms of the frequency of any grade of CRS and ICANS by Wilcoxon rank sum test according to exposure to PIM antibiotics within 4 weeks prior to CD19 CAR T cell infusion in patients with ALL and NHL (n=228), NHL (n=137), and ALL (n=91), respectively. Blue indicates the absence of any grade of CRS or ICANS, and red indicates the presence of any grade of CRS or ICANS. Abbreviations: Trimeth. / Sulfameth.: trimethoprim / sulfamethoxazole, IV: intravenous, NHL: non-Hodgkin's lymphoma, unexposed: patients with no PIM exposure and patients who did not receive any antibiotics within 4 weeks prior to CD19 CAR T-cell infusion, ALL: acute lymphoblastic leukemia, p: p-value, PIM: exposure to either piperacillin / tazobactam, imipenem / cilastatin, or meropenem within 4 weeks prior to CD19 CAR T-cell infusion, CRS: cytokine release syndrome, ICANS: immune effector cell-associated neurotoxicity. [Figure 1-3]Impact of antibiotic exposure in patients with hematological malignancies treated with anti-CD19 CAR T cell therapy. (A) The antibiotic cohort (left panel) consists of CD19 CAR T cell recipients from MSK (n=127) and Penn (n=101) evaluated in a retrospective observational study of antibiotic exposure (N=228). Frequency of antibiotic exposure (right panel) 4 weeks prior to CAR T cell infusion in patients with NHL and ALL (N=228). Percent frequency of exposure to piperacillin / tazobactam, imipenem / cilastatin, and meropenem is highlighted in yellow and indicates the antibiotics that make up the PIMs (also shown in yellow). Percent frequency of exposure to cefepime is shown in green. The blue graph indicates cumulative exposure to any antibiotic. "Other" includes all antibiotics administered to only one patient each (clindamycin, cephalexin, tobramycin, cefpodoxime, atovaquone, ampicillin / sulbactam, cefuroxime, cefazolin). (B) Kaplan-Meier overall survival curves by log-rank test in ALL and NHL populations by exposure to any antibiotic within 4 weeks prior to CD19 CAR T-cell infusion (N=228). Grey lines indicate patients not exposed to antibiotic treatment, and yellow lines indicate patients exposed to antibiotic treatment. (C, D, E) Kaplan-Meier curves of progression-free survival (PFS) and overall survival (OS) by log-rank test by exposure to PIM antibiotic within 4 weeks prior to CD19 CAR T-cell infusion in patients with ALL and NHL (OS only, N=228), NHL (n=137), and ALL (n=91), respectively. Grey lines indicate patients with no exposure to PIM antibiotics, and yellow lines indicate patients with exposure to PIM antibiotics. For Kaplan-Meier analysis, points represent data censored at the last time point when the patient was known to be alive and progression-free. Shading indicates 95% confidence intervals, and checkmarks indicate censored events.(F, G, H) Histograms of the frequency of any grade of CRS and ICANS by Wilcoxon rank sum test according to exposure to PIM antibiotics within 4 weeks prior to CD19 CAR T cell infusion in patients with ALL and NHL (n=228), NHL (n=137), and ALL (n=91), respectively. Blue indicates the absence of any grade of CRS or ICANS, and red indicates the presence of any grade of CRS or ICANS. Abbreviations: Trimeth. / Sulfameth.: trimethoprim / sulfamethoxazole, IV: intravenous, NHL: non-Hodgkin's lymphoma, unexposed: patients with no PIM exposure and patients who did not receive any antibiotics within 4 weeks prior to CD19 CAR T-cell infusion, ALL: acute lymphoblastic leukemia, p: p-value, PIM: exposure to either piperacillin / tazobactam, imipenem / cilastatin, or meropenem within 4 weeks prior to CD19 CAR T-cell infusion, CRS: cytokine release syndrome, ICANS: immune effector cell-associated neurotoxicity. [Figure 1-4]Impact of antibiotic exposure in patients with hematological malignancies treated with anti-CD19 CAR T cell therapy. (A) The antibiotic cohort (left panel) consists of CD19 CAR T cell recipients from MSK (n=127) and Penn (n=101) evaluated in a retrospective observational study of antibiotic exposure (N=228). Frequency of antibiotic exposure (right panel) 4 weeks prior to CAR T cell infusion in patients with NHL and ALL (N=228). Percent frequency of exposure to piperacillin / tazobactam, imipenem / cilastatin, and meropenem is highlighted in yellow and indicates the antibiotics that make up the PIMs (also shown in yellow). Percent frequency of exposure to cefepime is shown in green. The blue graph indicates cumulative exposure to any antibiotic. "Other" includes all antibiotics administered to only one patient each (clindamycin, cephalexin, tobramycin, cefpodoxime, atovaquone, ampicillin / sulbactam, cefuroxime, cefazolin). (B) Kaplan-Meier overall survival curves by log-rank test in ALL and NHL populations by exposure to any antibiotic within 4 weeks prior to CD19 CAR T-cell infusion (N=228). Grey lines indicate patients not exposed to antibiotic treatment, and yellow lines indicate patients exposed to antibiotic treatment. (C, D, E) Kaplan-Meier curves of progression-free survival (PFS) and overall survival (OS) by log-rank test by exposure to PIM antibiotic within 4 weeks prior to CD19 CAR T-cell infusion in patients with ALL and NHL (OS only, N=228), NHL (n=137), and ALL (n=91), respectively. Grey lines indicate patients with no exposure to PIM antibiotics, and yellow lines indicate patients with exposure to PIM antibiotics. For Kaplan-Meier analysis, points represent data censored at the last time point when the patient was known to be alive and progression-free. Shading indicates 95% confidence intervals, and checkmarks indicate censored events.(F, G, H) Histograms of the frequency of any grade of CRS and ICANS by Wilcoxon rank sum test according to exposure to PIM antibiotics within 4 weeks prior to CD19 CAR T cell infusion in patients with ALL and NHL (n=228), NHL (n=137), and ALL (n=91), respectively. Blue indicates the absence of any grade of CRS or ICANS, and red indicates the presence of any grade of CRS or ICANS. Abbreviations: Trimeth. / Sulfameth.: trimethoprim / sulfamethoxazole, IV: intravenous, NHL: non-Hodgkin's lymphoma, unexposed: patients with no PIM exposure and patients who did not receive any antibiotics within 4 weeks prior to CD19 CAR T-cell infusion, ALL: acute lymphoblastic leukemia, p: p-value, PIM: exposure to either piperacillin / tazobactam, imipenem / cilastatin, or meropenem within 4 weeks prior to CD19 CAR T-cell infusion, CRS: cytokine release syndrome, ICANS: immune effector cell-associated neurotoxicity. [Figure 1-5]Impact of antibiotic exposure in patients with hematological malignancies treated with anti-CD19 CAR T cell therapy. (A) The antibiotic cohort (left panel) consists of CD19 CAR T cell recipients from MSK (n=127) and Penn (n=101) evaluated in a retrospective observational study of antibiotic exposure (N=228). Frequency of antibiotic exposure (right panel) 4 weeks prior to CAR T cell infusion in patients with NHL and ALL (N=228). Percent frequency of exposure to piperacillin / tazobactam, imipenem / cilastatin, and meropenem is highlighted in yellow and indicates the antibiotics that make up the PIMs (also shown in yellow). Percent frequency of exposure to cefepime is shown in green. The blue graph indicates cumulative exposure to any antibiotic. "Other" includes all antibiotics administered to only one patient each (clindamycin, cephalexin, tobramycin, cefpodoxime, atovaquone, ampicillin / sulbactam, cefuroxime, cefazolin). (B) Kaplan-Meier overall survival curves by log-rank test in ALL and NHL populations by exposure to any antibiotic within 4 weeks prior to CD19 CAR T-cell infusion (N=228). Grey lines indicate patients not exposed to antibiotic treatment, and yellow lines indicate patients exposed to antibiotic treatment. (C, D, E) Kaplan-Meier curves of progression-free survival (PFS) and overall survival (OS) by log-rank test by exposure to PIM antibiotic within 4 weeks prior to CD19 CAR T-cell infusion in patients with ALL and NHL (OS only, N=228), NHL (n=137), and ALL (n=91), respectively. Grey lines indicate patients with no exposure to PIM antibiotics, and yellow lines indicate patients with exposure to PIM antibiotics. For Kaplan-Meier analysis, points represent data censored at the last time point when the patient was known to be alive and progression-free. Shading indicates 95% confidence intervals, and checkmarks indicate censored events.(F, G, H) Histograms of the frequency of any grade of CRS and ICANS by Wilcoxon rank sum test according to exposure to PIM antibiotics within 4 weeks prior to CD19 CAR T cell infusion in patients with ALL and NHL (n=228), NHL (n=137), and ALL (n=91), respectively. Blue indicates the absence of any grade of CRS or ICANS, and red indicates the presence of any grade of CRS or ICANS. Abbreviations: Trimeth. / Sulfameth.: trimethoprim / sulfamethoxazole, IV: intravenous, NHL: non-Hodgkin's lymphoma, unexposed: patients with no PIM exposure and patients who did not receive any antibiotics within 4 weeks prior to CD19 CAR T-cell infusion, ALL: acute lymphoblastic leukemia, p: p-value, PIM: exposure to either piperacillin / tazobactam, imipenem / cilastatin, or meropenem within 4 weeks prior to CD19 CAR T-cell infusion, CRS: cytokine release syndrome, ICANS: immune effector cell-associated neurotoxicity. [Figure 1-6]Impact of antibiotic exposure in patients with hematological malignancies treated with anti-CD19 CAR T cell therapy. (A) The antibiotic cohort (left panel) consists of CD19 CAR T cell recipients from MSK (n=127) and Penn (n=101) evaluated in a retrospective observational study of antibiotic exposure (N=228). Frequency of antibiotic exposure (right panel) 4 weeks prior to CAR T cell infusion in patients with NHL and ALL (N=228). Percent frequency of exposure to piperacillin / tazobactam, imipenem / cilastatin, and meropenem is highlighted in yellow and indicates the antibiotics that make up the PIMs (also shown in yellow). Percent frequency of exposure to cefepime is shown in green. The blue graph indicates cumulative exposure to any antibiotic. "Other" includes all antibiotics administered to only one patient each (clindamycin, cephalexin, tobramycin, cefpodoxime, atovaquone, ampicillin / sulbactam, cefuroxime, cefazolin). (B) Kaplan-Meier overall survival curves by log-rank test in ALL and NHL populations by exposure to any antibiotic within 4 weeks prior to CD19 CAR T-cell infusion (N=228). Grey lines indicate patients not exposed to antibiotic treatment, and yellow lines indicate patients exposed to antibiotic treatment. (C, D, E) Kaplan-Meier curves of progression-free survival (PFS) and overall survival (OS) by log-rank test by exposure to PIM antibiotic within 4 weeks prior to CD19 CAR T-cell infusion in patients with ALL and NHL (OS only, N=228), NHL (n=137), and ALL (n=91), respectively. Grey lines indicate patients with no exposure to PIM antibiotics, and yellow lines indicate patients with exposure to PIM antibiotics. For Kaplan-Meier analysis, points represent data censored at the last time point when the patient was known to be alive and progression-free. Shading indicates 95% confidence intervals, and checkmarks indicate censored events.(F, G, H) Histograms of the frequency of any grade of CRS and ICANS by Wilcoxon rank sum test according to exposure to PIM antibiotics within 4 weeks prior to CD19 CAR T cell infusion in patients with ALL and NHL (n=228), NHL (n=137), and ALL (n=91), respectively. Blue indicates the absence of any grade of CRS or ICANS, and red indicates the presence of any grade of CRS or ICANS. Abbreviations: Trimeth. / Sulfameth.: trimethoprim / sulfamethoxazole, IV: intravenous, NHL: non-Hodgkin's lymphoma, unexposed: patients with no PIM exposure and patients who did not receive any antibiotics within 4 weeks prior to CD19 CAR T-cell infusion, ALL: acute lymphoblastic leukemia, p: p-value, PIM: exposure to either piperacillin / tazobactam, imipenem / cilastatin, or meropenem within 4 weeks prior to CD19 CAR T-cell infusion, CRS: cytokine release syndrome, ICANS: immune effector cell-associated neurotoxicity. [Figure 1-7]Impact of antibiotic exposure in patients with hematological malignancies treated with anti-CD19 CAR T cell therapy. (A) The antibiotic cohort (left panel) consists of CD19 CAR T cell recipients from MSK (n=127) and Penn (n=101) evaluated in a retrospective observational study of antibiotic exposure (N=228). Frequency of antibiotic exposure (right panel) 4 weeks prior to CAR T cell infusion in patients with NHL and ALL (N=228). Percent frequency of exposure to piperacillin / tazobactam, imipenem / cilastatin, and meropenem is highlighted in yellow and indicates the antibiotics that make up the PIMs (also shown in yellow). Percent frequency of exposure to cefepime is shown in green. The blue graph indicates cumulative exposure to any antibiotic. "Other" includes all antibiotics administered to only one patient each (clindamycin, cephalexin, tobramycin, cefpodoxime, atovaquone, ampicillin / sulbactam, cefuroxime, cefazolin). (B) Kaplan-Meier overall survival curves by log-rank test in ALL and NHL populations by exposure to any antibiotic within 4 weeks prior to CD19 CAR T-cell infusion (N=228). Grey lines indicate patients not exposed to antibiotic treatment, and yellow lines indicate patients exposed to antibiotic treatment. (C, D, E) Kaplan-Meier curves of progression-free survival (PFS) and overall survival (OS) by log-rank test by exposure to PIM antibiotic within 4 weeks prior to CD19 CAR T-cell infusion in patients with ALL and NHL (OS only, N=228), NHL (n=137), and ALL (n=91), respectively. Grey lines indicate patients with no exposure to PIM antibiotics, and yellow lines indicate patients with exposure to PIM antibiotics. For Kaplan-Meier analysis, points represent data censored at the last time point when the patient was known to be alive and progression-free. Shading indicates 95% confidence intervals, and checkmarks indicate censored events.(F, G, H) Histograms of the frequency of any grade of CRS and ICANS by Wilcoxon rank sum test according to exposure to PIM antibiotics within 4 weeks prior to CD19 CAR T cell infusion in patients with ALL and NHL (n=228), NHL (n=137), and ALL (n=91), respectively. Blue indicates the absence of any grade of CRS or ICANS, and red indicates the presence of any grade of CRS or ICANS. Abbreviations: Trimeth. / Sulfameth.: trimethoprim / sulfamethoxazole, IV: intravenous, NHL: non-Hodgkin's lymphoma, unexposed: patients with no PIM exposure and patients who did not receive any antibiotics within 4 weeks prior to CD19 CAR T-cell infusion, ALL: acute lymphoblastic leukemia, p: p-value, PIM: exposure to either piperacillin / tazobactam, imipenem / cilastatin, or meropenem within 4 weeks prior to CD19 CAR T-cell infusion, CRS: cytokine release syndrome, ICANS: immune effector cell-associated neurotoxicity. [Figure 1-8]Impact of antibiotic exposure in patients with hematological malignancies treated with anti-CD19 CAR T cell therapy. (A) The antibiotic cohort (left panel) consists of CD19 CAR T cell recipients from MSK (n=127) and Penn (n=101) evaluated in a retrospective observational study of antibiotic exposure (N=228). Frequency of antibiotic exposure (right panel) 4 weeks prior to CAR T cell infusion in patients with NHL and ALL (N=228). Percent frequency of exposure to piperacillin / tazobactam, imipenem / cilastatin, and meropenem is highlighted in yellow and indicates the antibiotics that make up the PIMs (also shown in yellow). Percent frequency of exposure to cefepime is shown in green. The blue graph indicates cumulative exposure to any antibiotic. "Other" includes all antibiotics administered to only one patient each (clindamycin, cephalexin, tobramycin, cefpodoxime, atovaquone, ampicillin / sulbactam, cefuroxime, cefazolin). (B) Kaplan-Meier overall survival curves by log-rank test in ALL and NHL populations by exposure to any antibiotic within 4 weeks prior to CD19 CAR T-cell infusion (N=228). Grey lines indicate patients not exposed to antibiotic treatment, and yellow lines indicate patients exposed to antibiotic treatment. (C, D, E) Kaplan-Meier curves of progression-free survival (PFS) and overall survival (OS) by log-rank test by exposure to PIM antibiotic within 4 weeks prior to CD19 CAR T-cell infusion in patients with ALL and NHL (OS only, N=228), NHL (n=137), and ALL (n=91), respectively. Grey lines indicate patients with no exposure to PIM antibiotics, and yellow lines indicate patients with exposure to PIM antibiotics. For Kaplan-Meier analysis, points represent data censored at the last time point when the patient was known to be alive and progression-free. Shading indicates 95% confidence intervals, and checkmarks indicate censored events.(F, G, H) Histograms of the frequency of any grade of CRS and ICANS by Wilcoxon rank sum test according to exposure to PIM antibiotics within 4 weeks prior to CD19 CAR T cell infusion in patients with ALL and NHL (n=228), NHL (n=137), and ALL (n=91), respectively. Blue indicates the absence of any grade of CRS or ICANS, and red indicates the presence of any grade of CRS or ICANS. Abbreviations: Trimeth. / Sulfameth.: trimethoprim / sulfamethoxazole, IV: intravenous, NHL: non-Hodgkin's lymphoma, unexposed: patients with no PIM exposure and patients who did not receive any antibiotics within 4 weeks prior to CD19 CAR T-cell infusion, ALL: acute lymphoblastic leukemia, p: p-value, PIM: exposure to either piperacillin / tazobactam, imipenem / cilastatin, or meropenem within 4 weeks prior to CD19 CAR T-cell infusion, CRS: cytokine release syndrome, ICANS: immune effector cell-associated neurotoxicity. [Figure 2-1]Impact of antibiotic exposure in patients with hematological malignancies treated with anti-CD19 CAR T cell therapy by center. (A) Frequency of antibiotic exposure in patients with NHL and ALL within 4 weeks prior to CD19 CAR T cell infusion treated at MSK (top panel, n=127) and Penn (bottom panel, n=101). Purple indicates patients with ALL, orange indicates patients with NHL. (B and C) Kaplan-Meier curves of overall survival (OS) by log-rank test according to exposure to PIM antibiotics in patients with NHL and ALL within 4 weeks prior to CD19 CAR T cell infusion treated at MSK (B, n=127) and Penn (C, n=101). Grey lines indicate patients without exposure to PIM antibiotics, and yellow lines indicate patients with exposure to PIM antibiotics. For Kaplan-Meier analysis, points represent data censored at the last time point when the patient was known to be alive and progression-free. Shading indicates 95% confidence intervals and checkmarks indicate censored events. Abbreviations: Trimeth. / Sulfameth.: trimethoprim / sulfamethoxazole, IV: intravenous, NHL: non-Hodgkin lymphoma, ALL: acute lymphoblastic leukemia, MSK: Memorial Sloan Kettering Cancer Center, Penn: University of Pennsylvania, PIM: exposure to either piperacillin / tazobactam, imipenem / cilastatin, or meropenem within 4 weeks prior to CD19 CAR T-cell infusion, unexposed: patients exposed to non-PIMs and patients who did not receive any antibiotics, IV: intravenous, p: p-value. [Figure 2-2]Impact of antibiotic exposure in patients with hematological malignancies treated with anti-CD19 CAR T cell therapy by center. (A) Frequency of antibiotic exposure in patients with NHL and ALL within 4 weeks prior to CD19 CAR T cell infusion treated at MSK (top panel, n=127) and Penn (bottom panel, n=101). Purple indicates patients with ALL, orange indicates patients with NHL. (B and C) Kaplan-Meier curves of overall survival (OS) by log-rank test according to exposure to PIM antibiotics in patients with NHL and ALL within 4 weeks prior to CD19 CAR T cell infusion treated at MSK (B, n=127) and Penn (C, n=101). Grey lines indicate patients without exposure to PIM antibiotics, and yellow lines indicate patients with exposure to PIM antibiotics. For Kaplan-Meier analysis, points represent data censored at the last time point when the patient was known to be alive and progression-free. Shading indicates 95% confidence intervals and checkmarks indicate censored events. Abbreviations: Trimeth. / Sulfameth.: trimethoprim / sulfamethoxazole, IV: intravenous, NHL: non-Hodgkin lymphoma, ALL: acute lymphoblastic leukemia, MSK: Memorial Sloan Kettering Cancer Center, Penn: University of Pennsylvania, PIM: exposure to either piperacillin / tazobactam, imipenem / cilastatin, or meropenem within 4 weeks prior to CD19 CAR T-cell infusion, unexposed: patients exposed to non-PIMs and patients who did not receive any antibiotics, IV: intravenous, p: p-value. [Figure 2-3]Impact of antibiotic exposure in patients with hematological malignancies treated with anti-CD19 CAR T cell therapy by center. (A) Frequency of antibiotic exposure in patients with NHL and ALL within 4 weeks prior to CD19 CAR T cell infusion treated at MSK (top panel, n=127) and Penn (bottom panel, n=101). Purple indicates patients with ALL, orange indicates patients with NHL. (B and C) Kaplan-Meier curves of overall survival (OS) by log-rank test according to exposure to PIM antibiotics in patients with NHL and ALL within 4 weeks prior to CD19 CAR T cell infusion treated at MSK (B, n=127) and Penn (C, n=101). Grey lines indicate patients without exposure to PIM antibiotics, and yellow lines indicate patients with exposure to PIM antibiotics. For Kaplan-Meier analysis, points represent data censored at the last time point when the patient was known to be alive and progression-free. Shading indicates 95% confidence intervals and checkmarks indicate censored events. Abbreviations: Trimeth. / Sulfameth.: trimethoprim / sulfamethoxazole, IV: intravenous, NHL: non-Hodgkin lymphoma, ALL: acute lymphoblastic leukemia, MSK: Memorial Sloan Kettering Cancer Center, Penn: University of Pennsylvania, PIM: exposure to either piperacillin / tazobactam, imipenem / cilastatin, or meropenem within 4 weeks prior to CD19 CAR T-cell infusion, unexposed: patients exposed to non-PIMs and patients who did not receive any antibiotics, IV: intravenous, p: p-value. [Figure 3-1]Survival analysis comparison of different antibiotic exposures for non-Hodgkin's lymphoma patients treated with CD19 CAR T cells. (A and B) Kaplan-Meier curves for (A) progression-free survival (PFS) and (B) overall survival (OS) by log-rank test. Data represent combined NHL population (n=137) treated with different antibiotics within 4 weeks prior to CD19 CAR T cell infusion. Grey line represents patients with no exposure to PIM antibiotics or cefepime (n=107), yellow line represents patients with exposure to PIM antibiotics (n=21), and green line represents patients with no exposure to PIM antibiotics and exposure to cefepime (n=9). Points represent data censored at the last time point when the patient was known to be alive and progression-free. Shading indicates 95% confidence intervals and checkmarks indicate censored events. P-values are shown (log-rank analysis). Abbreviations: NHL: non-Hodgkin lymphoma; PIM: exposure to either piperacillin / tazobactam, imipenem / cilastatin, or meropenem within 4 weeks prior to CD19 CAR T-cell infusion; non-PIM antibiotic exposure: patients with non-PIM exposure and patients who did not receive any antibiotics within 4 weeks prior to CD19 CAR T-cell infusion; p: p-value. [Figure 3-2]Survival analysis comparison of different antibiotic exposures for non-Hodgkin's lymphoma patients treated with CD19 CAR T cells. (A and B) Kaplan-Meier curves for (A) progression-free survival (PFS) and (B) overall survival (OS) by log-rank test. Data represent combined NHL population (n=137) treated with different antibiotics within 4 weeks prior to CD19 CAR T cell infusion. Grey line represents patients with no exposure to PIM antibiotics or cefepime (n=107), yellow line represents patients with exposure to PIM antibiotics (n=21), and green line represents patients with no exposure to PIM antibiotics and exposure to cefepime (n=9). Points represent data censored at the last time point when the patient was known to be alive and progression-free. Shading indicates 95% confidence intervals and checkmarks indicate censored events. P-values are shown (log-rank analysis). Abbreviations: NHL: non-Hodgkin lymphoma; PIM: exposure to either piperacillin / tazobactam, imipenem / cilastatin, or meropenem within 4 weeks prior to CD19 CAR T-cell infusion; non-PIM antibiotic exposure: patients with non-PIM exposure and patients who did not receive any antibiotics within 4 weeks prior to CD19 CAR T-cell infusion; p: p-value. [Figure 4-1]Effect of PIM antibiotic exposure in patients with non-Hodgkin's lymphoma treated with anti-CD19 CAR T cells by CAR costimulatory domain. (A and B) Kaplan-Meier curves of (A) progression-free survival (PFS) and (B) overall survival (OS) by log-rank test according to exposure to PIM antibiotics within 4 weeks prior to CD19 CAR T cell infusion in NHL populations treated with CD19 CAR T cells with CD28 costimulatory domain (A, n=72) or CD19 CAR T cells with 4-1BB costimulatory domain (B, n=65). Grey lines indicate patients without exposure to PIM antibiotics, and yellow lines indicate patients with exposure to PIM antibiotics. Points represent data censored at the last time point when the patient was known to be alive and progression-free. Shading indicates 95% confidence intervals, and checkmarks indicate censored events. P values are shown (log-rank analysis). (C and D) Histograms show the frequency of CRS and ICANS by Wilcoxon rank sum test according to exposure to PIM antibiotics within 4 weeks prior to CD19 CAR T cell infusion in patients with NHL who received products with a CD28 costimulatory domain (C) and in patients with NHL who received products with a 4-1BB costimulatory domain (D). Blue indicates the absence of any grade of CRS or ICANS, and red indicates the presence of any grade of CRS or ICANS. Abbreviations: NHL: non-Hodgkin's lymphoma, PIM: exposure to either piperacillin / tazobactam, imipenem / cilastatin, or meropenem within 4 weeks prior to CD19 CAR T-cell infusion, non-PIM antibiotic exposure: patients with non-PIM exposure and patients who did not receive any antibiotic within 4 weeks prior to CD19 CAR T-cell infusion, PFS: progression-free survival, OS: overall survival, p: p-value, CRS: cytokine release syndrome, ICANS: immune effector cell-associated neurotoxicity [Figure 4-2]Effect of PIM antibiotic exposure in patients with non-Hodgkin's lymphoma treated with anti-CD19 CAR T cells by CAR costimulatory domain. (A and B) Kaplan-Meier curves of (A) progression-free survival (PFS) and (B) overall survival (OS) by log-rank test according to exposure to PIM antibiotics within 4 weeks prior to CD19 CAR T cell infusion in NHL populations treated with CD19 CAR T cells with CD28 costimulatory domain (A, n=72) or CD19 CAR T cells with 4-1BB costimulatory domain (B, n=65). Grey lines indicate patients without exposure to PIM antibiotics, and yellow lines indicate patients with exposure to PIM antibiotics. Points represent data censored at the last time point when the patient was known to be alive and progression-free. Shading indicates 95% confidence intervals, and checkmarks indicate censored events. P values are shown (log-rank analysis). (C and D) Histograms show the frequency of CRS and ICANS by Wilcoxon rank sum test according to exposure to PIM antibiotics within 4 weeks prior to CD19 CAR T cell infusion in patients with NHL who received products with a CD28 costimulatory domain (C) and in patients with NHL who received products with a 4-1BB costimulatory domain (D). Blue indicates the absence of any grade of CRS or ICANS, and red indicates the presence of any grade of CRS or ICANS. Abbreviations: NHL: non-Hodgkin's lymphoma, PIM: exposure to either piperacillin / tazobactam, imipenem / cilastatin, or meropenem within 4 weeks prior to CD19 CAR T-cell infusion, non-PIM antibiotic exposure: patients with non-PIM exposure and patients who did not receive any antibiotic within 4 weeks prior to CD19 CAR T-cell infusion, PFS: progression-free survival, OS: overall survival, p: p-value, CRS: cytokine release syndrome, ICANS: immune effector cell-associated neurotoxicity [Figure 4-3]Effect of PIM antibiotic exposure in patients with non-Hodgkin's lymphoma treated with anti-CD19 CAR T cells by CAR costimulatory domain. (A and B) Kaplan-Meier curves of (A) progression-free survival (PFS) and (B) overall survival (OS) by log-rank test according to exposure to PIM antibiotics within 4 weeks prior to CD19 CAR T cell infusion in NHL populations treated with CD19 CAR T cells with CD28 costimulatory domain (A, n=72) or CD19 CAR T cells with 4-1BB costimulatory domain (B, n=65). Grey lines indicate patients without exposure to PIM antibiotics, and yellow lines indicate patients with exposure to PIM antibiotics. Points represent data censored at the last time point when the patient was known to be alive and progression-free. Shading indicates 95% confidence intervals, and checkmarks indicate censored events. P values are shown (log-rank analysis). (C and D) Histograms show the frequency of CRS and ICANS by Wilcoxon rank sum test according to exposure to PIM antibiotics within 4 weeks prior to CD19 CAR T cell infusion in patients with NHL who received products with a CD28 costimulatory domain (C) and in patients with NHL who received products with a 4-1BB costimulatory domain (D). Blue indicates the absence of any grade of CRS or ICANS, and red indicates the presence of any grade of CRS or ICANS. Abbreviations: NHL: non-Hodgkin's lymphoma, PIM: exposure to either piperacillin / tazobactam, imipenem / cilastatin, or meropenem within 4 weeks prior to CD19 CAR T-cell infusion, non-PIM antibiotic exposure: patients with non-PIM exposure and patients who did not receive any antibiotic within 4 weeks prior to CD19 CAR T-cell infusion, PFS: progression-free survival, OS: overall survival, p: p-value, CRS: cytokine release syndrome, ICANS: immune effector cell-associated neurotoxicity [Figure 4-4]Effect of PIM antibiotic exposure in patients with non-Hodgkin's lymphoma treated with anti-CD19 CAR T cells by CAR costimulatory domain. (A and B) Kaplan-Meier curves of (A) progression-free survival (PFS) and (B) overall survival (OS) by log-rank test according to exposure to PIM antibiotics within 4 weeks prior to CD19 CAR T cell infusion in NHL populations treated with CD19 CAR T cells with CD28 costimulatory domain (A, n=72) or CD19 CAR T cells with 4-1BB costimulatory domain (B, n=65). Grey lines indicate patients without exposure to PIM antibiotics, and yellow lines indicate patients with exposure to PIM antibiotics. Points represent data censored at the last time point when the patient was known to be alive and progression-free. Shading indicates 95% confidence intervals, and checkmarks indicate censored events. P values are shown (log-rank analysis). (C and D) Histograms show the frequency of CRS and ICANS by Wilcoxon rank sum test according to exposure to PIM antibiotics within 4 weeks prior to CD19 CAR T cell infusion in patients with NHL who received products with a CD28 costimulatory domain (C) and in patients with NHL who received products with a 4-1BB costimulatory domain (D). Blue indicates the absence of any grade of CRS or ICANS, and red indicates the presence of any grade of CRS or ICANS. Abbreviations: NHL: non-Hodgkin's lymphoma, PIM: exposure to either piperacillin / tazobactam, imipenem / cilastatin, or meropenem within 4 weeks prior to CD19 CAR T-cell infusion, non-PIM antibiotic exposure: patients with non-PIM exposure and patients who did not receive any antibiotic within 4 weeks prior to CD19 CAR T-cell infusion, PFS: progression-free survival, OS: overall survival, p: p-value, CRS: cytokine release syndrome, ICANS: immune effector cell-associated neurotoxicity [Figure 5-1]Association of fecal microbiota with clinical response in recipients of CD19 CAR T cells. (A-J) Data shown in these panels are based on 16S rRNA gene sequencing data. (A) Schema of fecal sample collection and sequencing analysis. (B) Characterization of baseline fecal samples by their phylogenetic composition in stacked bar plots of bacterial taxa (n=45). Red asterisks indicate samples with dominance, defined as at least 30% relative abundance to any taxonomic unit. (C) Inverse Simpson diversity index of fecal microbiome in baseline fecal samples (n=45) and healthy volunteers (n=30) by Wilcoxon rank sum test. This healthy volunteer cohort has been investigated in a previous published study34. The middle line is the median, box limits represent upper and lower quartiles, box and whiskers indicate 1.5x interquartile range, and dots represent individual data points. (D) Fecal microbiome composition of CAR T cell patients and healthy volunteers shown by PCoA. Composition was assessed using beta diversity calculated by Bray-Curtis dissimilarity. Data were visualized at the ASV level. Red dots indicate CAR T cell patients and green dots indicate healthy volunteers. (E) Plot of estimated coefficients of the inverse of the Simpson diversity index for baseline fecal microbiome, CR at day 100, and toxicity using Bayesian logistic regression. Error bars represent 95% confidence intervals and dots represent point estimates. (F, G) Linear discriminant analysis (LDA) scores calculated for taxa differentially present in baseline fecal microbiomes from 16S sequencing, CR at day 100 (green), no CR at day 100 (purple), and no toxicity (blue). Lengths indicate effect sizes associated with taxa. LDA score >4. (H, J) Plots of estimated coefficients of log10 relative abundance of bacterial taxa at the genus level in baseline fecal samples for CR and toxicity at day 100. Error bars represent 95% confidence intervals and dots represent point estimates. (I, K) Patient samples with the highest (red) or lowest (blue) 10% relative abundance of genera.(H) Predicted probability of CR at day 100 for different abundances of Ruminococcus, and (J) predicted probability of virulence for different abundances of Bacteroides. (L,M) Data shown in these panels are based on metagenomic shotgun sequencing. LDA scores calculated for pathways differentially present in baseline fecal microbiome samples from metagenomic shotgun sequencing with day 100 CR (green) and no day 100 CR (purple), and no virulence (blue). Length indicates effect size associated with taxon. LDA score >2. (N,O) Linear discriminant analysis (LDA) scores calculated for taxa differentially present in baseline fecal microbiome samples from 16S sequencing with day 100 CR (green) and no day 100 CR (purple), and virulence (red) and (blue). Length indicates effect size associated with taxon. LDA score >2. (P) LDA scores calculated for taxa differentially present in baseline fecal microbiome samples from metagenomic shotgun sequencing with CR at day 100 (green) and no CR at day 100 (purple). (Q) LDA scores calculated for pathways differentially present in baseline fecal microbiome samples from metagenomic analysis. The healthy volunteer cohort was used in a previous publication. Abbreviations: LDA: Linear discriminant analysis, ASV: Amplicon sequence variant, NHL: Non-Hodgkin's lymphoma, PIM: exposure to either piperacillin / tazobactam, imipenem / cilastatin, or meropenem within 4 weeks prior to CD19 CAR T-cell infusion, PFS: progression-free survival, OS: overall survival, p: p-value. [Figure 5-2]Association of fecal microbiota with clinical response in recipients of CD19 CAR T cells. (A-J) Data shown in these panels are based on 16S rRNA gene sequencing data. (A) Schema of fecal sample collection and sequencing analysis. (B) Characterization of baseline fecal samples by their phylogenetic composition in stacked bar plots of bacterial taxa (n=45). Red asterisks indicate samples with dominance, defined as at least 30% relative abundance to any taxonomic unit. (C) Inverse Simpson diversity index of fecal microbiome in baseline fecal samples (n=45) and healthy volunteers (n=30) by Wilcoxon rank sum test. This healthy volunteer cohort has been investigated in a previous published study34. The middle line is the median, box limits represent upper and lower quartiles, box and whiskers indicate 1.5x interquartile range, and dots represent individual data points. (D) Fecal microbiome composition of CAR T cell patients and healthy volunteers shown by PCoA. Composition was assessed using beta diversity calculated by Bray-Curtis dissimilarity. Data were visualized at the ASV level. Red dots indicate CAR T cell patients and green dots indicate healthy volunteers. (E) Plot of estimated coefficients of the inverse of the Simpson diversity index for baseline fecal microbiome, CR at day 100, and toxicity using Bayesian logistic regression. Error bars represent 95% confidence intervals and dots represent point estimates. (F, G) Linear discriminant analysis (LDA) scores calculated for taxa differentially present in baseline fecal microbiomes from 16S sequencing, CR at day 100 (green), no CR at day 100 (purple), and no toxicity (blue). Lengths indicate effect sizes associated with taxa. LDA score >4. (H, J) Plots of estimated coefficients of log10 relative abundance of bacterial taxa at the genus level in baseline fecal samples for CR and toxicity at day 100. Error bars represent 95% confidence intervals and dots represent point estimates. (I, K) Patient samples with the highest (red) or lowest (blue) 10% relative abundance of genera.(H) Predicted probability of CR at day 100 for different abundances of Ruminococcus, and (J) predicted probability of virulence for different abundances of Bacteroides. (L,M) Data shown in these panels are based on metagenomic shotgun sequencing. LDA scores calculated for pathways differentially present in baseline fecal microbiome samples from metagenomic shotgun sequencing with day 100 CR (green) and no day 100 CR (purple), and no virulence (blue). Length indicates effect size associated with taxon. LDA score >2. (N,O) Linear discriminant analysis (LDA) scores calculated for taxa differentially present in baseline fecal microbiome samples from 16S sequencing with day 100 CR (green) and no day 100 CR (purple), and virulence (red) and (blue). Length indicates effect size associated with taxon. LDA score >2. (P) LDA scores calculated for taxa differentially present in baseline fecal microbiome samples from metagenomic shotgun sequencing with CR at day 100 (green) and no CR at day 100 (purple). (Q) LDA scores calculated for pathways differentially present in baseline fecal microbiome samples from metagenomic analysis. The healthy volunteer cohort was used in a previous publication. Abbreviations: LDA: Linear discriminant analysis, ASV: Amplicon sequence variant, NHL: Non-Hodgkin's lymphoma, PIM: exposure to either piperacillin / tazobactam, imipenem / cilastatin, or meropenem within 4 weeks prior to CD19 CAR T-cell infusion, PFS: progression-free survival, OS: overall survival, p: p-value. [Figure 5-3]Association of fecal microbiota with clinical response in recipients of CD19 CAR T cells. (A-J) Data shown in these panels are based on 16S rRNA gene sequencing data. (A) Schema of fecal sample collection and sequencing analysis. (B) Characterization of baseline fecal samples by their phylogenetic composition in stacked bar plots of bacterial taxa (n=45). Red asterisks indicate samples with dominance, defined as at least 30% relative abundance to any taxonomic unit. (C) Inverse Simpson diversity index of fecal microbiome in baseline fecal samples (n=45) and healthy volunteers (n=30) by Wilcoxon rank sum test. This healthy volunteer cohort has been investigated in a previous published study34. The middle line is the median, box limits represent upper and lower quartiles, box and whiskers indicate 1.5x interquartile range, and dots represent individual data points. (D) Fecal microbiome composition of CAR T cell patients and healthy volunteers shown by PCoA. Composition was assessed using beta diversity calculated by Bray-Curtis dissimilarity. Data were visualized at the ASV level. Red dots indicate CAR T cell patients and green dots indicate healthy volunteers. (E) Plot of estimated coefficients of the inverse of the Simpson diversity index for baseline fecal microbiome, CR at day 100, and toxicity using Bayesian logistic regression. Error bars represent 95% confidence intervals and dots represent point estimates. (F, G) Linear discriminant analysis (LDA) scores calculated for taxa differentially present in baseline fecal microbiomes from 16S sequencing, CR at day 100 (green), no CR at day 100 (purple), and no toxicity (blue). Lengths indicate effect sizes associated with taxa. LDA score >4. (H, J) Plots of estimated coefficients of log10 relative abundance of bacterial taxa at the genus level in baseline fecal samples for CR and toxicity at day 100. Error bars represent 95% confidence intervals and dots represent point estimates. (I, K) Patient samples with the highest (red) or lowest (blue) 10% relative abundance of genera.(H) Predicted probability of CR at day 100 for different abundances of Ruminococcus, and (J) predicted probability of virulence for different abundances of Bacteroides. (L,M) Data shown in these panels are based on metagenomic shotgun sequencing. LDA scores calculated for pathways differentially present in baseline fecal microbiome samples from metagenomic shotgun sequencing with day 100 CR (green) and no day 100 CR (purple), and no virulence (blue). Length indicates effect size associated with taxon. LDA score >2. (N,O) Linear discriminant analysis (LDA) scores calculated for taxa differentially present in baseline fecal microbiome samples from 16S sequencing with day 100 CR (green) and no day 100 CR (purple), and virulence (red) and (blue). Length indicates effect size associated with taxon. LDA score >2. (P) LDA scores calculated for taxa differentially present in baseline fecal microbiome samples from metagenomic shotgun sequencing with CR at day 100 (green) and no CR at day 100 (purple). (Q) LDA scores calculated for pathways differentially present in baseline fecal microbiome samples from metagenomic analysis. The healthy volunteer cohort was used in a previous publication. Abbreviations: LDA: Linear discriminant analysis, ASV: Amplicon sequence variant, NHL: Non-Hodgkin's lymphoma, PIM: exposure to either piperacillin / tazobactam, imipenem / cilastatin, or meropenem within 4 weeks prior to CD19 CAR T-cell infusion, PFS: progression-free survival, OS: overall survival, p: p-value. [Figure 5-4]Association of fecal microbiota with clinical response in recipients of CD19 CAR T cells. (A-J) Data shown in these panels are based on 16S rRNA gene sequencing data. (A) Schema of fecal sample collection and sequencing analysis. (B) Characterization of baseline fecal samples by their phylogenetic composition in stacked bar plots of bacterial taxa (n=45). Red asterisks indicate samples with dominance, defined as at least 30% relative abundance to any taxonomic unit. (C) Inverse Simpson diversity index of fecal microbiome in baseline fecal samples (n=45) and healthy volunteers (n=30) by Wilcoxon rank sum test. This healthy volunteer cohort has been investigated in a previous published study34. The middle line is the median, box limits represent upper and lower quartiles, box and whiskers indicate 1.5x interquartile range, and dots represent individual data points. (D) Fecal microbiome composition of CAR T cell patients and healthy volunteers shown by PCoA. Composition was assessed using beta diversity calculated by Bray-Curtis dissimilarity. Data were visualized at the ASV level. Red dots indicate CAR T cell patients and green dots indicate healthy volunteers. (E) Plot of estimated coefficients of the inverse of the Simpson diversity index for baseline fecal microbiome, CR at day 100, and toxicity using Bayesian logistic regression. Error bars represent 95% confidence intervals and dots represent point estimates. (F, G) Linear discriminant analysis (LDA) scores calculated for taxa differentially present in baseline fecal microbiomes from 16S sequencing, CR at day 100 (green), no CR at day 100 (purple), and no toxicity (blue). Lengths indicate effect sizes associated with taxa. LDA score >4. (H, J) Plots of estimated coefficients of log10 relative abundance of bacterial taxa at the genus level in baseline fecal samples for CR and toxicity at day 100. Error bars represent 95% confidence intervals and dots represent point estimates. (I, K) Patient samples with the highest (red) or lowest (blue) 10% relative abundance of genera.(H) Predicted probability of CR at day 100 for different abundances of Ruminococcus, and (J) predicted probability of virulence for different abundances of Bacteroides. (L,M) Data shown in these panels are based on metagenomic shotgun sequencing. LDA scores calculated for pathways differentially present in baseline fecal microbiome samples from metagenomic shotgun sequencing with day 100 CR (green) and no day 100 CR (purple), and no virulence (blue). Length indicates effect size associated with taxon. LDA score >2. (N,O) Linear discriminant analysis (LDA) scores calculated for taxa differentially present in baseline fecal microbiome samples from 16S sequencing with day 100 CR (green) and no day 100 CR (purple), and virulence (red) and (blue). Length indicates effect size associated with taxon. LDA score >2. (P) LDA scores calculated for taxa differentially present in baseline fecal microbiome samples from metagenomic shotgun sequencing with CR at day 100 (green) and no CR at day 100 (purple). (Q) LDA scores calculated for pathways differentially present in baseline fecal microbiome samples from metagenomic analysis. The healthy volunteer cohort was used in a previous publication. Abbreviations: LDA: Linear discriminant analysis, ASV: Amplicon sequence variant, NHL: Non-Hodgkin's lymphoma, PIM: exposure to either piperacillin / tazobactam, imipenem / cilastatin, or meropenem within 4 weeks prior to CD19 CAR T-cell infusion, PFS: progression-free survival, OS: overall survival, p: p-value. [Figure 5-5]Association of fecal microbiota with clinical response in recipients of CD19 CAR T cells. (A-J) Data shown in these panels are based on 16S rRNA gene sequencing data. (A) Schema of fecal sample collection and sequencing analysis. (B) Characterization of baseline fecal samples by their phylogenetic composition in stacked bar plots of bacterial taxa (n=45). Red asterisks indicate samples with dominance, defined as at least 30% relative abundance to any taxonomic unit. (C) Inverse Simpson diversity index of fecal microbiome in baseline fecal samples (n=45) and healthy volunteers (n=30) by Wilcoxon rank sum test. This healthy volunteer cohort has been investigated in a previous published study34. The middle line is the median, box limits represent upper and lower quartiles, box and whiskers indicate 1.5x interquartile range, and dots represent individual data points. (D) Fecal microbiome composition of CAR T cell patients and healthy volunteers shown by PCoA. Composition was assessed using beta diversity calculated by Bray-Curtis dissimilarity. Data were visualized at the ASV level. Red dots indicate CAR T cell patients and green dots indicate healthy volunteers. (E) Plot of estimated coefficients of the inverse of the Simpson diversity index for baseline fecal microbiome, CR at day 100, and toxicity using Bayesian logistic regression. Error bars represent 95% confidence intervals and dots represent point estimates. (F, G) Linear discriminant analysis (LDA) scores calculated for taxa differentially present in baseline fecal microbiomes from 16S sequencing, CR at day 100 (green), no CR at day 100 (purple), and no toxicity (blue). Lengths indicate effect sizes associated with taxa. LDA score >4. (H, J) Plots of estimated coefficients of log10 relative abundance of bacterial taxa at the genus level in baseline fecal samples for CR and toxicity at day 100. Error bars represent 95% confidence intervals and dots represent point estimates. (I, K) Patient samples with the highest (red) or lowest (blue) 10% relative abundance of genera.(H) Predicted probability of CR at day 100 for different abundances of Ruminococcus, and (J) predicted probability of virulence for different abundances of Bacteroides. (L,M) Data shown in these panels are based on metagenomic shotgun sequencing. LDA scores calculated for pathways differentially present in baseline fecal microbiome samples from metagenomic shotgun sequencing with day 100 CR (green) and no day 100 CR (purple), and no virulence (blue). Length indicates effect size associated with taxon. LDA score >2. (N,O) Linear discriminant analysis (LDA) scores calculated for taxa differentially present in baseline fecal microbiome samples from 16S sequencing with day 100 CR (green) and no day 100 CR (purple), and virulence (red) and (blue). Length indicates effect size associated with taxon. LDA score >2. (P) LDA scores calculated for taxa differentially present in baseline fecal microbiome samples from metagenomic shotgun sequencing with CR at day 100 (green) and no CR at day 100 (purple). (Q) LDA scores calculated for pathways differentially present in baseline fecal microbiome samples from metagenomic analysis. The healthy volunteer cohort was used in a previous publication. Abbreviations: LDA: Linear discriminant analysis, ASV: Amplicon sequence variant, NHL: Non-Hodgkin's lymphoma, PIM: exposure to either piperacillin / tazobactam, imipenem / cilastatin, or meropenem within 4 weeks prior to CD19 CAR T-cell infusion, PFS: progression-free survival, OS: overall survival, p: p-value. [Figure 5-6]Association of fecal microbiota with clinical response in recipients of CD19 CAR T cells. (A-J) Data shown in these panels are based on 16S rRNA gene sequencing data. (A) Schema of fecal sample collection and sequencing analysis. (B) Characterization of baseline fecal samples by their phylogenetic composition in stacked bar plots of bacterial taxa (n=45). Red asterisks indicate samples with dominance, defined as at least 30% relative abundance to any taxonomic unit. (C) Inverse Simpson diversity index of fecal microbiome in baseline fecal samples (n=45) and healthy volunteers (n=30) by Wilcoxon rank sum test. This healthy volunteer cohort has been investigated in a previous published study34. The middle line is the median, box limits represent upper and lower quartiles, box and whiskers indicate 1.5x interquartile range, and dots represent individual data points. (D) Fecal microbiome composition of CAR T cell patients and healthy volunteers shown by PCoA. Composition was assessed using beta diversity calculated by Bray-Curtis dissimilarity. Data were visualized at the ASV level. Red dots indicate CAR T cell patients and green dots indicate healthy volunteers. (E) Plot of estimated coefficients of the inverse of the Simpson diversity index for baseline fecal microbiome, CR at day 100, and toxicity using Bayesian logistic regression. Error bars represent 95% confidence intervals and dots represent point estimates. (F, G) Linear discriminant analysis (LDA) scores calculated for taxa differentially present in baseline fecal microbiomes from 16S sequencing, CR at day 100 (green), no CR at day 100 (purple), and no toxicity (blue). Lengths indicate effect sizes associated with taxa. LDA score >4. (H, J) Plots of estimated coefficients of log10 relative abundance of bacterial taxa at the genus level in baseline fecal samples for CR and toxicity at day 100. Error bars represent 95% confidence intervals and dots represent point estimates. (I, K) Patient samples with the highest (red) or lowest (blue) 10% relative abundance of genera.(H) Predicted probability of CR at day 100 for different abundances of Ruminococcus, and (J) predicted probability of virulence for different abundances of Bacteroides. (L,M) Data shown in these panels are based on metagenomic shotgun sequencing. LDA scores calculated for pathways differentially present in baseline fecal microbiome samples from metagenomic shotgun sequencing with day 100 CR (green) and no day 100 CR (purple), and no virulence (blue). Length indicates effect size associated with taxon. LDA score >2. (N,O) Linear discriminant analysis (LDA) scores calculated for taxa differentially present in baseline fecal microbiome samples from 16S sequencing with day 100 CR (green) and no day 100 CR (purple), and virulence (red) and (blue). Length indicates effect size associated with taxon. LDA score >2. (P) LDA scores calculated for taxa differentially present in baseline fecal microbiome samples from metagenomic shotgun sequencing with CR at day 100 (green) and no CR at day 100 (purple). (Q) LDA scores calculated for pathways differentially present in baseline fecal microbiome samples from metagenomic analysis. The healthy volunteer cohort was used in a previous publication. Abbreviations: LDA: Linear discriminant analysis, ASV: Amplicon sequence variant, NHL: Non-Hodgkin's lymphoma, PIM: exposure to either piperacillin / tazobactam, imipenem / cilastatin, or meropenem within 4 weeks prior to CD19 CAR T-cell infusion, PFS: progression-free survival, OS: overall survival, p: p-value. [Figure 5-7]Association of fecal microbiota with clinical response in recipients of CD19 CAR T cells. (A-J) Data shown in these panels are based on 16S rRNA gene sequencing data. (A) Schema of fecal sample collection and sequencing analysis. (B) Characterization of baseline fecal samples by their phylogenetic composition in stacked bar plots of bacterial taxa (n=45). Red asterisks indicate samples with dominance, defined as at least 30% relative abundance to any taxonomic unit. (C) Inverse Simpson diversity index of fecal microbiome in baseline fecal samples (n=45) and healthy volunteers (n=30) by Wilcoxon rank sum test. This healthy volunteer cohort has been investigated in a previous published study34. The middle line is the median, box limits represent upper and lower quartiles, box and whiskers indicate 1.5x interquartile range, and dots represent individual data points. (D) Fecal microbiome composition of CAR T cell patients and healthy volunteers shown by PCoA. Composition was assessed using beta diversity calculated by Bray-Curtis dissimilarity. Data were visualized at the ASV level. Red dots indicate CAR T cell patients and green dots indicate healthy volunteers. (E) Plot of estimated coefficients of the inverse of the Simpson diversity index for baseline fecal microbiome, CR at day 100, and toxicity using Bayesian logistic regression. Error bars represent 95% confidence intervals and dots represent point estimates. (F, G) Linear discriminant analysis (LDA) scores calculated for taxa differentially present in baseline fecal microbiomes from 16S sequencing, CR at day 100 (green), no CR at day 100 (purple), and no toxicity (blue). Lengths indicate effect sizes associated with taxa. LDA score >4. (H, J) Plots of estimated coefficients of log10 relative abundance of bacterial taxa at the genus level in baseline fecal samples for CR and toxicity at day 100. Error bars represent 95% confidence intervals and dots represent point estimates. (I, K) Patient samples with the highest (red) or lowest (blue) 10% relative abundance of genera.(H) Predicted probability of CR at day 100 for different abundances of Ruminococcus, and (J) predicted probability of virulence for different abundances of Bacteroides. (L,M) Data shown in these panels are based on metagenomic shotgun sequencing. LDA scores calculated for pathways differentially present in baseline fecal microbiome samples from metagenomic shotgun sequencing with day 100 CR (green) and no day 100 CR (purple), and no virulence (blue). Length indicates effect size associated with taxon. LDA score >2. (N,O) Linear discriminant analysis (LDA) scores calculated for taxa differentially present in baseline fecal microbiome samples from 16S sequencing with day 100 CR (green) and no day 100 CR (purple), and virulence (red) and (blue). Length indicates effect size associated with taxon. LDA score >2. (P) LDA scores calculated for taxa differentially present in baseline fecal microbiome samples from metagenomic shotgun sequencing with CR at day 100 (green) and no CR at day 100 (purple). (Q) LDA scores calculated for pathways differentially present in baseline fecal microbiome samples from metagenomic analysis. The healthy volunteer cohort was used in a previous publication. Abbreviations: LDA: Linear discriminant analysis, ASV: Amplicon sequence variant, NHL: Non-Hodgkin's lymphoma, PIM: exposure to either piperacillin / tazobactam, imipenem / cilastatin, or meropenem within 4 weeks prior to CD19 CAR T-cell infusion, PFS: progression-free survival, OS: overall survival, p: p-value. [Figure 5-8]Association of fecal microbiota with clinical response in recipients of CD19 CAR T cells. (A-J) Data shown in these panels are based on 16S rRNA gene sequencing data. (A) Schema of fecal sample collection and sequencing analysis. (B) Characterization of baseline fecal samples by their phylogenetic composition in stacked bar plots of bacterial taxa (n=45). Red asterisks indicate samples with dominance, defined as at least 30% relative abundance to any taxonomic unit. (C) Inverse Simpson diversity index of fecal microbiome in baseline fecal samples (n=45) and healthy volunteers (n=30) by Wilcoxon rank sum test. This healthy volunteer cohort has been investigated in a previous published study34. The middle line is the median, box limits represent upper and lower quartiles, box and whiskers indicate 1.5x interquartile range, and dots represent individual data points. (D) Fecal microbiome composition of CAR T cell patients and healthy volunteers shown by PCoA. Composition was assessed using beta diversity calculated by Bray-Curtis dissimilarity. Data were visualized at the ASV level. Red dots indicate CAR T cell patients and green dots indicate healthy volunteers. (E) Plot of estimated coefficients of the inverse of the Simpson diversity index for baseline fecal microbiome, CR at day 100, and toxicity using Bayesian logistic regression. Error bars represent 95% confidence intervals and dots represent point estimates. (F, G) Linear discriminant analysis (LDA) scores calculated for taxa differentially present in baseline fecal microbiomes from 16S sequencing, CR at day 100 (green), no CR at day 100 (purple), and no toxicity (blue). Lengths indicate effect sizes associated with taxa. LDA score >4. (H, J) Plots of estimated coefficients of log10 relative abundance of bacterial taxa at the genus level in baseline fecal samples for CR and toxicity at day 100. Error bars represent 95% confidence intervals and dots represent point estimates. (I, K) Patient samples with the highest (red) or lowest (blue) 10% relative abundance of genera.(H) Predicted probability of CR at day 100 for different abundances of Ruminococcus, and (J) predicted probability of virulence for different abundances of Bacteroides. (L,M) Data shown in these panels are based on metagenomic shotgun sequencing. LDA scores calculated for pathways differentially present in baseline fecal microbiome samples from metagenomic shotgun sequencing with day 100 CR (green) and no day 100 CR (purple), and no virulence (blue). Length indicates effect size associated with taxon. LDA score >2. (N,O) Linear discriminant analysis (LDA) scores calculated for taxa differentially present in baseline fecal microbiome samples from 16S sequencing with day 100 CR (green) and no day 100 CR (purple), and virulence (red) and (blue). Length indicates effect size associated with taxon. LDA score >2. (P) LDA scores calculated for taxa differentially present in baseline fecal microbiome samples from metagenomic shotgun sequencing with CR at day 100 (green) and no CR at day 100 (purple). (Q) LDA scores calculated for pathways differentially present in baseline fecal microbiome samples from metagenomic analysis. The healthy volunteer cohort was used in a previous publication. Abbreviations: LDA: Linear discriminant analysis, ASV: Amplicon sequence variant, NHL: Non-Hodgkin's lymphoma, PIM: exposure to either piperacillin / tazobactam, imipenem / cilastatin, or meropenem within 4 weeks prior to CD19 CAR T-cell infusion, PFS: progression-free survival, OS: overall survival, p: p-value. [Figure 5-9]Association of fecal microbiota with clinical response in recipients of CD19 CAR T cells. (A-J) Data shown in these panels are based on 16S rRNA gene sequencing data. (A) Schema of fecal sample collection and sequencing analysis. (B) Characterization of baseline fecal samples by their phylogenetic composition in stacked bar plots of bacterial taxa (n=45). Red asterisks indicate samples with dominance, defined as at least 30% relative abundance to any taxonomic unit. (C) Inverse Simpson diversity index of fecal microbiome in baseline fecal samples (n=45) and healthy volunteers (n=30) by Wilcoxon rank sum test. This healthy volunteer cohort has been investigated in a previous published study34. The middle line is the median, box limits represent upper and lower quartiles, box and whiskers indicate 1.5x interquartile range, and dots represent individual data points. (D) Fecal microbiome composition of CAR T cell patients and healthy volunteers shown by PCoA. Composition was assessed using beta diversity calculated by Bray-Curtis dissimilarity. Data were visualized at the ASV level. Red dots indicate CAR T cell patients and green dots indicate healthy volunteers. (E) Plot of estimated coefficients of the inverse of the Simpson diversity index for baseline fecal microbiome, CR at day 100, and toxicity using Bayesian logistic regression. Error bars represent 95% confidence intervals and dots represent point estimates. (F, G) Linear discriminant analysis (LDA) scores calculated for taxa differentially present in baseline fecal microbiomes from 16S sequencing, CR at day 100 (green), no CR at day 100 (purple), and no toxicity (blue). Lengths indicate effect sizes associated with taxa. LDA score >4. (H, J) Plots of estimated coefficients of log10 relative abundance of bacterial taxa at the genus level in baseline fecal samples for CR and toxicity at day 100. Error bars represent 95% confidence intervals and dots represent point estimates. (I, K) Patient samples with the highest (red) or lowest (blue) 10% relative abundance of genera.(H) Predicted probability of CR at day 100 for different abundances of Ruminococcus, and (J) predicted probability of virulence for different abundances of Bacteroides. (L,M) Data shown in these panels are based on metagenomic shotgun sequencing. LDA scores calculated for pathways differentially present in baseline fecal microbiome samples from metagenomic shotgun sequencing with day 100 CR (green) and no day 100 CR (purple), and no virulence (blue). Length indicates effect size associated with taxon. LDA score >2. (N,O) Linear discriminant analysis (LDA) scores calculated for taxa differentially present in baseline fecal microbiome samples from 16S sequencing with day 100 CR (green) and no day 100 CR (purple), and virulence (red) and (blue). Length indicates effect size associated with taxon. LDA score >2. (P) LDA scores calculated for taxa differentially present in baseline fecal microbiome samples from metagenomic shotgun sequencing with CR at day 100 (green) and no CR at day 100 (purple). (Q) LDA scores calculated for pathways differentially present in baseline fecal microbiome samples from metagenomic analysis. The healthy volunteer cohort was used in a previous publication. Abbreviations: LDA: Linear discriminant analysis, ASV: Amplicon sequence variant, NHL: Non-Hodgkin's lymphoma, PIM: exposure to either piperacillin / tazobactam, imipenem / cilastatin, or meropenem within 4 weeks prior to CD19 CAR T-cell infusion, PFS: progression-free survival, OS: overall survival, p: p-value. [Figure 5-10]Association of fecal microbiota with clinical response in recipients of CD19 CAR T cells. (A-J) Data shown in these panels are based on 16S rRNA gene sequencing data. (A) Schema of fecal sample collection and sequencing analysis. (B) Characterization of baseline fecal samples by their phylogenetic composition in stacked bar plots of bacterial taxa (n=45). Red asterisks indicate samples with dominance, defined as at least 30% relative abundance to any taxonomic unit. (C) Inverse Simpson diversity index of fecal microbiome in baseline fecal samples (n=45) and healthy volunteers (n=30) by Wilcoxon rank sum test. This healthy volunteer cohort has been investigated in a previous published study34. The middle line is the median, box limits represent upper and lower quartiles, box and whiskers indicate 1.5x interquartile range, and dots represent individual data points. (D) Fecal microbiome composition of CAR T cell patients and healthy volunteers shown by PCoA. Composition was assessed using beta diversity calculated by Bray-Curtis dissimilarity. Data were visualized at the ASV level. Red dots indicate CAR T cell patients and green dots indicate healthy volunteers. (E) Plot of estimated coefficients of the inverse of the Simpson diversity index for baseline fecal microbiome, CR at day 100, and toxicity using Bayesian logistic regression. Error bars represent 95% confidence intervals and dots represent point estimates. (F, G) Linear discriminant analysis (LDA) scores calculated for taxa differentially present in baseline fecal microbiomes from 16S sequencing, CR at day 100 (green), no CR at day 100 (purple), and no toxicity (blue). Lengths indicate effect sizes associated with taxa. LDA score >4. (H, J) Plots of estimated coefficients of log10 relative abundance of bacterial taxa at the genus level in baseline fecal samples for CR and toxicity at day 100. Error bars represent 95% confidence intervals and dots represent point estimates. (I, K) Patient samples with the highest (red) or lowest (blue) 10% relative abundance of genera.(H) Predicted probability of CR at day 100 for different abundances of Ruminococcus, and (J) predicted probability of virulence for different abundances of Bacteroides. (L,M) Data shown in these panels are based on metagenomic shotgun sequencing. LDA scores calculated for pathways differentially present in baseline fecal microbiome samples from metagenomic shotgun sequencing with day 100 CR (green) and no day 100 CR (purple), and no virulence (blue). Length indicates effect size associated with taxon. LDA score >2. (N,O) Linear discriminant analysis (LDA) scores calculated for taxa differentially present in baseline fecal microbiome samples from 16S sequencing with day 100 CR (green) and no day 100 CR (purple), and virulence (red) and (blue). Length indicates effect size associated with taxon. LDA score >2. (P) LDA scores calculated for taxa differentially present in baseline fecal microbiome samples from metagenomic shotgun sequencing with CR at day 100 (green) and without CR at day 100 (purple). (Q) LDA scores calculated for pathways differentially present in baseline fecal microbiome samples from metagenomic analysis. The healthy volunteer cohort was used in a previous publication. Abbreviations: LDA: Linear discriminant analysis, ASV: Amplicon sequence variant, NHL: Non-Hodgkin's lymphoma, PIM: exposure to either piperacillin / tazobactam, imipenem / cilastatin, or meropenem within 4 weeks prior to CD19 CAR T-cell infusion, PFS: Progression-free survival, OS: Overall survival, p: p-value. (Figure 5K) Association between fecal microbiota and clinical response in recipients of CD19 CAR T cells. (A-J) Data shown in these panels are based on 16S rRNA gene sequencing data. (A) Schema of fecal sample collection and sequencing analysis. (B) Characterization of baseline fecal samples by their phylogenetic composition in stacked bar plots of bacterial taxa (n=45). Red asterisks indicate samples with dominance, defined as a relative abundance of at least 30% for any taxonomic unit.(C) Inverse Simpson diversity index of fecal microbiome in baseline fecal samples (n=45) and healthy volunteers (n=30) by Wilcoxon rank sum test. This healthy volunteer cohort has been investigated in a previous published study. The middle line is the median, box limits represent upper and lower quartiles, box whiskers indicate 1.5x interquartile range, and dots represent individual data points. (D) Fecal microbiome composition of CAR T cell patients and healthy volunteers shown by PCoA. Composition was assessed using beta diversity calculated by Bray-Curtis dissimilarity. Data were visualized at the ASV level. Red dots indicate CAR T cell patients and green dots indicate healthy volunteers. (E) Plot of estimated coefficients of inverse Simpson diversity index of baseline fecal microbiome, CR at day 100, and toxicity using Bayesian logistic regression. Error bars represent 95% confidence intervals and dots represent point estimates. (F, G) Linear discriminant analysis (LDA) scores calculated for differentially present taxa in baseline fecal microbiomes from 16S sequencing with CR at day 100 (green), no CR at day 100 (purple), and no toxicity (blue). Length indicates effect size associated with taxa. LDA score >4. (H, J) Plots of estimated coefficients of log10 relative abundance of bacterial taxa at genus level in baseline fecal samples for CR and toxicity at day 100. Error bars represent 95% confidence intervals and dots represent point estimates. (I, K) Patient samples with the highest (red) or lowest (blue) 10% relative abundance of genera. (H) Predicted probability of CR at day 100 with different abundances of Ruminococcus, and (J) predicted probability of toxicity with different abundances of Bacteroides. (L, M) Data shown in these panels are based on metagenomic shotgun sequencing. LDA scores calculated for pathways differentially present in baseline fecal microbiome samples from metagenomic shotgun sequencing with day 100 CR (green) and no CR at day 100 (purple), as well as no toxicity (blue). Lengths indicate effect sizes associated with taxa.LDA score >2. (N,O) Linear discriminant analysis (LDA) scores calculated for taxa differentially present in baseline fecal microbiome samples from 16S sequencing with day 100 CR (green) and day 100 no CR (purple), and virulence (red) and (blue). Length indicates effect size associated with taxon. LDA score >2. (P) LDA scores calculated for taxa differentially present in baseline fecal microbiome samples from metagenomic shotgun sequencing with day 100 CR (green) and day 100 no CR (purple). (Q) LDA scores calculated for pathways differentially present in baseline fecal microbiome samples from metagenomic analysis. Healthy volunteer cohorts were used in previous publications34. Abbreviations: LDA: linear discriminant analysis; ASV: amplicon sequence variants; NHL: non-Hodgkin lymphoma; PIM: exposure to either piperacillin / tazobactam, imipenem / cilastatin, or meropenem within 4 weeks prior to CD19 CAR T-cell infusion; PFS: progression-free survival; OS: overall survival; p: p-value. [Figure 5-11]Association of fecal microbiota with clinical response in recipients of CD19 CAR T cells. (A-J) Data shown in these panels are based on 16S rRNA gene sequencing data. (A) Schema of fecal sample collection and sequencing analysis. (B) Characterization of baseline fecal samples by their phylogenetic composition in stacked bar plots of bacterial taxa (n=45). Red asterisks indicate samples with dominance, defined as at least 30% relative abundance to any taxonomic unit. (C) Inverse Simpson diversity index of fecal microbiome in baseline fecal samples (n=45) and healthy volunteers (n=30) by Wilcoxon rank sum test. This healthy volunteer cohort has been investigated in a previous published study34. The middle line is the median, box limits represent upper and lower quartiles, box and whiskers indicate 1.5x interquartile range, and dots represent individual data points. (D) Fecal microbiome composition of CAR T cell patients and healthy volunteers shown by PCoA. Composition was assessed using beta diversity calculated by Bray-Curtis dissimilarity. Data were visualized at the ASV level. Red dots indicate CAR T cell patients and green dots indicate healthy volunteers. (E) Plot of estimated coefficients of the inverse of the Simpson diversity index for baseline fecal microbiome, CR at day 100, and toxicity using Bayesian logistic regression. Error bars represent 95% confidence intervals and dots represent point estimates. (F, G) Linear discriminant analysis (LDA) scores calculated for taxa differentially present in baseline fecal microbiomes from 16S sequencing, CR at day 100 (green), no CR at day 100 (purple), and no toxicity (blue). Lengths indicate effect sizes associated with taxa. LDA score >4. (H, J) Plots of estimated coefficients of log10 relative abundance of bacterial taxa at the genus level in baseline fecal samples for CR and toxicity at day 100. Error bars represent 95% confidence intervals and dots represent point estimates. (I, K) Patient samples with the highest (red) or lowest (blue) 10% relative abundance of genera.(H) Predicted probability of CR at day 100 for different abundances of Ruminococcus, and (J) predicted probability of virulence for different abundances of Bacteroides. (L,M) Data shown in these panels are based on metagenomic shotgun sequencing. LDA scores calculated for pathways differentially present in baseline fecal microbiome samples from metagenomic shotgun sequencing with day 100 CR (green) and no day 100 CR (purple), and no virulence (blue). Length indicates effect size associated with taxon. LDA score >2. (N,O) Linear discriminant analysis (LDA) scores calculated for taxa differentially present in baseline fecal microbiome samples from 16S sequencing with day 100 CR (green) and no day 100 CR (purple), and virulence (red) and (blue). Length indicates effect size associated with taxon. LDA score >2. (P) LDA scores calculated for taxa differentially present in baseline fecal microbiome samples from metagenomic shotgun sequencing with CR at day 100 (green) and no CR at day 100 (purple). (Q) LDA scores calculated for pathways differentially present in baseline fecal microbiome samples from metagenomic analysis. The healthy volunteer cohort was used in a previous publication. Abbreviations: LDA: Linear discriminant analysis, ASV: Amplicon sequence variant, NHL: Non-Hodgkin's lymphoma, PIM: exposure to either piperacillin / tazobactam, imipenem / cilastatin, or meropenem within 4 weeks prior to CD19 CAR T-cell infusion, PFS: progression-free survival, OS: overall survival, p: p-value. [Figure 5-12]Association of fecal microbiota with clinical response in recipients of CD19 CAR T cells. (A-J) Data shown in these panels are based on 16S rRNA gene sequencing data. (A) Schema of fecal sample collection and sequencing analysis. (B) Characterization of baseline fecal samples by their phylogenetic composition in stacked bar plots of bacterial taxa (n=45). Red asterisks indicate samples with dominance, defined as at least 30% relative abundance to any taxonomic unit. (C) Inverse Simpson diversity index of fecal microbiome in baseline fecal samples (n=45) and healthy volunteers (n=30) by Wilcoxon rank sum test. This healthy volunteer cohort has been investigated in a previous published study34. The middle line is the median, box limits represent upper and lower quartiles, box and whiskers indicate 1.5x interquartile range, and dots represent individual data points. (D) Fecal microbiome composition of CAR T cell patients and healthy volunteers shown by PCoA. Composition was assessed using beta diversity calculated by Bray-Curtis dissimilarity. Data were visualized at the ASV level. Red dots indicate CAR T cell patients and green dots indicate healthy volunteers. (E) Plot of estimated coefficients of the inverse of the Simpson diversity index for baseline fecal microbiome, CR at day 100, and toxicity using Bayesian logistic regression. Error bars represent 95% confidence intervals and dots represent point estimates. (F, G) Linear discriminant analysis (LDA) scores calculated for taxa differentially present in baseline fecal microbiomes from 16S sequencing, CR at day 100 (green), no CR at day 100 (purple), and no toxicity (blue). Lengths indicate effect sizes associated with taxa. LDA score >4. (H, J) Plots of estimated coefficients of log10 relative abundance of bacterial taxa at the genus level in baseline fecal samples for CR and toxicity at day 100. Error bars represent 95% confidence intervals and dots represent point estimates. (I, K) Patient samples with the highest (red) or lowest (blue) 10% relative abundance of genera.(H) Predicted probability of CR at day 100 for different abundances of Ruminococcus, and (J) predicted probability of virulence for different abundances of Bacteroides. (L,M) Data shown in these panels are based on metagenomic shotgun sequencing. LDA scores calculated for pathways differentially present in baseline fecal microbiome samples from metagenomic shotgun sequencing with day 100 CR (green) and no day 100 CR (purple), and no virulence (blue). Length indicates effect size associated with taxon. LDA score >2. (N,O) Linear discriminant analysis (LDA) scores calculated for taxa differentially present in baseline fecal microbiome samples from 16S sequencing with day 100 CR (green) and no day 100 CR (purple), and virulence (red) and (blue). Length indicates effect size associated with taxon. LDA score >2. (P) LDA scores calculated for taxa differentially present in baseline fecal microbiome samples from metagenomic shotgun sequencing with CR at day 100 (green) and no CR at day 100 (purple). (Q) LDA scores calculated for pathways differentially present in baseline fecal microbiome samples from metagenomic analysis. The healthy volunteer cohort was used in a previous publication. Abbreviations: LDA: Linear discriminant analysis, ASV: Amplicon sequence variant, NHL: Non-Hodgkin's lymphoma, PIM: exposure to either piperacillin / tazobactam, imipenem / cilastatin, or meropenem within 4 weeks prior to CD19 CAR T-cell infusion, PFS: progression-free survival, OS: overall survival, p: p-value. [Figure 5-13] Same as above. [Figure 5-14]Association of fecal microbiota with clinical response in recipients of CD19 CAR T cells. (A-J) Data shown in these panels are based on 16S rRNA gene sequencing data. (A) Schema of fecal sample collection and sequencing analysis. (B) Characterization of baseline fecal samples by their phylogenetic composition in stacked bar plots of bacterial taxa (n=45). Red asterisks indicate samples with dominance, defined as at least 30% relative abundance to any taxonomic unit. (C) Inverse Simpson diversity index of fecal microbiome in baseline fecal samples (n=45) and healthy volunteers (n=30) by Wilcoxon rank sum test. This healthy volunteer cohort has been investigated in a previous published study34. The middle line is the median, box limits represent upper and lower quartiles, box and whiskers indicate 1.5x interquartile range, and dots represent individual data points. (D) Fecal microbiome composition of CAR T cell patients and healthy volunteers shown by PCoA. Composition was assessed using beta diversity calculated by Bray-Curtis dissimilarity. Data were visualized at the ASV level. Red dots indicate CAR T cell patients and green dots indicate healthy volunteers. (E) Plot of estimated coefficients of the inverse of the Simpson diversity index for baseline fecal microbiome, CR at day 100, and toxicity using Bayesian logistic regression. Error bars represent 95% confidence intervals and dots represent point estimates. (F, G) Linear discriminant analysis (LDA) scores calculated for taxa differentially present in baseline fecal microbiomes from 16S sequencing, CR at day 100 (green), no CR at day 100 (purple), and no toxicity (blue). Lengths indicate effect sizes associated with taxa. LDA score >4. (H, J) Plots of estimated coefficients of log10 relative abundance of bacterial taxa at the genus level in baseline fecal samples for CR and toxicity at day 100. Error bars represent 95% confidence intervals and dots represent point estimates. (I, K) Patient samples with the highest (red) or lowest (blue) 10% relative abundance of genera.(H) Predicted probability of CR at day 100 for different abundances of Ruminococcus, and (J) predicted probability of virulence for different abundances of Bacteroides. (L,M) Data shown in these panels are based on metagenomic shotgun sequencing. LDA scores calculated for pathways differentially present in baseline fecal microbiome samples from metagenomic shotgun sequencing with day 100 CR (green) and no day 100 CR (purple), and no virulence (blue). Length indicates effect size associated with taxon. LDA score >2. (N,O) Linear discriminant analysis (LDA) scores calculated for taxa differentially present in baseline fecal microbiome samples from 16S sequencing with day 100 CR (green) and no day 100 CR (purple), and virulence (red) and (blue). Length indicates effect size associated with taxon. LDA score >2. (P) LDA scores calculated for taxa differentially present in baseline fecal microbiome samples from metagenomic shotgun sequencing with CR at day 100 (green) and no CR at day 100 (purple). (Q) LDA scores calculated for pathways differentially present in baseline fecal microbiome samples from metagenomic analysis. The healthy volunteer cohort was used in a previous publication. Abbreviations: LDA: Linear discriminant analysis, ASV: Amplicon sequence variant, NHL: Non-Hodgkin's lymphoma, PIM: exposure to either piperacillin / tazobactam, imipenem / cilastatin, or meropenem within 4 weeks prior to CD19 CAR T-cell infusion, PFS: progression-free survival, OS: overall survival, p: p-value. [Figure 5-15]Association of fecal microbiota with clinical response in recipients of CD19 CAR T cells. (A-J) Data shown in these panels are based on 16S rRNA gene sequencing data. (A) Schema of fecal sample collection and sequencing analysis. (B) Characterization of baseline fecal samples by their phylogenetic composition in stacked bar plots of bacterial taxa (n=45). Red asterisks indicate samples with dominance, defined as at least 30% relative abundance to any taxonomic unit. (C) Inverse Simpson diversity index of fecal microbiome in baseline fecal samples (n=45) and healthy volunteers (n=30) by Wilcoxon rank sum test. This healthy volunteer cohort has been investigated in a previous published study34. The middle line is the median, box limits represent upper and lower quartiles, box and whiskers indicate 1.5x interquartile range, and dots represent individual data points. (D) Fecal microbiome composition of CAR T cell patients and healthy volunteers shown by PCoA. Composition was assessed using beta diversity calculated by Bray-Curtis dissimilarity. Data were visualized at the ASV level. Red dots indicate CAR T cell patients and green dots indicate healthy volunteers. (E) Plot of estimated coefficients of the inverse of the Simpson diversity index for baseline fecal microbiome, CR at day 100, and toxicity using Bayesian logistic regression. Error bars represent 95% confidence intervals and dots represent point estimates. (F, G) Linear discriminant analysis (LDA) scores calculated for taxa differentially present in baseline fecal microbiomes from 16S sequencing, CR at day 100 (green), no CR at day 100 (purple), and no toxicity (blue). Lengths indicate effect sizes associated with taxa. LDA score >4. (H, J) Plots of estimated coefficients of log10 relative abundance of bacterial taxa at the genus level in baseline fecal samples for CR and toxicity at day 100. Error bars represent 95% confidence intervals and dots represent point estimates. (I, K) Patient samples with the highest (red) or lowest (blue) 10% relative abundance of genera.(H) Predicted probability of CR at day 100 for different abundances of Ruminococcus, and (J) predicted probability of virulence for different abundances of Bacteroides. (L,M) Data shown in these panels are based on metagenomic shotgun sequencing. LDA scores calculated for pathways differentially present in baseline fecal microbiome samples from metagenomic shotgun sequencing with day 100 CR (green) and no day 100 CR (purple), and no virulence (blue). Length indicates effect size associated with taxon. LDA score >2. (N,O) Linear discriminant analysis (LDA) scores calculated for taxa differentially present in baseline fecal microbiome samples from 16S sequencing with day 100 CR (green) and no day 100 CR (purple), and virulence (red) and (blue). Length indicates effect size associated with taxon. LDA score >2. (P) LDA scores calculated for taxa differentially present in baseline fecal microbiome samples from metagenomic shotgun sequencing with CR at day 100 (green) and no CR at day 100 (purple). (Q) LDA scores calculated for pathways differentially present in baseline fecal microbiome samples from metagenomic analysis. The healthy volunteer cohort was used in a previous publication. Abbreviations: LDA: Linear discriminant analysis, ASV: Amplicon sequence variant, NHL: Non-Hodgkin's lymphoma, PIM: exposure to either piperacillin / tazobactam, imipenem / cilastatin, or meropenem within 4 weeks prior to CD19 CAR T-cell infusion, PFS: progression-free survival, OS: overall survival, p: p-value. [Figure 5-16]Association of fecal microbiota with clinical response in recipients of CD19 CAR T cells. (A-J) Data shown in these panels are based on 16S rRNA gene sequencing data. (A) Schema of fecal sample collection and sequencing analysis. (B) Characterization of baseline fecal samples by their phylogenetic composition in stacked bar plots of bacterial taxa (n=45). Red asterisks indicate samples with dominance, defined as at least 30% relative abundance to any taxonomic unit. (C) Inverse Simpson diversity index of fecal microbiome in baseline fecal samples (n=45) and healthy volunteers (n=30) by Wilcoxon rank sum test. This healthy volunteer cohort has been investigated in a previous published study34. The middle line is the median, box limits represent upper and lower quartiles, box and whiskers indicate 1.5x interquartile range, and dots represent individual data points. (D) Fecal microbiome composition of CAR T cell patients and healthy volunteers shown by PCoA. Composition was assessed using beta diversity calculated by Bray-Curtis dissimilarity. Data were visualized at the ASV level. Red dots indicate CAR T cell patients and green dots indicate healthy volunteers. (E) Plot of estimated coefficients of the inverse of the Simpson diversity index for baseline fecal microbiome, CR at day 100, and toxicity using Bayesian logistic regression. Error bars represent 95% confidence intervals and dots represent point estimates. (F, G) Linear discriminant analysis (LDA) scores calculated for taxa differentially present in baseline fecal microbiomes from 16S sequencing, CR at day 100 (green), no CR at day 100 (purple), and no toxicity (blue). Lengths indicate effect sizes associated with taxa. LDA score >4. (H, J) Plots of estimated coefficients of log10 relative abundance of bacterial taxa at the genus level in baseline fecal samples for CR and toxicity at day 100. Error bars represent 95% confidence intervals and dots represent point estimates. (I, K) Patient samples with the highest (red) or lowest (blue) 10% relative abundance of genera.(H) Predicted probability of CR at day 100 for different abundances of Ruminococcus, and (J) predicted probability of virulence for different abundances of Bacteroides. (L,M) Data shown in these panels are based on metagenomic shotgun sequencing. LDA scores calculated for pathways differentially present in baseline fecal microbiome samples from metagenomic shotgun sequencing with day 100 CR (green) and no day 100 CR (purple), and no virulence (blue). Length indicates effect size associated with taxon. LDA score >2. (N,O) Linear discriminant analysis (LDA) scores calculated for taxa differentially present in baseline fecal microbiome samples from 16S sequencing with day 100 CR (green) and no day 100 CR (purple), and virulence (red) and (blue). Length indicates effect size associated with taxon. LDA score >2. (P) LDA scores calculated for taxa differentially present in baseline fecal microbiome samples from metagenomic shotgun sequencing with CR at day 100 (green) and no CR at day 100 (purple). (Q) LDA scores calculated for pathways differentially present in baseline fecal microbiome samples from metagenomic analysis. The healthy volunteer cohort was used in a previous publication. Abbreviations: LDA: Linear discriminant analysis, ASV: Amplicon sequence variant, NHL: Non-Hodgkin's lymphoma, PIM: exposure to either piperacillin / tazobactam, imipenem / cilastatin, or meropenem within 4 weeks prior to CD19 CAR T-cell infusion, PFS: progression-free survival, OS: overall survival, p: p-value. [Figure 5-17]Association of fecal microbiota with clinical response in recipients of CD19 CAR T cells. (A-J) Data shown in these panels are based on 16S rRNA gene sequencing data. (A) Schema of fecal sample collection and sequencing analysis. (B) Characterization of baseline fecal samples by their phylogenetic composition in stacked bar plots of bacterial taxa (n=45). Red asterisks indicate samples with dominance, defined as at least 30% relative abundance to any taxonomic unit. (C) Inverse Simpson diversity index of fecal microbiome in baseline fecal samples (n=45) and healthy volunteers (n=30) by Wilcoxon rank sum test. This healthy volunteer cohort has been investigated in a previous published study34. The middle line is the median, box limits represent upper and lower quartiles, box and whiskers indicate 1.5x interquartile range, and dots represent individual data points. (D) Fecal microbiome composition of CAR T cell patients and healthy volunteers shown by PCoA. Composition was assessed using beta diversity calculated by Bray-Curtis dissimilarity. Data were visualized at the ASV level. Red dots indicate CAR T cell patients and green dots indicate healthy volunteers. (E) Plot of estimated coefficients of the inverse of the Simpson diversity index for baseline fecal microbiome, CR at day 100, and toxicity using Bayesian logistic regression. Error bars represent 95% confidence intervals and dots represent point estimates. (F, G) Linear discriminant analysis (LDA) scores calculated for taxa differentially present in baseline fecal microbiomes from 16S sequencing, CR at day 100 (green), no CR at day 100 (purple), and no toxicity (blue). Lengths indicate effect sizes associated with taxa. LDA score >4. (H, J) Plots of estimated coefficients of log10 relative abundance of bacterial taxa at the genus level in baseline fecal samples for CR and toxicity at day 100. Error bars represent 95% confidence intervals and dots represent point estimates. (I, K) Patient samples with the highest (red) or lowest (blue) 10% relative abundance of genera.(H) Predicted probability of CR at day 100 for different abundances of Ruminococcus, and (J) predicted probability of virulence for different abundances of Bacteroides. (L,M) Data shown in these panels are based on metagenomic shotgun sequencing. LDA scores calculated for pathways differentially present in baseline fecal microbiome samples from metagenomic shotgun sequencing with day 100 CR (green) and no day 100 CR (purple), and no virulence (blue). Length indicates effect size associated with taxon. LDA score >2. (N,O) Linear discriminant analysis (LDA) scores calculated for taxa differentially present in baseline fecal microbiome samples from 16S sequencing with day 100 CR (green) and no day 100 CR (purple), and virulence (red) and (blue). Length indicates effect size associated with taxon. LDA score >2. (P) LDA scores calculated for taxa differentially present in baseline fecal microbiome samples from metagenomic shotgun sequencing with CR at day 100 (green) and no CR at day 100 (purple). (Q) LDA scores calculated for pathways differentially present in baseline fecal microbiome samples from metagenomic analysis. The healthy volunteer cohort was used in a previous publication. Abbreviations: LDA: Linear discriminant analysis, ASV: Amplicon sequence variant, NHL: Non-Hodgkin's lymphoma, PIM: exposure to either piperacillin / tazobactam, imipenem / cilastatin, or meropenem within 4 weeks prior to CD19 CAR T-cell infusion, PFS: progression-free survival, OS: overall survival, p: p-value. [Figure 6]Flow diagram of fecal microbiome sample collection. Fifty-one unique patients were collected based on informed consent. Of the 51 patients, one patient did not have enough fecal material for sequencing, and two patients failed during the amplification or quality control steps. Following these exclusions, there were 48 patients in the fecal microbiome cohort. Of these patients, the 16S ribosomal RNA gene was successfully amplified and sequenced with ≥200 reads per sample from 45 patients. Forty-five patients passed quality control measures for metagenomic shotgun sequencing. There were three non-overlapping patients in the 16S and shotgun sequencing cohorts. Thus, there were 48 unique patients in the fecal microbiome cohort. [Figure 7]Association of gut microbiome with clinical response in recipients of CD19 CAR T cells, including subset analysis sites. (A-E) All data reported in this figure are based on 16S rRNA gene sequencing data. (A) Inverse Simpson diversity index of fecal microbiome in baseline fecal samples by sites MSK (n=26) and Penn (n=19) compared to healthy volunteers (n=30) by Wilcoxon rank sum test. The center line is the median, box limits represent upper and lower quartiles, box whiskers indicate 1.5x interquartile range, and dots represent individual data points. (B-C) β diversity was calculated using Bray-Curtis dissimilarity between a reference point defined by the mean of healthy volunteers and each of the 30 samples from healthy volunteers. Healthy volunteers were compared by Wilcoxon rank sum test to 45 baseline patient samples (B) and across centers (MSK n=26, Penn n=19) (C). This healthy volunteer cohort has been investigated in a previous published study. The center line is the median, box limits represent upper and lower quartiles, whiskers indicate 1.5x interquartile range, and dots represent individual data points. (D-E) Patient samples with high (1 standard deviation above the mean) (red) or low (1 standard deviation below the mean) (blue) inverse Simpson diversity index. Coefficients of predicted probability of (C) CR and (D) toxicity at day 100 by inverse Simpson diversity index. Coefficients correspond to the Bayesian models for CR and toxicity at day 100 in Figure 5E, respectively. [Figure 8-1]Impact of antibiotic exposure in patients with non-Hodgkin's lymphoma treated with anti-CD19 CAR T-cell therapy. (A and B) Kaplan-Meier (A) progression-free (PFS) and (B) overall survival (OS) curves by log-rank test in the NHL population (n=137) according to exposure to any antibiotic within 4 weeks prior to CD19 CAR T-cell infusion. Grey lines indicate patients not exposed to antibiotic treatment, and yellow lines indicate patients exposed to antibiotic treatment. (C) Histogram of frequency of any grade CRS and ICANS by Wilcoxon rank-sum test (n=137) in patients with NHL (n=137) according to exposure to any antibiotic within 4 weeks prior to CD19 CAR T-cell infusion. Blue indicates absence of any grade CRS or ICANS, and red indicates presence of any grade CRS or ICANS. Abbreviations: NHL: non-Hodgkin's lymphoma, p: p-value, CRS: cytokine release syndrome, ICANS: immune effector cell-associated neurotoxicity. [Figure 8-2] Impact of antibiotic exposure in patients with non-Hodgkin's lymphoma treated with anti-CD19 CAR T-cell therapy. (A and B) Kaplan-Meier (A) progression-free (PFS) and (B) overall survival (OS) curves by log-rank test in the NHL population (n=137) according to exposure to any antibiotic within 4 weeks prior to CD19 CAR T-cell infusion. Grey lines indicate patients not exposed to antibiotic treatment, and yellow lines indicate patients exposed to antibiotic treatment. (C) Histogram of frequency of any grade CRS and ICANS by Wilcoxon rank-sum test (n=137) in patients with NHL (n=137) according to exposure to any antibiotic within 4 weeks prior to CD19 CAR T-cell infusion. Blue indicates absence of any grade CRS or ICANS, and red indicates presence of any grade CRS or ICANS. Abbreviations: NHL: non-Hodgkin's lymphoma, p: p-value, CRS: cytokine release syndrome, ICANS: immune effector cell-associated neurotoxicity. [Figure 8-3]Impact of antibiotic exposure in patients with non-Hodgkin's lymphoma treated with anti-CD19 CAR T-cell therapy. (A and B) Kaplan-Meier (A) progression-free (PFS) and (B) overall survival (OS) curves by log-rank test in the NHL population (n=137) according to exposure to any antibiotic within 4 weeks prior to CD19 CAR T-cell infusion. Grey lines indicate patients not exposed to antibiotic treatment, and yellow lines indicate patients exposed to antibiotic treatment. (C) Histogram of frequency of any grade CRS and ICANS by Wilcoxon rank-sum test (n=137) in patients with NHL (n=137) according to exposure to any antibiotic within 4 weeks prior to CD19 CAR T-cell infusion. Blue indicates absence of any grade CRS or ICANS, and red indicates presence of any grade CRS or ICANS. Abbreviations: NHL: non-Hodgkin's lymphoma, p: p-value, CRS: cytokine release syndrome, ICANS: immune effector cell-associated neurotoxicity. [Figure 9-1] Comparison of survival analyses of piperacillin / tazobactam exposure compared to cefepime in non-Hodgkin lymphoma patients treated with CD19 CAR T cells. (A and B) Kaplan-Meier curves for (A) progression-free survival (PFS) and (B) overall survival (OS) by log-rank test. Data represent patients from the combined NHL population treated with piperacillin / tazobactam or cefepime within 4 weeks prior to CD19 CAR T cell infusion. Blue lines represent patients exposed to piperacillin / tazobactam (n=18) and green lines represent patients exposed to cefepime (n=12). Points represent data censored at the last time point the patient was known to be alive and progression-free. Shading indicates 95% confidence intervals and checkmarks indicate censored events. P values are shown (log-rank analysis). P values are not stratified by center. Abbreviations: NHL: non-Hodgkin's lymphoma, p: p-value. [Figure 9-2]Comparison of survival analyses of piperacillin / tazobactam exposure compared to cefepime in non-Hodgkin lymphoma patients treated with CD19 CAR T cells. (A and B) Kaplan-Meier curves for (A) progression-free survival (PFS) and (B) overall survival (OS) by log-rank test. Data represent patients from the combined NHL population treated with piperacillin / tazobactam or cefepime within 4 weeks prior to CD19 CAR T cell infusion. Blue lines represent patients exposed to piperacillin / tazobactam (n=18) and green lines represent patients exposed to cefepime (n=12). Points represent data censored at the last time point the patient was known to be alive and progression-free. Shading indicates 95% confidence intervals and checkmarks indicate censored events. P values are shown (log-rank analysis). P values are not stratified by center. Abbreviations: NHL: non-Hodgkin's lymphoma, p: p-value. [Figure 10-1] Comparison of survival analysis of PIM exposure vs. non-PIM exposure in non-Hodgkin lymphoma patients treated with CD19 CAR T cells. (A and B) Kaplan-Meier curves for (A) progression-free survival (PFS) and (B) overall survival (OS) by log-rank test. Data represent patients from the combined NHL population treated with PIM or non-PIM antibiotics within 4 weeks prior to CD19 CAR T cell infusion. Patients who did not receive any antibiotics during the 30 days prior to CAR T cell infusion are excluded from this analysis. Grey line represents patients exposed to PIM antibiotics (n=21) and yellow line represents patients exposed to non-PIM antibiotics (n=60). Points represent data censored at the last time point when the patient was known to be alive and progression-free. Shading indicates 95% confidence intervals and checkmarks indicate censored events. P-values are shown (log-rank analysis). P-values are not stratified by center. Abbreviations: NHL: non-Hodgkin lymphoma, p: p-value [Figure 10-2]Comparison of survival analysis of PIM exposure vs. non-PIM exposure in non-Hodgkin lymphoma patients treated with CD19 CAR T cells. (A and B) Kaplan-Meier curves for (A) progression-free survival (PFS) and (B) overall survival (OS) by log-rank test. Data represent patients from the combined NHL population treated with PIM or non-PIM antibiotics within 4 weeks prior to CD19 CAR T cell infusion. Patients who did not receive any antibiotics during the 30 days prior to CAR T cell infusion are excluded from this analysis. Grey line represents patients exposed to PIM antibiotics (n=21) and yellow line represents patients exposed to non-PIM antibiotics (n=60). Points represent data censored at the last time point when the patient was known to be alive and progression-free. Shading indicates 95% confidence intervals and checkmarks indicate censored events. P-values are shown (log-rank analysis). P-values are not stratified by center. Abbreviations: NHL: non-Hodgkin lymphoma, p: p-value [Figure 11] Timing of fecal sample collection relative to the start of conditioning chemotherapy and CD19 CAR T-cell infusion. 48 patients were evaluated in the fecal microbiome cohort. Of the 48 patients, 14 fecal samples were collected before the start of conditioning chemotherapy, whereas 34 fecal samples were collected after the start of conditioning chemotherapy. All baseline fecal microbiome samples were collected before CD19 CAR T-cell infusion. Red boxes indicate the start of conditioning chemotherapy. Black circles indicate the collection of baseline fecal samples before CAR T-cell infusion. Day 0 indicates the day of CD19 CAR T-cell infusion. [Figure 12] Principal coordinate analysis (PCoA) visualization of beta diversity in fecal samples from CAR T cell patients and healthy volunteers. Fecal microbiome composition of CAR T cell patients and healthy volunteers is shown by PCoA. Composition was assessed using beta diversity calculated by Bray-Curtis dissimilarity. Data are visualized at the genus level. Red dots indicate CAR T cell patients and green dots indicate healthy volunteers. All data reported in this figure are based on 16S rRNA gene sequencing data. [Figure 13] Box plots of relative abundance of selected taxa from LEfSe in CR at day 100. Relative abundance of Bacteroides, Bifidobacterium, Blautia, Faecalibacterium, Longicatena, and Ruminococcus are shown. Data are categorized by patients who did not achieve CR at day 100 (No) and patients who achieved CR at day 100 (Yes). Dots indicate relative abundance baseline fecal samples from CAR T cell patients. p-values were calculated using Wilcoxon rank sum test and p-values were adjusted for multiple hypothesis testing. [Figure 14] Box plot of selected taxa of relative abundance from LEfSe of toxicity. Relative abundance of Bacteroides, Blautia, Faecalibacterium, and Ruminococcus is shown. Data are categorized into patients who did not experience toxicity (no) and patients who experienced toxicity (yes). Dots indicate relative abundance baseline fecal samples from CAR T cell patients. p-values were calculated using Wilcoxon rank sum test and p-values were adjusted for multiple hypothesis testing. [Figure 15] Principal coordinate analysis (PCoA) visualization of pools of 16S sequencing of baseline fecal samples from CAR T cell patients. Compositional diversity of baseline patient samples (n=45) is shown by principal coordinate analysis (PCoA). Dots are colored to indicate sequencing pools (n=13). All data reported in this figure are based on 16S rRNA gene sequencing data. [Figure 16] Correlation between centered log ratios and log10 transformed counts of the five genera. The scatter plot shows the Pearson correlation between centered log ratios and log10 transformed counts of the five genera in the Bayesian model. All data reported in this figure are based on 16S rRNA gene sequencing data. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0032] The present disclosure relates to compositions and methods for identifying subjects who are being considered for or undergoing chimeric antigen receptor (CAR) T-cell therapy and who are likely or unlikely to show cancer survival or toxicity associated with CAR T-cell therapy after CAR T-cell therapy by analyzing the gut microbiome of these subjects before or during CAR T-cell therapy. The present disclosure further provides therapeutic bacteria and methods for improving the chances of cancer survival after CAR T-cell therapy and / or reducing the chances of CAR T-cell therapy-related toxicity in a subject. The present disclosure is based in part on the discovery that the chances of cancer survival or the chances of CAR T-cell toxicity after CAR T-cell therapy are associated with the presence and / or high abundance of certain bacteria. Surprisingly, this association is generalizable across treatment centers and CAR T-cell therapies.
[0033] For clarity of explanation, and not by way of limitation, this section is divided into the following subsections: I. Definition; II. Diagnostic methods; III. Therapeutic bacteria; IV. Pharmaceutical Compositions; V. Treatment method; VI. Kits; and VII. Exemplary Embodiments
[0034] I. Definition The terms used herein generally have their ordinary meaning in the art, within the context of this disclosure and in the specific context in which each term is used. Certain terms are discussed below or elsewhere in the specification to provide additional guidance to the practitioner in describing the compositions and methods of the present disclosure and how to make and use them.
[0035] As used herein, the use of the terms "a" or "an" when used in conjunction with the term "comprising" in the claims and / or this specification may mean "one," but it is also consistent with the meanings of "one or more," "at least one," and "one or more." Furthermore, the terms "having," "including," "containing," and "comprising" are interchangeable, and one of ordinary skill in the art will recognize that these terms are open-ended terms.
[0036] The term "about" or "approximately" means within an acceptable error range for a particular value as determined by one of ordinary skill in the art, which depends in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, "about" can mean within 3 or more than 3 standard deviations, as is customary in the art. Alternatively, "about" can mean a range of up to 20%, preferably up to 10%, more preferably up to 5%, and even more preferably up to 1% of a given value. Alternatively, particularly with respect to biological systems or processes, the term can mean within an order of magnitude, preferably within 5-fold, more preferably within 2-fold of a value.
[0037] An "individual" or "subject" or "patient" herein is a vertebrate, e.g., a human or a non-human animal, e.g., a mammal. Mammals include, but are not limited to, humans, primates, farm animals, sport animals, rodents, and pets. Non-limiting examples of non-human animal subjects include birds, such as poultry, including chickens, turkeys, ducks, and geese; rodents, such as mice, rats, hamsters, and guinea pigs, rabbits, dogs, cats, sheep, pigs, goats, cows, horses, and non-human primates, such as apes and monkeys.
[0038] As used herein, "microbiota" refers to a community of microorganisms living within or on an individual body, both persistently and transiently, including eukaryotes, archaea, bacteria, and viruses (including bacterial viruses (i.e., phages)).
[0039] "Microbiome" refers to the genetic content of the community of microbial organisms that reside in and on the body, both persistently and transiently, including eukaryotes, archaea, bacteria, and viruses (including bacterial viruses (i.e., phages)), where "genetic content" includes genomic DNA, RNA such as microRNA and ribosomal RNA (rRNA), the epigenome, plasmids, and all other types of genetic information.
[0040] The term "isolated," as used herein, may refer to bacteria or other substances or organisms that have been separated from at least some of the components with which they were associated when originally produced (whether in nature or in an experimental environment) and / or when produced, prepared, purified, and / or manufactured. In certain embodiments, isolated bacteria may be separated from at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or more of the other components with which they were originally associated. In certain embodiments, isolated bacteria are greater than about 80%, greater than about 85%, greater than about 90%, greater than about 91%, greater than about 92%, greater than about 93%, greater than about 94%, greater than about 95%, greater than about 96%, greater than about 97%, greater than about 98%, greater than about 99%, or greater than about 99% pure. In certain embodiments, a substance or organism, e.g., bacteria, is "pure" when it is substantially free of other components.
[0041] As used herein, the terms "purified," "to purify," and "purified" may refer to a bacterium or other material that has been separated from at least some of the components with which it was associated when it was first produced or generated (e.g., whether in nature or in an experimental environment), or any time period after its initial production. In certain embodiments, a bacterium or bacterial population may be considered purified if it is isolated, e.g., from a material or environment containing the bacterium or bacterial population, at or after production, and a purified bacterium or bacterial population may contain up to about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or more than about 90% other materials and still be considered "isolated." In certain embodiments, a purified bacterial population is greater than about 80%, greater than about 85%, greater than about 90%, greater than about 91%, greater than about 92%, greater than about 93%, greater than about 94%, greater than about 95%, greater than about 96%, greater than about 97%, greater than about 98%, greater than about 99%, or greater than about 99% pure. In certain embodiments of the bacterial compositions described herein, one or more bacteria present in the composition can be purified independently from one or more other bacteria produced and / or present in the material or environment comprising the bacterial species.
[0042] As used herein, "CAR T cell therapy" refers to the killing of cancer cells using T cells genetically modified to express a chimeric antigen receptor (CAR) that binds to the cancer cells, resulting in activation of the patient's immune system to kill the cancer cells. CAR T cell therapy may be particularly useful in the treatment of acute lymphoblastic leukemia (ALL), non-Hodgkin's lymphoma (NHL), CD19 malignancies, myeloma, or other B-cell-related or hematological malignancies, or in the treatment of solid tumors such as ovarian cancer.
[0043] "CAR T toxicity" is an early response to CAR T cell therapy and includes cytokine release syndrome (CRS) and neurotoxicity. Although CAR T toxicity is often considered an adverse reaction, it is due to T cell activity and is therefore also an indicator of the potential efficacy of CAR T cell therapy.
[0044] "Cytokine release syndrome" or "CRS" is characterized by high fever, myalgia, fatigue, respiratory failure, hemodynamic instability, and capillary leakage accompanied by hypotension, tachycardia, hypoxia, tachypnea, hemophagocytic lymphohistiocytosis / macrophage activation, or other organ toxicity associated with elevated serum cytokine concentrations. Elevated cytokines and related molecules include interferon (IFN)-γ, IL-2, soluble IL-2Rα, IL-6, soluble IL-6R, granulocyte-macrophage colony-stimulating factor (GM-CSF), and other cytokines secreted primarily by monocytes and / or macrophages, such as IL-1, IL-6, IL-8, IL-10, IL-12, tumor necrosis factor (TNF)-α, IFN-α, monocyte chemotactic protein (MCP)-1, macrophage inflammatory protein (MIP) 1α. CRS usually occurs within a few days of administering genetically modified T cells to the patient.
[0045] "Neurotoxicity" associated with CAR T cell therapy is characterized by encephalopathy, headache, delirium, anxiety, tremors, aphasia, decreased level of consciousness, confusion, seizures, or cerebral edema. Neurotoxicity may be associated with elevated serum concentrations of IL-6, IFN-γ, and TNF-α.
[0046] As the term is used herein, an "effective amount" of a substance is an amount sufficient to achieve a beneficial or desired result, including a clinical result, and thus, "effective amount" depends on the context in which it is applied. In certain embodiments, an effective amount of a composition, e.g., a pharmaceutical composition comprising a therapeutic bacterium, as described herein, is an amount sufficient to improve clinical outcomes and / or promote cancer survival. For example, and without limitation, an effective amount of a composition, e.g., a pharmaceutical composition comprising a therapeutic bacterium, as described herein, is an amount sufficient to increase the likelihood of cancer survival by 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, or 99%. In certain embodiments, an effective amount of a composition, as described herein, is an amount sufficient to reduce the likelihood of CAR T cell therapy-related toxicity. In certain embodiments, the reduction in the likelihood of CAR T cell therapy-related toxicity can be a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, or 99% reduction. An effective amount can be administered in one or more administrations.
[0047] As used herein and as is well known in the art, a "treatment" or administration of a "therapeutic agent" is an approach to obtain beneficial or desired results, including clinical results. For purposes of this subject matter, beneficial or desired clinical results include, but are not limited to, an increased likelihood of cancer survival following CAR T cell therapy, a decreased likelihood of CAR T cell-associated toxicity, alleviation or amelioration of one or more signs or symptoms, reduction in the extent of disease, a stabilized (i.e., non-worsening) state of disease, prevention of disease, delay or slowing of disease progression, remission of disease (e.g., cancer remission), and / or alleviation or amelioration of the disease state. The reduction can be a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, or 99% reduction in complications, e.g., toxicity, severity of signs or symptoms. The increase can be a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, or 99% increase in the length of cancer survival. "Treatment" can also mean prolonging survival as compared to expected cancer survival in the absence of treatment. "Treatment" can also refer to increasing the chances of cancer survival and / or decreasing the chances of CAR T cell therapy associated toxicity.
[0048] The terms "prevent," "preventing," and "prevention," as used herein, refer to partially or completely delaying the onset of one or more symptoms, characteristics, or clinical symptoms of cancer, partially or completely delaying the onset of one or more symptoms, characteristics, or symptoms of cancer (including, but not limited to, fatigue or decreased ability to exercise), partially or completely delaying progression from cancer, partially or completely delaying CAR T-cell associated toxicity, and / or reducing the risk of developing pathology associated with cancer.
[0049] "Operational Taxonomic Unit" or "OTU" is used herein to classify bacteria based on sequence similarity and is a cluster of similar sequence variants of 16S rRNA gene sequences. For example, but not by way of limitation, OTU clusters are typically defined by a 97% identity threshold to distinguish bacteria at the genus level.
[0050] As used herein, the term "cluster" or "cluster of related bacteria" can include two or more bacterial species or strains related by rRNA sequence, e.g., 16S rRNA gene (e.g., a variable region of the 16S rRNA gene sequence such as V1, V2, V3, V4 or V5), similarity and / or evolutionary distance.
[0051] "Probiotics," as used herein, are microorganisms or groups of microorganisms that, when consumed, ingested, or otherwise administered to a subject, provide a health benefit to the subject, or are non-pathogenic, e.g., reducing the likelihood of recurrence after cancer treatment. As used herein, the term probiotics can be used, for example, to describe probiotic bacteria, and can include the bacteria described herein as well as other bacteria.
[0052] As used herein, "prebiotics" are substances that promote the growth, proliferation, and / or survival of one or more bacteria or yeasts.As used herein, the term prebiotics can be used to describe dietary supplements that include, for example, plant fiber, or one or more of poorly absorbed complex carbohydrates, oligosaccharides, inulin-type fructans, or arabinoxylans.
[0053] As used herein, "postbiotics" are substances derived from probiotic organisms. As used herein, the term postbiotics can be used to describe, for example, proteins expressed by one or more bacteria, metabolic products of one or more bacteria, or media from the culture of one or more bacterial strains.
[0054] As used herein, the term "microbiota diversity" refers to the number and abundance distribution of different types of microorganisms within a given body habitat, and unless otherwise specified, it is measured in terms of Simpson's inverse number.
[0055] As used herein, the term "microbiota impairment" refers to a loss of diversity in the microbiota composition, or a composition that differs from a baseline, or a composition that differs from that of a healthy individual, or a composition dominated by a single taxon.
[0056] As used herein, the term "cancer survival" refers to the survival of a subject having cancer for a period of time (e.g., at least about 3 months, at least about 6 months, at least about 1 year, at least about 2 years, at least about 3 years, at least about 4 years, at least about 5 years, at least about 6 years, at least about 7 years, at least about 8 years, at least about 9 years, at least about 10 years, at least about 11 years, at least about 12 years, at least about 13 years, at least about 14 years, at least about 15 years or more) following CAR T cell therapy. In certain embodiments, survival or cancer survival can be determined by measuring the percentage of subjects who survive 100 days following CAR T cell therapy.
[0057] As used herein, the term "recombinant cells" refers to cells that have some genetic modification from the original parent cell from which they are derived. Such cells may also be referred to as "genetically engineered cells." Such genetic modification may be the result of the introduction of a heterologous gene (or nucleic acid) for the expression of a gene product, e.g., a recombinant protein.
[0058] II. Diagnostic methods In certain embodiments, the present disclosure provides methods for determining whether a subject with cancer has a likelihood of exhibiting increased or decreased cancer survival following CAR T cell therapy, hi certain embodiments, the present disclosure provides methods for determining whether a subject with cancer has a likelihood of exhibiting increased or decreased CAR T cell associated toxicity.
[0059] In certain embodiments, the disclosed methods include analysis of a subject's microbiome, e.g., a microbiome sample. For example, but not by way of limitation, the disclosed methods include analysis of the level of bacteria or spores thereof in a sample from a subject compared to a reference level of bacteria or spores thereof. In certain embodiments, the disclosed methods include analysis of the level of a bacterial gene in a sample from a subject compared to a reference level of the bacterial gene.
[0060] In certain embodiments, a method of determining whether a subject having cancer has a likelihood of exhibiting increased or decreased cancer survival following CAR T cell therapy comprises determining a level of the bacteria or spores thereof in a sample from the subject, comparing the level of the bacteria or spores thereof to a reference level, and identifying the subject as having an increased likelihood of cancer survival following CAR T cell therapy based on the comparison, or identifying the subject as having a decreased likelihood of cancer survival following CAR T cell therapy based on the comparison. In certain embodiments, the bacteria or spores thereof can be detected prior to treating the subject, for example prior to T cell therapy.
[0061] In certain embodiments, bacteria in a sample from a cancer subject that is analyzed to determine whether a subject with cancer is likely to exhibit increased or decreased cancer survival following CAR T cell therapy are provided in Figure 5, e.g., Figure 5F, Figure 5N, and Figure 5P. For example, and without limitation, bacteria or spores thereof include Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Clostridium methoxybenzovorans, Hungatella effluvii, Coprobacillus cateniformis, Atopobium parvulum, Faecalicoccus acidiformans, Lactococcus lactis, Anaerobacterium chartisolvens, Clostridium innocuum, Bacteroides thetaiotamicron, Ruminococcus bromii, Bifidobacterium breve, Blautia luti, Longicatena caecimuris, Escherichia coli, Faecalibacterium prausnitzii, and any combination thereof.In certain embodiments, the bacteria or spores thereof are Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Clostridium methoxybenzovorans, Hungatella effluvii, Coprobacillus cateniformis, Atopobium parvulum, Faecalicoccus acidiformans, Lactococcus lactis, Anaerobacterium chartisolvens, Clostridium innocuum, Bacteroides thetaiotamicron, Ruminococcus bromii, Bifidobacterium breve, Blautia luti, Longicatena caecimuris, Escherichia coli, Faecalibacterium The present invention also includes a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of S. prausnitzii, and / or combinations thereof.
[0062] In certain embodiments, bacteria in a sample from a cancer subject that is analyzed to determine whether a subject with cancer is likely to exhibit increased or decreased cancer survival following CAR T cell therapy are provided in Figure 5, e.g., Figure 5F, Figure 5N, and Figure 5P. For example, but not by way of limitation, the bacterium or spore thereof is selected from the group consisting of Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Clostridium methoxybenzovorans, Hungatella effluvii, Coprobacillus cateniformis, Atopobium parvulum, Faecalicoccus acidiformans, Lactococcus lactis, Anaerobacterium chartisolvens, Clostridium innocuum, Bacteroides thetaiotamicron, and any combination thereof.In certain embodiments, the bacterium or spores thereof comprise a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Clostridium methoxybenzovorans, Hungatella effluvii, Coprobacillus cateniformis, Atopobium parvulum, Faecalicoccus acidiformans, Lactococcus lactis, Anaerobacterium chartisolvens, Clostridium innocuum, and Bacteroides thetaiotamicron, or any combination thereof.
[0063] In certain embodiments, bacteria in a sample from a cancer subject that is analyzed to determine whether a subject with cancer is likely to exhibit increased or decreased cancer survival following CAR T cell therapy are provided in Figure 5, e.g., Figure 5F, Figure 5N, and Figure 5P. For example, but not by way of limitation, the bacterium or spore thereof is selected from the group consisting of Ruminococcus gnavus, Eubacterium siraeum, Roseburia faecis, Streptococcus thermophilus, Enterorhabdus caecimuris, Lachnospiraceae bacterium2 1 46FAA, Anaeromassilibacillus sp An172, Eubacterium sp CAG251, Gordonibacter pamelaeae, Bifidobacterium animalis, Citrobacter pasteurii, Streptococcus sp A12, Parabacteroides goldsteinii, Coprobacter fastidiosus, Bacteroides finegoldii, Bacteroides thetaiotamicron, and any combination thereof.In certain embodiments, the bacterium or spore thereof comprises a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Ruminococcus gnavus, Eubacterium siraeum, Roseburia faecis, Streptococcus thermophilus, Enterorhabdus caecimuris, Lachnospiraceae bacterium2 1 46FAA, Anaeromassilibacillus sp An172, Eubacterium sp CAG251, Gordonibacter pamelaeae, Bifidobacterium animalis, Citrobacter pasteurii, Streptococcus sp A12, Parabacteroides goldsteinii, Coprobacter fastidiosus, Bacteroides finegoldii, Bacteroides thetaiotamicron, and any combination thereof.
[0064] In certain embodiments, bacteria in a sample of a subject that is analyzed to determine whether a subject with cancer has a likelihood of exhibiting increased or decreased cancer survival following CAR T cell therapy are provided in Figure 5, e.g., Figure 5F, Figure 5N, and Figure 5P. For example, but not limited to, the bacteria or spores thereof are selected from the group consisting of Ruminococcus bromii, Bifidobacterium breve, Blautia luti, Longicatena caecimuris, Escherichia coli, Faecalibacterium prausnitzii, and any combination thereof. In certain embodiments, the bacterium or spore thereof comprises a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Ruminococcus bromii, Bifidobacterium breve, Blautia luti, Longicatena caecimuris, Escherichia coli, Faecalibacterium prausnitzii, or any combination thereof.
[0065] In certain embodiments, the bacterium or a spore thereof is a species from the family Lachnospiraceae, Ruminococcaceae, Bacteroidaceae, Erysipelotrichaceae, Enterobacteriaceae, Bifidobacteriaceae, and / or Veillonellaceae. In certain embodiments, the bacterium or a spore thereof comprises a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to a 16S rRNA gene sequence of a bacterium or a spore thereof that is a species from the family Lachnospiraceae, Ruminococcaceae, Bacteroidaceae, Erysipelotrichaceae, Enterobacteriaceae, Bifidobacteriaceae, and / or Veillonellaceae.
[0066] In certain embodiments, the bacterium or spore thereof is a species from the genera Lactococcus, Coprobacillus, Atopobiaceae, Atopobium, and / or Faecalicoccus. In certain embodiments, the bacterium or spore thereof comprises a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to a 16S rRNA gene sequence of a bacterium or spore thereof that is a species from the genera Lactococcus, Coprobacillus, Atopobiaceae, Atopobium, and / or Faecalicoccus.
[0067] In certain embodiments, the bacterium or spore thereof is a species from the genus Blautia, Bacteroides, Ruminococcus, Bifidobacterium, Erysipelatoclostridium, Longicatena, Escherichia, and / or Faecalibacterium. In certain embodiments, the bacterium or spore thereof comprises a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to a 16S rRNA gene sequence of a bacterium or spore thereof that is a species from the genus Blautia, Bacteroides, Ruminococcus, Bifidobacterium, Erysipelatoclostridium, Longicatena, Escherichia, and / or Faecalibacterium.
[0068] In certain embodiments, the bacteria in a subject's sample that is analyzed to determine whether a subject with cancer has a likelihood of exhibiting increased or decreased cancer survival following CAR T cell therapy is selected from the group consisting of Faecalibacterium prausnitzii, Blautia luti, Escherichia coli, Longicatena caecimuris, Bifidobacterium breve, and Ruminococcus bromii. In certain embodiments, the bacteria or spores thereof comprise a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7%, or 99% sequence identity to the 16S rRNA gene sequence of Faecalibacterium prausnitzii, Blautia luti, Escherichia coli, Longicatena caecimuris, Bifidobacterium breve, and / or Ruminococcus bromii.
[0069] In certain embodiments, the bacteria for determining whether a subject has a likelihood of exhibiting increased or decreased cancer survival are of the family Ruminococcacea. In certain embodiments, the bacteria for determining whether a subject has a likelihood of exhibiting increased or decreased cancer survival are of the genus Ruminococcus, such as Ruminococcus gnavus or Ruminococcus bromii. In certain non-limiting embodiments, the bacteria may include one or more strains of the bacterial species Ruminococcus gnavus, for example, those found in the taxon NCBI:txid33038, or a bacterium that includes a 16S rRNA gene sequence that has at least about 94.5%, 95%, 97%, 98%, 98.7%, or 99% sequence identity with the 16S rRNA gene sequence of Ruminococcus gnavus. In certain non-limiting embodiments, the bacteria may include one or more strains of the bacterial species Ruminococcus bromii, e.g., found within the taxon NCBI:txid 40518, or a bacterium comprising a 16S rRNA gene sequence having at least about 94.5%, 95%, 97%, 98%, 98.7%, or 99% sequence identity to the 16S rRNA gene sequence of Ruminococcus bromii.
[0070] In certain embodiments, the bacterium for determining whether a subject has a likelihood of exhibiting increased or decreased cancer survival is of the genus Blautia, for example, Blautia schinkii or Blautia luti. In certain non-limiting embodiments, the bacterium may include one or more strains of the bacterial species Blautia schinkii, for example, found in taxon NCBI:txid180164, or a bacterium that comprises a 16S rRNA gene sequence with at least about 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity with the 16S rRNA gene sequence of Blautia schinkii. In certain non-limiting embodiments, the bacteria may include one or more strains of the bacterial species Blautia luti, e.g., found within the taxon NCBI:txid89014, or a bacterium comprising a 16S rRNA gene sequence having at least about 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Blautia luti.
[0071] In certain embodiments, the bacteria for determining whether a subject has a likelihood of exhibiting increased or decreased cancer survival are of the family Bacteroidaceae. In certain embodiments, the bacteria for determining whether a subject has a likelihood of exhibiting increased or decreased cancer survival are of the genus Bacteroides, for example, Bacteroides finegoldii. In certain non-limiting embodiments, the bacteria may include one or more strains of the bacterial species Bacteroides finegoldii, for example, those found in the taxon NCBI:txid338188, or a bacterium that includes a 16S rRNA gene sequence that has at least about 94.5%, 95%, 97%, 98%, 98.7%, or 99% sequence identity with the 16S rRNA gene sequence of Bacteroides finegoldii.
[0072] In certain embodiments, the bacterium for determining whether a subject has a likelihood of exhibiting increased or decreased cancer survival is Clostridium glycyrrhizinilyticum. In certain non-limiting embodiments, the bacterium may include one or more strains of the bacterial species Clostridium glycyrrhizinilyticum, for example, found in the taxon NCBI:txid342942, or a bacterium that includes a 16S rRNA gene sequence that has at least about 94.5%, 95%, 97%, 98%, 98.7%, or 99% sequence identity with the 16S rRNA gene sequence of Clostridium glycyrrhizinilyticum.
[0073] In certain embodiments, the bacterium for determining whether a subject has a likelihood of exhibiting increased or decreased cancer survival is Clostridium saccharolyticum. In certain non-limiting embodiments, the bacterium may include one or more strains of bacterial species Clostridium saccharolyticum, for example, found in taxon NCBI:txid84030, or a bacterium that comprises a 16S rRNA gene sequence with at least about 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity with the 16S rRNA gene sequence of Clostridium saccharolyticum.
[0074] In certain embodiments, the bacterium for determining whether a subject has a likelihood of exhibiting increased or decreased cancer survival is Clostridium celerecrescens. In certain non-limiting embodiments, the bacterium may include one or more strains of the bacterial species Clostridium celerecrescens, for example, found in taxon NCBI:txid29354, or a bacterium that comprises a 16S rRNA gene sequence with at least about 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity with the 16S rRNA gene sequence of Clostridium celerecrescens.
[0075] In certain embodiments, the bacterium for determining whether a subject has a likelihood of exhibiting increased or decreased cancer survival is Anaeromassilibacillus senegalensis. In certain non-limiting embodiments, the bacterium may include one or more strains of the bacterial species Anaeromassilibacillus senegalensis, for example, found in the taxon NCBI:txid1673717, or a bacterium that includes a 16S rRNA gene sequence that has at least about 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity with the 16S rRNA gene sequence of Anaeromassilibacillus senegalensis.
[0076] In certain embodiments, the bacterium for determining whether a subject has a likelihood of exhibiting increased or decreased cancer survival is Clostridium methoxybenzovorans. In certain non-limiting embodiments, the bacterium may include one or more strains of the bacterial species Clostridium methoxybenzovorans, for example, found in taxon NCBI:txid81424, or a bacterium that comprises a 16S rRNA gene sequence that has at least about 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity with the 16S rRNA gene sequence of Clostridium methoxybenzovorans.
[0077] In certain embodiments, the bacterium for determining whether a subject has a likelihood of exhibiting increased or decreased cancer survival is Hungatella effluvii. In certain non-limiting embodiments, the bacterium may include one or more strains of the bacterial species Hungatella effluvii, for example, found in the taxon NCBI:txid1096246, or a bacterium that comprises a 16S rRNA gene sequence that has at least about 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity with the 16S rRNA gene sequence of Hungatella effluvii.
[0078] In certain embodiments, the bacterium for determining whether a subject has a likelihood of exhibiting increased or decreased cancer survival is of the genus Coprobacillus, for example, Coprobacillus cateniformis. In certain non-limiting embodiments, the bacterium may include one or more strains of the bacterial species Coprobacillus cateniformis, for example, found in the taxon NCBI:txid100884, or a bacterium that includes a 16S rRNA gene sequence that has at least about 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity with the 16S rRNA gene sequence of Coprobacillus cateniformis.
[0079] In certain embodiments, the bacteria for determining whether a subject has a likelihood of exhibiting increased or decreased cancer survival are of the genus Atopobium, such as Atopobium parvulum. In certain non-limiting embodiments, the bacteria may include one or more strains of the bacterial species Atopobium parvulum, such as those found in the taxon NCBI:txid1382, or a bacterium that includes a 16S rRNA gene sequence that has at least about 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity with the 16S rRNA gene sequence of Atopobium parvulum.
[0080] In certain embodiments, the bacteria for determining whether a subject has a likelihood of exhibiting increased or decreased cancer survival are of the genus Lactococcus, such as Lactococcus lactis. In certain non-limiting embodiments, the bacteria may include one or more strains of the bacterial species Lactococcus lactis, such as those found in the taxon NCBI:txid1358, or a bacterium that includes a 16S rRNA gene sequence that has at least about 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity with the 16S rRNA gene sequence of Lactococcus lactis.
[0081] In certain embodiments, the bacterium for determining whether a subject has a likelihood of exhibiting increased or decreased cancer survival is of the genus Faecalicoccus, such as Faecalicoccus acidiformans. In certain non-limiting embodiments, the bacterium may include one or more strains of the bacterial species Faecalicoccus acidiformans, for example, those found within the taxon NCBI:txid915173, or a bacterium that includes a 16S rRNA gene sequence having at least about 94.5%, 95%, 97%, 98%, 98.7%, or 99% sequence identity to the 16S rRNA gene sequence of Faecalicoccus acidiformans.
[0082] In certain embodiments, the bacterium for determining whether a subject has a likelihood of exhibiting increased or decreased cancer survival is of the genus Faecalibacterium, for example, Faecalibacterium prausnitzii. In certain non-limiting embodiments, the bacterium may include one or more strains of the bacterial species Faecalibacterium prausnitzii, for example, those found in the taxon NCBI:txid853, or a bacterium that includes a 16S rRNA gene sequence that has at least about 94.5%, 95%, 97%, 98%, 98.7%, or 99% sequence identity with the 16S rRNA gene sequence of Faecalibacterium prausnitzii.
[0083] In certain embodiments, the bacterium for determining whether a subject has a likelihood of exhibiting increased or decreased cancer survival is of the genus Longicatena, such as Longicatena caecimuris. In certain non-limiting embodiments, the bacterium may include one or more strains of the bacterial species Longicatena caecimuris, such as those found in the taxon NCBI:txid1796635, or a bacterium that includes a 16S rRNA gene sequence that has at least about 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity with the 16S rRNA gene sequence of Longicatena caecimuris.
[0084] In certain embodiments, the bacterium for determining whether a subject has a likelihood of showing increased or decreased cancer survival is of the Bifidobacteriacea family. In certain embodiments, the bacterium for determining whether a subject has a likelihood of showing increased or decreased cancer survival is of the Bifidobacterium genus, for example, Bifidobacterium breve. In certain non-limiting embodiments, the bacterium may include one or more strains of the bacterial species Bifidobacterium breve, for example, found in taxon NCBI:txid1685, or a bacterium that comprises a 16S rRNA gene sequence with at least about 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity with the 16S rRNA gene sequence of Bifidobacterium breve.
[0085] In certain embodiments, the bacteria for determining whether a subject has a likelihood of exhibiting increased or decreased cancer survival is of the Escherichia genus, e.g., Escherichia coli. In certain non-limiting embodiments, the bacteria may include one or more strains of the bacterial species Escherichia coli, e.g., found in the taxon NCBI:txid562, or a bacterium that includes a 16S rRNA gene sequence that has at least about 94.5%, 95%, 97%, 98%, 98.7%, or 99% sequence identity with the 16S rRNA gene sequence of Escherichia coli.
[0086] In certain embodiments, the bacterium for determining whether a subject has a likelihood of exhibiting increased or decreased cancer survival is Anaerobacterium chartisolvens. In certain non-limiting embodiments, the bacterium may include one or more strains of the bacterial species Anaerobacterium chartisolvens, for example, found in the taxon NCBI:txid1297424, or a bacterium that includes a 16S rRNA gene sequence that has at least about 94.5%, 95%, 97%, 98%, 98.7%, or 99% sequence identity with the 16S rRNA gene sequence of Anaerobacterium chartisolvens.
[0087] In certain embodiments, the bacteria for determining whether a subject has a likelihood of exhibiting increased or decreased cancer survival are of the genus Atopobiaceae. In certain non-limiting embodiments, the one or more bacteria can include, for example, one or more species from the bacterial genus Atopobiaceae found within the taxon NCBI:txid 1643824.
[0088] In certain embodiments, the bacteria for determining whether a subject has a likelihood of exhibiting increased or decreased cancer survival are of the family Erysipelotrichaceae. In certain embodiments, the bacteria for determining whether a subject has a likelihood of exhibiting increased or decreased cancer survival are of the genus Erysipelatoclostridium. In certain non-limiting embodiments, the one or more bacteria may include, for example, one or more species from the genus Erysipelatoclostridium bacteria found within the taxon NCBI:txid1505663.
[0089] In certain embodiments, the bacterium for determining whether a subject has a likelihood of exhibiting increased or decreased cancer survival is Clostridium innocuum. In certain non-limiting embodiments, the bacterium may include one or more strains of the bacterial species Clostridium innocuum, for example, found in taxon NCBI:txid1522, or a bacterium that includes a 16S rRNA gene sequence that has at least about 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity with the 16S rRNA gene sequence of Clostridium innocuum.
[0090] In certain embodiments, the bacteria for determining whether a subject has a likelihood of exhibiting increased or decreased cancer survival are of the family Veillonellaceae. In certain non-limiting embodiments, the one or more bacteria can include, for example, one or more species from the bacterial family Veillonellaceae found within the taxon NCBI:txid31977.
[0091] In certain embodiments, the bacteria for determining whether a subject has a likelihood of exhibiting increased or decreased cancer survival is of the genus Bacteroides, such as Bacteroides thetaiotamicron. In certain non-limiting embodiments, the bacteria can include one or more strains of the bacterial species Bacteroides thetaiotaomicron, such as those found within the taxon NCBI:txid818, or a bacterium that includes a 16S rRNA gene sequence that has at least about 94.5%, 95%, 97%, 98%, 98.7%, or 99% sequence identity to the 16S rRNA gene sequence of Bacteroides thetaiotaomicron.
[0092] In certain embodiments, the bacteria for determining whether a subject has a likelihood of exhibiting increased or decreased cancer survival are of the family Enterobacteriaceae. In certain non-limiting embodiments, the bacteria comprises a 16S rRNA gene sequence having at least about 94.5%, 95%, 97%, 98%, 98.7%, or 99% sequence identity to a 16S rRNA gene sequence of a bacterium of the family Enterobacteriaceae.
[0093] In certain embodiments, the bacteria for determining whether a subject has a likelihood of exhibiting increased or decreased cancer survival are of the family Lachnospiraceae. In certain non-limiting embodiments, the bacteria comprises a 16S rRNA gene sequence having at least about 94.5%, 95%, 97%, 98%, 98.7%, or 99% sequence identity to a 16S rRNA gene sequence of a bacterium of the family Lachnospiraceae.
[0094] In certain embodiments, the methods of the present disclosure include identifying a subject as having an increased likelihood of cancer survival if the level of a bacteria identified as associated with increased day 100 CR in Figure 5, e.g., Figures 5F, 5N, and 5P, such as Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Clostridium methoxybenzovorans, Faecalibacterium prausnitzii, Blautia luti, Escherichia coli, Longicatena caecimuris, Bifidobacterium breve, and / or Ruminococcus bromii, is higher in the subject's sample than the reference bacterial level.In certain embodiments, the methods of the disclosure provide for the detection of bacteria that are identified as associated with increased day 100 CR in FIG. 5, e.g., FIG. 5F, FIG. 5N, and FIG. 5P, or that contain a 16S rRNA gene that has at least 94.5, 95%, 97%, 98, 98.7%, or 99% sequence identity to a 16S rRNA gene of a bacteria identified as associated with increased day 100 CR in FIG. 5, e.g., FIG. 5F, FIG. 5N, and FIG. 5P, Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Clostridium methoxybenzovorans, Faecalibacterium prausnitzii, Blautia luti, Escherichia coli, Longicatena The method includes identifying the subject as having an increased likelihood of cancer survival if the level of B. caecimuris, Bifidobacterium breve, and / or Ruminococcus bromii is higher in the subject's sample than the reference bacterial level.
[0095] In certain embodiments, the methods of the present disclosure include identifying a subject as having an increased likelihood of cancer survival if the level of a bacterium identified as associated with increased day 100 CR in Figure 5, e.g., Figure 5F, Figure 5N, and Figure 5P, such as Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, and / or Clostridium methoxybenzovorans, is higher in the subject's sample than the reference bacterial level. For example, but not limited to, a subject is identified as having an increased likelihood of cancer survival if the level of Ruminococcus gnavus or spores thereof is higher in the subject's sample than the reference bacterial level. In certain embodiments, the reference bacterial level is the level of the bacterium or spores thereof from a subject treated with CAR T cell therapy and exhibiting cancer survival.
[0096] In certain embodiments, the method of the present disclosure includes identifying a subject as having an increased likelihood of cancer survival if the level of bacteria identified as associated with increased 100-day CR in Figure 5, e.g., Figure 5F, Figure 5N, and Figure 5P, such as Faecalibacterium prausnitzii, Blautia luti, Escherichia coli, Longicatena caecimuris, Bifidobacterium breve, and / or Ruminococcus bromii, is higher in the subject's sample than the reference bacterial level. For example, but not limited to, a subject is identified as having an increased likelihood of cancer survival if the level of Faecalibacterium prausnitzii or its spores is higher in the subject's sample than the reference bacterial level. In certain embodiments, the reference bacterial level is the level of bacteria or its spores from a subject treated with CAR T cell therapy and exhibiting cancer survival.
[0097] In certain embodiments, the methods of the present disclosure include identifying a subject as having a decreased likelihood of cancer survival if the level of a bacterium identified as associated with increased day 100 CR in Figure 5, e.g., Figures 5F, 5N, and 5P, or a bacterium comprising a 16S rRNA gene sequence having at least 94.5, 95%, 97%, 98, 98.7%, or 99% sequence identity to a 16S rRNA gene of a bacterium identified as associated with increased day 100 CR in Figure 5, e.g., Figures 5F, 5N, and 5P, is higher in the subject's sample than a reference bacterial level. In certain embodiments, the methods of the present disclosure include identifying a subject as having a decreased likelihood of cancer survival if the level of a bacterium identified as associated with increased day 100 CR in Figure 5, e.g., Figure 5F, Figure 5N, and Figure 5P, e.g., Hungatella effluvii, Coprobacillus cateniformis, Atopobium parvulum, Faecalicoccus acidiformans, Coprobacillus, Lactococcus lactis, Anaerobacterium chartisolvens, Clostridium innocuum, and / or Bacteroides thetaiotaomicron, is higher in the subject's sample than the reference bacterial level. For example, but not limited to, a subject is identified as having a decreased likelihood of cancer survival if the level of Bacteroides thetaiotaomicron or spores thereof in the subject's sample is higher than the reference bacterial level in the subject's sample. In certain embodiments, the reference bacterial level is the level of bacteria or spores thereof from a subject who was treated with CAR T cell therapy and did not demonstrate cancer survival.
[0098] In certain embodiments, the methods of the present disclosure include identifying a subject as having a decreased likelihood of cancer survival if the level of a bacterium identified as associated with increased day 100 CR in Figure 5, e.g., Figures 5F, 5N, and 5P, or a bacterium comprising a 16S rRNA gene sequence having at least 94.5, 95%, 97%, 98, 98.7%, or 99% sequence identity to a 16S rRNA gene of a bacterium identified as associated with increased day 100 CR in Figure 5, e.g., Figures 5F, 5N, and 5P, is higher in the subject's sample than a reference bacterial level. In certain embodiments, the methods of the present disclosure include identifying a subject as having a decreased likelihood of cancer survival if the level of a bacterial species of a genus identified as associated with increased day 100 CR in Figure 5, e.g., Figures 5F, 5N, and 5P, e.g., Lactococcus, Coprobacillus, Atopobiaceae, Atopobium, and / or Faecalicoccus, is higher in the subject's sample than the reference bacterial level.
[0099] In certain embodiments, the methods of the present disclosure include identifying a subject as having a decreased likelihood of cancer survival if the level of a bacterial species of a family identified as associated with increased day 100 CR in Figure 5, e.g., Figures 5F, 5N, and 5P, e.g., the Veillonellaceae family, is higher in the subject's sample than a reference bacterial level.
[0100] In certain embodiments, cancer survival refers to the survival of a subject at least about 100 days after cancer treatment (e.g., CAR T cell therapy). In certain embodiments, cancer survival refers to the survival of a subject at least 3 months, at least 6 months, at least about 1 year, at least about 2 years, at least about 3 years, at least about 4 years, at least about 5 years, at least about 6 years, at least about 7 years, at least about 8 years, at least about 9 years, at least about 10 years, at least about 15 years, at least about 20 years, or more after cancer treatment. In certain embodiments, cancer survival refers to the survival of a subject at least about 100 days after cancer treatment, e.g., CAR T cell therapy.
[0101] In certain embodiments, a method of determining whether a subject having cancer has a likelihood of exhibiting increased cancer survival following CAR T cell therapy comprises determining a level of a bacterial gene in a sample from the subject, comparing the level of the bacterial gene to a reference level of the bacterial gene, and identifying the subject as having a likelihood of exhibiting increased cancer survival following CAR T cell therapy based on the comparison.
[0102] In certain embodiments, non-limiting examples of bacterial genes associated with cancer survival likelihood are provided in Figure 5, e.g., Figure 5L and Figure 5Q. In certain embodiments, the bacterial genes determined in the subject's sample include purine nucleoside degradation (e.g., PWY1296), chorismate biosynthesis (e.g., ARO PWY), antigen building block biosynthesis (e.g., O Antigen Pathway) Calvin Benson Bassam Cycle (e.g., Calvin PWY), peptidoglycan biosynthesis IV Enterococcus faecium (e.g., PWY6471), adenine and adenosine salvage III (e.g., PWY6609), aromatic amino acid biosynthesis superpathway (e.g., COMPLETE ARO PWY), UDP N-acetylglucosamine biosynthesis (e.g., UDP NAGSYN PWY), chorismate biosynthesis from 3-dehydroguinate (e.g., PWY6163), L-methionine biosynthesis III (e.g., HSERMETANA PWY), and / or methylglucosamine biosynthesis (e.g., HSERMETANA PWY). PWY), peptidoglycan biosynthesis V beta-lactam resistance (e.g., PWY6470), pyrimidine ribonucleoside salvage superpathway (e.g., PWY7196), heterolactic acid fermentation (e.g., P122PWY), allantoin degradation glyoxylate II (e.g., PWY5692), anaerobic energy metabolism (e.g., PWY7384), allantoin degradation superpathway (e.g., URDEGR PWY), anaerobic energy metabolism superpathway (e.g., PWY7389), unsaturated fatty acid biosynthesis superpathway (e.g., PWY6284), enterobactin biosynthesis (e.g., ENTBACSYN PWY), NAD salvage pathway III (e.g., NAD Biosynthesis II), fatty acid biosynthesis superpathway (e.g., PWY6285), pyrimidine deoxyribonucleotide biosynthesis from CTP (e.g., PWY7210), mycolate biosynthesis superpathway (e.g., PWY6113), NAD NADH phosphorylation and dephosphorylation (e.g., PWY5083), palmitic acid biosynthesis II bacteria and plants (e.g., PWY5971), biotin biosynthesis I (e.g., BIOTIN BIOSYNTHESISPWY), CMP3-deoxy-D-manno-octulosonate biosynthesis (e.g., PWY1269), lipid IVA biosynthesis (e.g., NAGLIPASYN), CMP-regionaminate biosynthesis (e.g., PWY6749), and / or Pre Q0 biosynthesis (e.g., PWY6703). In certain embodiments, the bacterial gene determined in the subject's sample is selected from the group consisting of genes involved in aromatic amino acid biosynthesis (e.g., chorismate biosynthesis E. coli and aromatic amino acid biosynthesis superpathway (e.g., COMPLETE ARO PWY)), and / or peptidoglycan biosynthesis (peptidoglycan biosynthesis IV Enterococcus faecium (e.g., PWY6471) and peptidoglycan biosynthesis V beta-lactam resistance (e.g., PWY6470)). In certain embodiments, the bacterial gene determined in the subject's sample is a gene involved in peptidoglycan biosynthesis (peptidoglycan biosynthesis IV Enterococcus faecium (e.g., PWY6471)). In certain embodiments, the bacterial gene determined in the subject's sample is a gene involved in CMP-legionaminate biosynthesis (e.g., PWY6749) and / or Pre Q0 biosynthesis (e.g., PWY6703).
[0103] In certain embodiments, the bacterial genes identified as associated with increased day 100 CR in FIG. 5, e.g., in FIG. 5L and FIG. 5Q, e.g., purine nucleoside degradation (e.g., PWY1296), chorismate biosynthesis (e.g., ARO PWY), antigen building block biosynthesis (e.g., O Antigen Pathway), Calvin Benson Bassham cycle (e.g., Calvin PWY), peptidoglycan biosynthesis IV (e.g., PWY6471), adenine and adenosine salvage III (e.g., PWY6609), aromatic amino acid biosynthesis superpathway (e.g., COMPLETE ARO PWY), UDP N-acetylglucosamine biosynthesis (e.g., UDP NAGSYN PWY), chorismate biosynthesis from 3-dehydrogenate (e.g., PWY6163), L-methionine biosynthesis III (e.g., HSERMETANA PWY), and the like are also included. A subject is identified as having an increased chance of survival of cancer survival if the level of a bacterial gene involved in the superpathway of pyrimidine ribonucleoside salvage (e.g., PWY), peptidoglycan biosynthesis V beta-lactam resistance (e.g., PWY6470), and / or pyrimidine ribonucleoside salvage (e.g., PWY7196) is higher in the subject's sample than the reference bacterial gene level. For example, but not limited to, a subject is identified as having an increased chance of survival of cancer survival if the level of one or more genes involved in aromatic amino acid biosynthesis (e.g., chorismate biosynthesis and aromatic amino acid biosynthesis superpathway (COMPLETE ARO PWY)), peptidoglycan biosynthesis (peptidoglycan biosynthesis IV (PWY6471) and / or peptidoglycan biosynthesis V beta-lactam resistance (PWY6470)) is higher in the subject's sample than the reference bacterial gene level. In certain embodiments, the reference bacterial gene level is the bacterial gene level from a subject who has been treated with CAR T cell therapy and has demonstrated cancer survival. In certain embodiments, a subject is identified as having an increased chance of cancer survival if the level of one or more genes involved in peptidoglycan biosynthesis (e.g., peptidoglycan biosynthesis IV (PWY6471)) is higher in the subject's sample than a reference level of the bacterial gene.
[0104] In certain embodiments, bacterial genes identified in FIG. 5, e.g., in FIG. 5L and FIG. 5Q, as being associated with reduced CR at day 100, such as heterofermentation (e.g., P122PWY), allantoin degradation glyoxylate II (e.g., PWY5692), anaerobic energy metabolism (e.g., PWY7384), superpathway of allantoin degradation (e.g., URDEGR PWY), superpathway of anaerobic energy metabolism (e.g., PWY7389), superpathway of unsaturated fatty acid biosynthesis (PWY6284), enterobactin biosynthesis (e.g., ENTBACSYN PWY), NAD salvage pathway III (e.g., NAD Biosynthesis Pathway ... II), fatty acid biosynthesis superpathway (e.g., PWY6285), pyrimidine deoxyribonucleotide biosynthesis from CTP (e.g., PWY7210), mycolate biosynthesis superpathway (e.g., PWY6113), NAD NADH phosphorylation and dephosphorylation (e.g., PWY 5083), palmitic acid biosynthesis II bacteria and plants (e.g., PWY5971), biotin synthesis I (e.g., BIOTIN BIOSYNTHESIS PWY), CMP 3-deoxy-D-manno-octulosonate biosynthesis (e.g., PWY1269), CMP-regionaminate biosynthesis (e.g., PWY6749), Pre If the level of the bacterial gene involved in Q0 biosynthesis (e.g., PWY6703) and / or lipid IVA biosynthesis (e.g., NAGLIPASYN) is higher than the bacterial gene level in the subject's sample, the subject is identified as having a decreased chance of cancer survival. For example, but not limited to, if the level of one or more genes involved in lipid IVA biosynthesis is higher than the reference level of bacterial genes in the subject's sample, the subject is identified as having a decreased chance of cancer survival. In certain embodiments, if the level of one or more genes involved in CMP-regionaminate biosynthesis (e.g., PWY6749) and / or Pre Q0 biosynthesis (e.g., PWY6703) is higher than the reference level of bacterial genes in the subject's sample, the subject is identified as having a decreased chance of cancer survival.In certain embodiments, the reference level of the bacterial gene is the level of the bacterial gene from a subject who was treated with CAR T cell therapy and did not exhibit cancer survival.
[0105] In certain embodiments, the method of determining whether a subject having cancer has a likelihood of exhibiting increased or decreased cancer survival following CAR T cell therapy comprises determining whether the subject has been administered an antibiotic prior to CAR T cell therapy. In certain embodiments, the antibiotic is administered less than about 8 weeks, less than about 7 weeks, less than about 6 weeks, less than about 5 weeks, less than about 4 weeks, less than about 3 weeks, less than about 2 weeks, or less than about 1 week prior to CAR T cell therapy. In certain embodiments, the antibiotic is administered less than about 4 weeks prior to CAR T cell therapy. In certain embodiments, the antibiotic is administered about 4 weeks prior to CAR T cell therapy.
[0106] In certain embodiments, a subject is identified as having a decreased chance of cancer survival after CAR T cell therapy if the subject is administered piperacillin-tazobactam, imipenem-cilastatin, meropenem, or a combination thereof prior to CAR T cell therapy. In certain embodiments, a subject with a B cell malignancy is identified as having a decreased chance of cancer survival after CAR T cell therapy if the subject is administered piperacillin-tazobactam, imipenem-cilastatin, meropenem, or a combination thereof prior to CAR T cell therapy. In certain embodiments, a subject with NHL or ALL is identified as having a decreased chance of cancer survival after CAR T cell therapy if the subject is administered piperacillin-tazobactam, imipenem-cilastatin, meropenem, or a combination thereof prior to CAR T cell therapy. In certain embodiments, a subject is identified as having a decreased likelihood of cancer survival after CAR T cell therapy if the subject has been administered an antibiotic targeted obligate anaerobe prior to CAR T cell therapy.
[0107] The present disclosure further provides a method of identifying a subject as having an increased or decreased potential for CAR T cell-associated toxicity. For example, but not limited to, CAR T cell-associated toxicity is cytokine release syndrome or neurotoxicity. In certain embodiments, the method of identifying a subject as having an increased or decreased potential for CAR T cell-associated toxicity comprises determining a level of bacteria or spores thereof in a sample from the subject, comparing the level of bacteria or spores thereof to a reference level, and identifying the subject as having an increased or decreased potential for CAR T cell-associated toxicity based on the comparison.
[0108] In certain embodiments, the bacteria or spores thereof in a subject's sample that are analyzed to determine whether the subject has an increased or decreased potential for CAR T cell-associated toxicity are provided in Figure 5, e.g., Figures 5G and 5O. For example, but not limited to, the bacteria or spores thereof in a sample of a subject that are analyzed to determine whether a subject has a potential for increased CAR T cell-associated toxicity or a potential for decreased CAR T cell-associated toxicity can be selected from the group consisting of Streptococcus salivarius, Oscillibacter ruminantium, Eubacterium ramulus, Streptococcus gordonii, Caproiciproducens galactitolivorans, Clostridium hylemonae, Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, Schaalia odontolytica, Lactobacillus salivarius, and combinations thereof, or combinations thereof, such as Streptococcus salivarius, Oscillibacter ruminantium, Eubacterium ramulus, Streptococcus gordonii, Caproiciproducens galactitolivorans, Clostridium hylemonae, Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, Schaalia odontolytica, Lactobacillus salivarius, and combinations thereof, or combinations thereof, such as Streptococcus salivarius, Oscillibacter thermophila, Agathobaculum butyriciproducens, Schaalia odontolytica, and / or Lactobacillus salivarius.
[0109] In certain embodiments, the bacteria for determining whether a subject has the potential for reduced CAR T cell-associated toxicity are bacteria from the genus Blautia, Ruminococcus, Bacteroides, and / or Faecalibacterium or that contain a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7%, or 99% sequence identity to a 16S rRNA gene sequence of the genus Blautia, Ruminococcus, Bacteroides, and / or Faecalibacterium. In certain embodiments, the bacterium for determining whether a subject has the potential for reduced CAR T cell-associated toxicity is Faecalibacterium prausnitzii and / or Blautia luti, or is a bacterium that comprises a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Faecalibacterium prausnitzii and / or Blautia luti.
[0110] In certain embodiments, the bacteria for determining whether a subject has the potential for reduced CAR T cell-associated toxicity are bacteria from the families Lachnospiraceae, Ruminococcacea, Bacteroidaceae, Veillonellaceae, Erysipelotrichaceae, and / or Enterobacteriaceae or that contain a 16S rRNA gene sequence with at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to a 16S rRNA gene sequence of the families Lachnospiraceae, Ruminococcacea, Bacteroidaceae, Veillonellaceae, Erysipelotrichaceae, and / or Enterobacteriaceae.
[0111] In certain embodiments, the bacterium for determining whether a subject has increased or decreased CAR T cell-associated toxicity potential is Streptococcus salivarius. In certain non-limiting embodiments, the bacterium may include one or more strains of the bacterial species Streptococcus salivarius, for example, found within the taxon NCBI:txid1304, or a bacterium that includes a 16S rRNA gene sequence having at least about 94.5%, 95%, 97%, 98%, 98.7%, or 99% sequence identity to the 16S rRNA gene sequence of Streptococcus salivarius.
[0112] In certain embodiments, the bacterium for determining whether a subject has increased or decreased CAR T cell-associated toxicity potential is Oscillibacter ruminantium. In certain non-limiting embodiments, the bacterium may include one or more strains of the bacterial species Oscillibacter ruminantium, for example, found within the taxon NCBI:txid1263547, or a bacterium that includes a 16S rRNA gene sequence having at least about 94.5%, 95%, 97%, 98%, 98.7%, or 99% sequence identity to the 16S rRNA gene sequence of Oscillibacter ruminantium.
[0113] In certain embodiments, the bacterium for determining whether a subject has increased or decreased CAR T cell-associated toxicity potential is Eubacterium ramulus. In certain non-limiting embodiments, the bacterium may include one or more strains of the bacterial species Eubacterium ramulus, for example, found within the taxon NCBI:txid39490, or a bacterium that includes a 16S rRNA gene sequence having at least about 94.5%, 95%, 97%, 98%, 98.7%, or 99% sequence identity to the 16S rRNA gene sequence of Eubacterium ramulus.
[0114] In certain embodiments, the bacterium for determining whether a subject has a potential for increased or decreased CAR T cell-associated toxicity is Streptococcus gordonii. In certain non-limiting embodiments, the bacterium may include one or more strains of the bacterial species Streptococcus gordonii found, for example, within the taxon NCBI:txid1302, or a bacterium that includes a 16S rRNA gene sequence having at least about 94.5%, 95%, 97%, 98%, 98.7%, or 99% sequence identity to the 16S rRNA gene sequence of Streptococcus gordonii.
[0115] In certain embodiments, the bacterium for determining whether a subject has increased or decreased CAR T cell-associated toxicity potential is Caproiciproducens galactitolivorans. In certain non-limiting embodiments, the bacterium may include one or more strains of the bacterial species Caproiciproducens galactitolivorans, for example, found within the taxon NCBI:txid642589, or a bacterium that includes a 16S rRNA gene sequence having at least about 94.5%, 95%, 97%, 98%, 98.7%, or 99% sequence identity to the 16S rRNA gene sequence of Caproiciproducens galactitolivorans.
[0116] In certain embodiments, the bacterium for determining whether a subject has increased or decreased CAR T cell-associated toxicity potential is Clostridium hylemonae. In certain non-limiting embodiments, the bacterium may include one or more strains of the bacterial species Clostridium hylemonae, for example, found within the taxon NCBI:txid89153, or a bacterium that includes a 16S rRNA gene sequence having at least about 94.5%, 95%, 97%, 98%, 98.7%, or 99% sequence identity to the 16S rRNA gene sequence of Clostridium hylemonae.
[0117] In certain embodiments, the bacterium for determining whether a subject has increased or decreased CAR T cell-associated toxicity potential is Streptococcus oralis. In certain non-limiting embodiments, the bacterium may include one or more strains of the bacterial species Streptococcus oralis found, for example, within the taxon NCBI:txid1303, or a bacterium that includes a 16S rRNA gene sequence having at least about 94.5%, 95%, 97%, 98%, 98.7%, or 99% sequence identity to the 16S rRNA gene sequence of Streptococcus oralis.
[0118] In certain embodiments, the bacterium for determining whether a subject has increased or decreased CAR T cell-associated toxicity potential is Lutispora thermophila. In certain non-limiting embodiments, the bacterium may include one or more strains of the bacterial species Lutispora thermophila, for example, found within the taxon NCBI:txid288966, or a bacterium that includes a 16S rRNA gene sequence having at least about 94.5%, 95%, 97%, 98%, 98.7%, or 99% sequence identity to the 16S rRNA gene sequence of Lutispora thermophila.
[0119] In certain embodiments, the bacterium for determining whether a subject has increased or decreased CAR T cell-associated toxicity potential is Agathobaculum butyriciproducens. In certain non-limiting embodiments, the bacterium may include one or more strains of the bacterial species Agathobaculum butyriciproducens found, for example, within the taxon NCBI:txid1628085, or a bacterium that includes a 16S rRNA gene sequence having at least about 94.5%, 95%, 97%, 98%, 98.7%, or 99% sequence identity to the 16S rRNA gene sequence of Agathobaculum butyriciproducens.
[0120] In certain embodiments, the bacterium for determining whether a subject has an increased or decreased potential for CAR T cell-associated toxicity is Schaalia odontolytica. In certain non-limiting embodiments, the bacterium may include one or more strains of the bacterial species Schaalia odontolytica, for example, found within the taxon NCBI:txid1660, or a bacterium that includes a 16S rRNA gene sequence having at least about 94.5%, 95%, 97%, 98%, 98.7%, or 99% sequence identity to the 16S rRNA gene sequence of Schaalia odontolytica.
[0121] In certain embodiments, the bacterium for determining whether a subject has increased or decreased CAR T cell-associated toxicity potential is Lactobacillus salivarius. In certain non-limiting embodiments, the bacterium may include one or more strains of the bacterial species Lactobacillus salivarius, for example, found within the taxon NCBI:txid1624, or a bacterium that includes a 16S rRNA gene sequence having at least about 94.5%, 95%, 97%, 98%, 98.7%, or 99% sequence identity to the 16S rRNA gene sequence of Lactobacillus salivarius.
[0122] In certain embodiments, a subject is identified as having a potential for increased CAR T cell-associated toxicity if the level of a bacterium identified as associated with increased toxicity potential in Figure 5, e.g., Figures 5G and 5O, in the subject's sample is higher than the reference level of the bacterium or its spores, e.g., Streptococcus salivarius, Oscillibacter ruminantium, Eubacterium ramulus, Streptococcus gordonii, Caproiciproducens galactitolivorans, and / or Clostridium hylemonae. For example, but not limited to, a subject is identified as having a potential for increased CAR T cell-associated toxicity if the level of Streptococcus salivarius and / or Oscillibacter ruminantium is higher in the subject's sample than the reference bacterial level in the subject's sample. In certain embodiments, the reference bacterial level is the level of the bacterium or its spores from a subject treated with CAR T cell therapy and exhibiting CAR T cell-associated toxicity.
[0123] In certain embodiments, a subject is identified as having a potential for reduced CAR T cell-associated toxicity if the level of a bacterium identified as associated with reduced toxicity potential in Figure 5, e.g., Figures 5G and 5O, in the subject's sample is higher than the reference level of the bacterium or its spores, e.g., Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, Lactobacillus salivarius, and / or Schaalia odontolytica. For example, but not limited to, a subject is identified as having a potential for reduced CAR T cell-associated toxicity if the level of Lactobacillus salivarius is higher in the subject's sample than the reference level of the bacterium or its spores.
[0124] In certain embodiments, a subject is identified as having a potential for reduced CAR T cell-associated toxicity if the level of a bacterium identified as associated with increased toxicity potential in Figure 5, e.g., Figures 5G and 5O, in the subject's sample is higher than the reference level of the bacterium or its spore, e.g., Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, Lactobacillus salivarius, Schaalia odontolytica, Faecalibacterium prausnitzii, and / or Blautia luti. For example, but not limited to, a subject is identified as having a potential for reduced CAR T cell-associated toxicity if the level of Lactobacillus salivarius is higher than the reference level of the bacterium or its spore in the subject's sample. In certain embodiments, a subject is identified as having a potential for reduced CAR T cell-associated toxicity if the level of Faecalibacterium prausnitzii is higher than the reference level of the bacterium or its spore in the subject's sample. In certain embodiments, the reference bacterial level is the level of bacteria or spores thereof from a subject who has been treated with CAR T cell therapy and has not exhibited CAR T cell-associated toxicity.
[0125] In certain embodiments, the bacterial genes in a subject's sample that are analyzed to determine whether the subject has a potential for increased CAR T cell-associated toxicity or decreased CAR T cell-associated toxicity are provided in Figure 5, e.g., Figure 5M. For example, but not by way of limitation, bacterial genes may be included that encode genes encoding the nonoxidative branch of the pentose phosphate pathway (e.g., nonoxypent PWY), L-isoleucine biosynthesis (e.g., PWY5104), pyruvate fermentation to acetate and lactate II (PWY5100), the superpathway of glycerol degradation to 1,3-propanediol (e.g., GOLPDLCAT PWY), formaldehyde assimilation III, the dihydroxyacetone cycle (e.g., PWY P185), pyrimidine deoxyribonucleotide de novo biosynthesis IV (e.g., PWY7198), acetyl-CoA fermentation to butanoate II (e.g., PWY5676), glycerol degradation to butanol (e.g., PWY7003), the superpathway of (R,R)-butanediol biosynthesis (e.g., PWY P125), biotin biosynthesis II (e.g., PWY5005), CMP-regionaminate biosynthesis (e.g., PWY6749), chondroitin sulfate degradation I, bacteria (e.g., PWY6572), polyamine biosynthesis II superpathway (e.g., polyaminesin3PWY), TCA cycle, prokaryotes (e.g., TCA), pyrimidine deoxyribonucleotide de novo biosynthesis (e.g., PWY71 84), GDP-mannose biosynthesis (e.g., PWY5659), NAD salvage pathway II (e.g., NAD biosynthesis II), CMP3-deoxy-D-manno-octorsonate biosynthesis (e.g., PWY1269), pyrimidine nucleobase salvage superpathway (e.g., PWY7208), thiamine diphosphate biosynthesis II (e.g., PWY6895), polyisoprenoid biosynthesis, E.coli (e.g., polyisoprensyn PWY), thiamine diphosphate salvage II (e.g., PWY6897), superpathway of phospholipid biosynthesis I, bacteria (e.g., Phoslipsyn PWY), L-arginine biosynthesis III (via N-acetyl-L-citrulline) (e.g., PWY5154), superpathway of purine nucleotide de novo biosynthesis (e.g., PWY841), superpathway of L-aspartate and L-asparagine biosynthesis (e.g., ASPASN PWY), flavin biosynthesis III, fungi (e.g., PWY 6168), Pre Q0 biosynthesis (e.g., PWY6703), L-histidine degradation III (e.g., PWY6168), superpathway of thiamine diphosphate biosynthesis III, eukaryotic synthesis (e.g., THISYNARA PWY), L-ornithine biosynthesis (e.g., Arginine Syn4 PWY), 6-hydroxymethyl-dihydropterin diphosphate biosynthesis I (e.g., PWY6147), 6-hydroxymethyl-dihydropterin diphosphate biosynthesis III (e.g., PWY7539), chlamydia (e.g., PWY7539) and / or bacterial genes involved in dTDP-β-L-rhamnose biosynthesis (e.g., DTDPRHAMSYN PWY).
[0126] In certain embodiments, one or more genes identified in FIG. 5M as being associated with increased toxicity potential are identified as being associated with increased toxicity potential, such as the nonoxidative branch of the pentose phosphate pathway (e.g., nonoxypent PWY), L-isoleucine biosynthesis (e.g., PWY5104), pyruvate fermentation to acetate and lactate II (PWY5100), the superpathway of glycerol degradation to 1,3-propanediol (e.g., GOLPDLCAT PWY), formaldehyde assimilation III, the dihydroxyacetone cycle (e.g., PWY P185), pyrimidine deoxyribonucleotide de novo biosynthesis IV (e.g., PWY7198), acetyl-CoA fermentation to butanoate II (e.g., PWY5676), glycerol degradation to butanol (e.g., PWY7003), and / or the superpathway of (R,R)-butanediol biosynthesis (e.g., PWY The subject is identified as having a potential for increased CAR T cell therapy toxicity if the level of one or more genes involved in the non-oxidative branch of the pentose phosphate pathway (e.g., nonoxypent PWY) is higher in the subject's sample than the reference level of the bacterial gene. In certain embodiments, the subject is identified as having a potential for increased CAR T cell therapy toxicity if the level of one or more genes involved in the non-oxidative branch of the pentose phosphate pathway (e.g., nonoxypent PWY) is higher in the subject's sample than the reference level of the bacterial gene.
[0127] In certain embodiments, the subject is administered a gene encoding one or more genes identified in FIG. 5M as being associated with decreased toxicity potential, e.g., biotin biosynthesis II (e.g., PWY5005), CMP-regionaminate biosynthesis (e.g., PWY6749), chondroitin sulfate degradation I, bacteria (e.g., PWY6572), polyamine biosynthesis II superpathway (e.g., polyaminesin3 PWY), TCA cycle, prokaryotes (e.g., TCA), pyrimidine deoxyribonucleoside (PWY), or ribosomal protein (PWY). ... Dode novo biosynthesis (e.g., PWY7184), GDP-mannose biosynthesis (e.g., PWY5659), NAD salvage pathway II (e.g., NAD biosynthesis II), CMP 3-deoxy-D-manno-octulosonate biosynthesis (e.g., PWY1269), pyrimidine nucleobase salvage superpathway (e.g., PWY7208), thiamine diphosphate biosynthesis II (e.g., PWY6895), polyisoprenoid biosynthesis, E.coli (e.g., polyisoprensyn PWY), thiamine diphosphate salvage II (e.g., PWY6897), superpathway of phospholipid biosynthesis I, bacteria (e.g., Phoslipsyn PWY), L-arginine biosynthesis III (via N-acetyl-L-citrulline) (e.g., PWY5154), superpathway of purine nucleotide de novo biosynthesis (e.g., PWY841), superpathway of L-aspartate and L-asparagine biosynthesis (e.g., ASPASN PWY), flavin biosynthesis III, fungi (e.g., PWY 6168), Pre Q0 biosynthesis (e.g., PWY6703), L-histidine degradation III (e.g., PWY6168), superpathway of thiamine diphosphate biosynthesis III, eukaryotic synthesis (e.g., THISYNARA PWY), L-ornithine biosynthesis (e.g., Arginine Syn4 The subject is identified as having a reduced likelihood of CAR T cell therapy toxicity if the level of a bacterial gene involved in 6-hydroxymethyl-dihydropterin diphosphate biosynthesis I (e.g., PWY6147), 6-hydroxymethyl-dihydropterin diphosphate biosynthesis III, Chlamydia (e.g., PWY7539), and / or dTDP-β-L-rhamnose biosynthesis (e.g., DTDPRHAMSYN PWY) is higher in the subject's sample than a reference level of the bacterial gene. In certain embodiments, the reference level of the bacterial gene is the level of the bacterial gene from a subject who has been treated with CAR T cell therapy and has not exhibited CAR T cell therapy toxicity.
[0128] In certain embodiments, the method of identifying a subject as having an increased or decreased likelihood of CAR T cell-associated toxicity comprises determining whether the subject has been administered an antibiotic prior to CAR T cell therapy, e.g., prior to the initiation of CAR T cell therapy. In certain embodiments, the antibiotic is administered prior to CAR T cell therapy, e.g., less than about 8 weeks, less than about 7 weeks, less than about 6 weeks, less than about 5 weeks, less than about 4 weeks, less than about 3 weeks, less than about 2 weeks, less than about 1 week prior to the initiation of CAR T cell therapy. In certain embodiments, the antibiotic is administered prior to CAR T cell therapy, e.g., less than about 4 weeks prior to the initiation of CAR T cell therapy. In certain embodiments, the antibiotic is administered prior to CAR T cell therapy, e.g., about 4 weeks prior to the initiation of CAR T cell therapy. In certain embodiments, the subject is identified as having a decreased likelihood of CAR T cell-associated toxicity if the subject has been administered piperacillin-tazobactam, imipenem-cilastatin, meropenem, or a combination thereof prior to CAR T cell therapy. In certain embodiments, a subject with NHL is identified as having a potential for increased CAR T cell-associated toxicity if the subject has been administered piperacillin-tazobactam, imipenem-cilastatin, meropenem, or a combination thereof prior to CAR T cell therapy.
[0129] In certain embodiments, subjects identified as having increased potential for CAR T cell-associated toxicity may be monitored for signs of severe toxicity and may receive preventative measures to reduce the chance or impact of severe toxicity without unduly inhibiting the efficacy of the CAR T cell therapy or combination thereof, for example, by administration of a therapeutic bacteria disclosed herein.
[0130] The increased or decreased level of the bacteria or its spores or bacterial genes described herein is determined relative to the level of a reference bacteria or its spores or reference bacterial gene level. In certain embodiments, the level (e.g., the measured level and the reference level) may be based on the relative abundance in the gut microbiome. For example, but not limited to, the level may represent the proportion of the bacteria or its spores of all bacteria or its spores in the gut microbiome. In certain embodiments, the level may also be an absolute number.
[0131] In certain embodiments, the reference level is the level of the bacteria or its spores, or bacterial genes from (a) a population of subjects who are candidates for CAR T cell therapy, (b) subjects who have been treated with CAR T cell therapy and have shown cancer survival, (c) subjects who have been treated with CAR T cell therapy and have not shown cancer survival, (d) subjects who have been treated with CAR T cell therapy and have shown CAR T cell-associated toxicity, and / or (e) subjects who have been treated with CAR T cell therapy and have not shown CAR T cell-associated toxicity. In certain embodiments, the reference level is the level of the bacteria or its spores, or bacterial genes from a sample of the same subject collected at an earlier time point. In certain embodiments, the reference level may be based on previous testing in the same subject, or based on levels found in a patient population, such as subjects who are candidates for CAR T cell therapy, or subjects with cancer who have been treated with CAR T cell therapy and have shown cancer survival. In certain embodiments, the reference level may be the abundance of the bacteria or its spores, or bacterial genes in the microbiota of subjects with cancer who have survived for at least about 100 days after CAR T cell therapy.
[0132] In certain embodiments, the method may further include treating the subject identified as having an increased likelihood of cancer survival or decreased CAR T cell-associated toxicity following CAR T cell therapy with CAR T cell therapy. Any CAR T cell therapy known in the art may be used with the subject matter of the present disclosure. In certain embodiments, the CAR T cell therapy may include a CAR T cell that includes an extracellular binding domain that binds to mucin 16 (MUC16), B cell maturation antigen (BCMA), CD19, or a combination thereof. In certain embodiments, the CAR T cell therapy is a CD19 CAR T cell therapy. In certain embodiments, the CAR T cell therapy may include a CD28 or 4-1BB costimulatory domain.
[0133] In certain embodiments, the method may further include treating a subject identified as having a decreased likelihood of cancer survival or an increased likelihood of CAR T cell-associated toxicity following CAR T cell therapy with a therapeutic bacterium or pharmaceutical composition thereof disclosed herein, such as a composition disclosed in Section IV. In certain embodiments, the subject may receive a prophylactic therapeutic bacterium or pharmaceutical composition thereof described herein prior to administration of CAR T cell therapy, prior to harvesting of cells for modification, prior to harvesting of cells, between harvesting of cells and administration of genetically modified T cells, or following administration of genetically modified T cells in CAR T cell therapy.
[0134] In certain embodiments, the subject has cancer. In certain embodiments, the cancer is selected from the group consisting of acute lymphoblastic leukemia, acute myeloid leukemia, biliary cancer, breast cancer, cervical cancer, chronic lymphocytic leukemia, chronic myeloid leukemia, colorectal cancer, endometrial cancer, esophageal, gastric, head and neck cancer, Hodgkin's lymphoma, lung cancer, medullary thyroid cancer, non-Hodgkin's lymphoma, multiple myeloma, kidney cancer, ovarian cancer, pancreatic cancer, glioma, melanoma, liver cancer, prostate cancer, and urinary bladder cancer, CD19 malignancies, and other B-cell related or hematological malignancies. In certain embodiments, the cancer is ovarian cancer, multiple myeloma, or B-cell malignancies, and any combination thereof. Non-limiting examples of B-cell malignancies include acute lymphoblastic leukemia (ALL), chronic lymphoblastic leukemia (CLL), or non-Hodgkin's lymphoma (NHL). In certain embodiments, the cancer is ALL. In certain embodiments, the cancer is NHL.
[0135] In certain embodiments, the bacterial level or abundance can be determined by quantifying bacterial nucleic acid molecules (e.g., DNA or RNA molecules) in a sample. In certain embodiments, the bacterial DNA or RNA comprises 16S rRNA or RNA encoded by a bacterial gene specific to the bacterial species. In certain embodiments, the bacterial DNA (e.g., 16S rDNA) or RNA level (e.g., 16S rRNA) is determined by a sequencing method, such as metagenomic sequencing or shotgun metagenomic sequencing. In certain embodiments, the sequencing is performed using an Illumina MiSeq platform or an Illumina HiSeq 2000 platform. In certain embodiments, the bacterial DNA or RNA level (e.g., copy number) is determined by an amplification-based method, such as polymerase chain reaction (PCR), including reverse transcription-polymerase chain reaction (RT-PCR) for RNA quantitative analysis. In certain embodiments, the amplification of bacterial DNA or RNA in a sample can be accomplished by any known method, including, but not limited to, ligase chain reaction (LCR), transcription amplification, and self-sustained sequence replication or nucleic acid sequence-based amplification (NASBA). In certain embodiments, the level of bacterial DNA or RNA can be determined by size fractionation (e.g., gel electrophoresis), whether or not proceeded by an amplification step. In certain embodiments, the level of bacterial nucleic acid molecules (e.g., DNA or RNA molecules) can be determined by sequence-specific probe hybridization. In certain embodiments, the level of bacterial DNA or RNA can be determined by mass spectrometry, PCR, microarray hybridization, thermal sequencing, capillary array sequencing, or solid-phase sequencing.
[0136] In certain embodiments, the level or abundance of bacteria refers to the relative abundance of bacteria in a sample. The relative abundance of bacteria refers to the proportion of a specific bacterium in the entire bacterial flora in a sample. The relative abundance of bacteria can be determined, for example, from the total number of bacterial cells constituting the bacterial flora and the number of specific bacterial cells contained in the bacterial flora. More specifically, for example, the relative abundance of a specific bacterium can be determined by comprehensively decoding genes having a nucleotide sequence common to the bacteria contained in the bacterial flora and a nucleotide sequence specific to each bacterial species (e.g., 16S rRNA gene), and specifying the total number of decoded genes and the total number of genes belonging to a specific bacterial species as the total number of bacterial cells constituting the bacterial flora and the number of specific bacterial cells, respectively.
[0137] In certain embodiments, the level of a bacterial gene is determined by measuring the level of bacterial nucleic acid, including DNA and RNA that includes at least a portion of the bacterial gene, bacterial mRNA or cDNA transcribed from the bacterial gene, or sequences that are complementary or homologous thereto (including, but not limited to, antisense or small interfering RNA). The nucleic acid may include naturally occurring nucleotides and may optionally include non-naturally occurring nucleotide bases. In certain embodiments, the level of a bacterial gene is determined by measuring the level of a bacterial protein encoded by the bacterial gene.
[0138] Any suitable method known in the art for measuring nucleic acid and protein levels can be used with the methods of the present disclosure. In certain embodiments, methods for measuring nucleic acid levels include, but are not limited to, real-time PCR (RT-PCR), quantitative PCR, quantitative real-time polymerase chain reaction (qRT-PCR), fluorescent PCR, RT-MSP (RT methylation specific polymerase chain reaction), PicoGreen™ (Molecular Probes, Eugene, OR) DNA detection, radioimmunoassay or direct radiolabeling of DNA, in situ hybridization visualization, fluorescent in situ hybridization (FISH), microarray, sequencing. In certain embodiments, methods for measuring protein levels include, but are not limited to, mass spectrometry techniques, 1-D or 2-D gel-based analysis systems, chromatography, enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), enzyme-linked immunosorbent assay (EIA), Western blotting, immunoprecipitation, and immunohistochemistry.
[0139] In certain embodiments, the amount and / or type of bacteria present in a sample may be determined by measuring the amount or presence of bacterial nucleic acids specific to the type of bacteria, such as 16S rRNA. In certain embodiments, the amount and / or type of bacteria present in a sample may be determined by shotgun sequencing of bacterial DNA, PCR amplification of specific genes carried by the bacteria, quantitative PCR of transcripts specifically expressed by the bacteria, antibody-based methods of bacterial detection, metabolic detection of bacterial metabolites, proteomic detection of bacterial proteins, and / or culture methods of the microbiota sample.
[0140] In certain embodiments, the amount and / or type of bacterial genes present in a sample can be determined by PCR amplification of specific genes or quantitative PCR of transcripts specifically expressed by bacteria, or by testing for the effect of expression of such genes, e.g., degradation of secondary bile acids by the microbiota sample.
[0141] In certain embodiments, the subject is a candidate for CAR T cell therapy and has not previously received CAR T cell therapy. In certain embodiments, the subject has previously received CAR T cell therapy. In certain embodiments, the subject has received CAR T cell therapy.
[0142] In certain embodiments, a microbiota sample can be collected from a subject up to about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 or more days prior to treatment with CAR T cell therapy. In certain embodiments, a microbiota sample can be collected from a subject up to about 30 days prior to treatment with CAR T cell therapy. For example, but not by way of limitation, a microbiota sample can be collected from a subject up to about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 or more days before cells are harvested from the subject for modification to CAR T cell therapy or modified T cells are administered to the patient in CAR T cell therapy. A microbiota sample can be collected from a subject after cells are harvested from a patient for CAR T cell therapy but prior to administration of the modified T cells. A microbiota sample can also be collected from a patient 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 days after modified T cells are administered to the patient or the patient shows symptoms of toxicity.
[0143] In certain embodiments, a sample from a subject, e.g., a microbiota sample, can be a fecal sample or a bowel content sample, e.g., a rectal swab.
[0144] In certain embodiments, the subject is a human subject.
[0145] III. Therapeutic bacteria The present disclosure provides therapeutic bacteria or spores thereof for administration to a subject. In certain embodiments, the present disclosure provides therapeutic bacteria or spores thereof for treating cancer in combination with CAR T cell therapy. In certain embodiments, the therapeutic bacteria can be used to improve the subject's chances of cancer survival after CAR T cell therapy and / or to reduce the subject's risk of toxicity after CAR T cell therapy.
[0146] In certain embodiments, the therapeutic bacteria may include one or more bacteria associated with increased chances of cancer survival, for example, as disclosed in Figure 5. In certain embodiments, the therapeutic bacteria may include one or more bacteria that include a gene associated with increased chances of cancer survival, for example, as disclosed in Figure 5.
[0147] In certain embodiments, the therapeutic bacteria may include one or more bacteria associated with reduced CAR T cell therapy toxicity potential, for example, as disclosed in Figure 5. In certain embodiments, the therapeutic bacteria of the present disclosure may include one or more bacteria that include a gene associated with reduced CAR T cell therapy toxicity potential, for example, as disclosed in Figure 5.
[0148] In certain embodiments, the therapeutic bacteria used in the present disclosure include one or more of the following bacteria or spores: Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Clostridium methoxybenzovorans, Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, Lactobacillus salivarius, Schaalia odontolytica, Ruminococcus bromii, Longicatena caecimuris, Bifidobacterium breve, Blautia luti, and / or Faecalibacterium prausnitzii.In certain embodiments, the therapeutic bacteria is a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Clostridium methoxybenzovorans, Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, Lactobacillus salivarius, Ruminococcus bromii, Longicatena caecimuris, Bifidobacterium breve, Blautia luti, and / or Faecalibacterium prausnitzii. It includes one or more bacteria or spores that contain rRNA gene sequences.
[0149] In certain embodiments, the therapeutic bacteria for improving a subject's chances of cancer survival is one or more bacteria or spores thereof of Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Clostridium methoxybenzovorans, Ruminococcus bromii, Longicatena caecimuris, Bifidobacterium breve, Blautia luti, Faecalibacterium prausnitzii, or combinations thereof. The present invention also includes bacteria containing a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Acinetobacter celerecrescens, Anaeromassilibacillus senegalensis, Clostridium methoxybenzovorans, Ruminococcus bromii, Longicatena caecimuris, Bifidobacterium breve, Blautia luti, and / or Faecalibacterium prausnitzii.
[0150] In certain embodiments, the therapeutic bacteria that reduce the risk of subject toxicity associated with CAR T cell therapy include one or more bacteria or spores thereof of Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, Lactobacillus salivarius, Schaalia odontolytica, Blautia luti, Faecalibacterium prausnitzii, or combinations thereof, or a bacterium that includes a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7%, or 99% sequence identity to the 16S rRNA gene sequence of Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, Lactobacillus salivarius, Schaalia odontolytica, Blautia luti, and / or Faecalibacterium prausnitzii.
[0151] In certain embodiments, the therapeutic bacteria that reduce the risk of toxicity in a subject associated with CAR T cell therapy include one or more bacteria or spores thereof of Lutispora thermophila, Lactobacillus salivarius, Schaalia odontolytica, Blautia luti, Faecalibacterium prausnitzii, or combinations thereof, or a bacterium that comprises a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7%, or 99% sequence identity to the 16S rRNA gene sequence of Lutispora thermophila, Lactobacillus salivarius, Schaalia odontolytica, Blautia luti, and / or Faecalibacterium prausnitzii.
[0152] In certain embodiments, the therapeutic bacteria comprises Ruminococcus gnavus, Streptococcus salivarius, Oscillibacter ruminantium, Ruminococcus bromii, Blautia luti, Faecalibacterium prausnitzii, or combinations thereof, or a bacterium comprising a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Ruminococcus gnavus, Streptococcus salivarius, Oscillibacter ruminantium, Ruminococcus bromii, Blautia luti, and / or Faecalibacterium prausnitzii.
[0153] In certain embodiments, the therapeutic bacteria is a member of a class of pathways that mediate the synthesis of purine nucleosides (e.g., PWY1296), chorismate biosynthesis (e.g., ARO PWY), antigen building block biosynthesis (e.g., O Antigen Pathway), Calvin Benson Bassam cycle (e.g., Calvin PWY), peptidoglycan biosynthesis IV (e.g., PWY6471), adenine and adenosine salvage III (e.g., PWY6609), aromatic amino acid biosynthesis superpathway (e.g., COMPLETE ARO PWY), UDP N-acetylglucosamine biosynthesis (e.g., UDP NAGSYN PWY), chorismate biosynthesis from 3-dehydrogynate (e.g., PWY6163), L-methionine biosynthesis III (e.g., HSERMETANA PWY), or a combination of these pathways. PWY), peptidoglycan biosynthesis V beta-lactam resistance (e.g., PWY6470), and / or pyrimidine ribonucleoside salvage superpathway (e.g., PWY7196). In certain embodiments, the therapeutic bacterium may include a bacterium that includes one or more genes involved in aromatic amino acid biosynthesis (e.g., chorismate biosynthesis and aromatic amino acid biosynthesis superpathway (COMPLETE ARO PWY)), peptidoglycan biosynthesis (peptidoglycan biosynthesis IV (PWY6471), and / or peptidoglycan biosynthesis V beta-lactam resistance (PWY6470)) (e.g., peptidoglycan biosynthesis IV (PWY6471)). In certain embodiments, the therapeutic bacterium may include a bacterium that includes a gene involved in peptidoglycan biosynthesis IV (e.g., PWY6471).
[0154] In certain embodiments, the therapeutic bacteria is a bacterium that is involved in the synthesis of a gene that encodes a phosphodiesterase (e.g., PWY6572), a phosphodiesterase (e.g., PWY6573), a phosphodiesterase (e.g., PWY6574), a phosphodiesterase (e.g., PWY6575), a phosphodiesterase (e.g., PWY6576), a phosphodiesterase (e.g., PWY6577), a phosphodiesterase (e.g., PWY6578), a phosphodiesterase (e.g., PWY6579), a phosphodiesterase (e.g., PWY6572), a phosphodiesterase (e.g., PWY6573), a phosphodiesterase (e.g., PWY6574 ... DP-mannose biosynthesis (e.g., PWY5659), NAD salvage pathway II (e.g., NAD biosynthesis II), CMP3-deoxy-D-manno-octorsonate biosynthesis (e.g., PWY1269), pyrimidine nucleobase salvage superpathway (e.g., PWY7208), thiamine diphosphate biosynthesis II (e.g., PWY6895), polyisoprenoid biosynthesis, E. coli (e.g., polyisoprensyn PWY), thiamine diphosphate salvage II (e.g., PWY6897), superpathway of phospholipid biosynthesis I, bacteria (e.g., Phoslipsyn PWY), L-arginine biosynthesis III (via N-acetyl-L-citrulline) (e.g., PWY5154), superpathway of purine nucleotide de novo biosynthesis (e.g., PWY841), superpathway of L-aspartate and L-asparagine biosynthesis (e.g., ASPASN PWY), flavin biosynthesis III, fungi (e.g., PWY 6168), Pre Q0 biosynthesis (e.g., PWY6703), L-histidine degradation III (e.g., PWY6168), superpathway of thiamine diphosphate biosynthesis III, eukaryotic synthesis (e.g., THISYNARA PWY), L-ornithine biosynthesis (e.g., Arginine Syn4 PWY), 6-hydroxymethyl-dihydropterin diphosphate biosynthesis I (e.g., PWY6147), 6-hydroxymethyl-dihydropterin diphosphate biosynthesis III, Chlamydia (e.g., PWY7539), and / or bacteria containing one or more genes involved in dTDP-β-L-rhamnose biosynthesis (e.g., DTDPRHAMSYN PWY).
[0155] In certain embodiments, a subject may be administered at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, or at least twelve bacterial species to improve the subject's chances of cancer survival. For example, but not limited to, a subject may be administered Ruminococcus gnavus. In certain embodiments, a subject may be administered Streptococcus salivarius. In certain embodiments, a subject may be administered Oscillibacter ruminantium. In certain embodiments, a subject may be administered Blautia luti. In certain embodiments, a subject may be administered Faecalibacterium prausnitzii. In certain embodiments, a subject may be administered Ruminococcus bromii. In certain embodiments, a subject may be administered Ruminococcus gnavus and Streptococcus salivarius. In certain embodiments, the subject can be administered Ruminococcus gnavus and Oscillibacter ruminantium. In certain embodiments, the subject can be administered Ruminococcus gnavus, Streptococcus salivarius, and Oscillibacter ruminantium. In certain embodiments, the subject can be administered Streptococcus salivarius and Oscillibacter ruminantium.
[0156] In certain embodiments, a subject may be administered at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, or at least thirteen bacterial species to improve the subject's chances of cancer survival. For example, but not by way of limitation, a subject may be administered Ruminococcus gnavus. In certain embodiments, a subject may be administered Blautia schinkii. In certain embodiments, a subject may be administered Bacteroides finegoldii. In certain embodiments, a subject may be administered Clostridium glycyrrhizinilyticum. In certain embodiments, a subject may be administered Clostridium saccharolyticum. In certain embodiments, a subject may be administered Clostridium celerecrescens. In certain embodiments, a subject may be administered Anaeromassilibacillus senegalensis. In certain embodiments, the subject can be administered Clostridium methoxybenzovorans. In certain embodiments, the subject can be administered Faecalibacterium prausnitzii. In certain embodiments, the subject can be administered Blautia luti. In certain embodiments, the subject can be administered Longicatena caecimuris. In certain embodiments, the subject can be administered Bifidobacterium breve. In certain embodiments, the subject can be administered Ruminococcus bromii.
[0157] In certain embodiments, the subject may be administered at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, or at least twelve bacterial species to reduce the risk of toxicity associated with the subject's CAR T cell therapy. For example, but not limited to, the subject may be administered Streptococcus oralis. In certain embodiments, the subject may be administered Lutispora thermophila. In certain embodiments, the subject may be administered Agathobaculum butyriciproducens. In certain embodiments, the subject may be administered Lactobacillus salivarius. In certain embodiments, the subject may be administered Schaalia odontolytica. In certain embodiments, the subject may be administered Blautia luti. In certain embodiments, the subject may be administered Faecalibacterium prausnitzii. In certain embodiments, a subject can be administered Lactobacillus salivarius and Lutispora thermophila. In certain embodiments, a subject can be administered Lactobacillus salivarius, Schaalia odontolytica, and Lutispora thermophila.
[0158] In certain embodiments, the present disclosure provides a composition comprising at least one of the bacteria of the present disclosure or a spore thereof, or a cluster comprising at least one of the bacteria of the present disclosure.
[0159] In certain embodiments, the therapeutic bacteria of the present disclosure may be administered in a vegetative or dormant state, or as spores, or a mixture thereof.
[0160] The therapeutic bacteria described herein, any combination thereof, or clusters comprising any one or more of the therapeutic bacteria may be administered in the form of purified bacteria or spores or other precursors, or alternatively, may be administered as a component in a mixture of bacterial species, optionally including additional bacteria, e.g., one or more species or clusters of probiotic bacteria, probiotic yeast, prebiotics, postbiotics and / or antibiotics.
[0161] The therapeutic bacteria of the present disclosure may be administered in the form of a liquid, suspension, dry (eg, lyophilized) powder, tablet, capsule, or suppository, and may be administered orally, nasogastric, or rectally.
[0162] In certain embodiments, the therapeutic bacteria of the present disclosure can be administered in a food product, such as a yogurt food. "Food product" can mean a product or composition intended for consumption by humans or non-human animals. Such food products include foods, feeds, snacks, food supplements, liquids, beverages, sweets, toys (chewable toys and / or consumable toys), meal replacements, or whole foods.
[0163] The disclosure further provides isolated and / or purified therapeutic bacteria, compositions comprising combinations of isolated therapeutic bacteria together, or clusters comprising any one or more isolated therapeutic bacteria. In certain embodiments, the bacteria may be in a formulation for administration to a patient.
[0164] The present disclosure provides compositions comprising isolated therapeutic bacteria, which may be one or more of the therapeutic bacteria described herein, although alternative or additional bacteria may be included in other compositions described herein, e.g., bacteria that may be naturally occurring bacteria that are present in clusters with any one or more of the therapeutic bacteria.
[0165] IV. Pharmaceutical Compositions The present disclosure provides pharmaceutical compositions comprising one or more of the therapeutic bacteria disclosed herein. In certain embodiments, the pharmaceutical compositions of the present disclosure comprise a therapeutic bacteria or a spore thereof and a pharmaceutical carrier.
[0166] In certain embodiments, a pharmaceutical composition of the present disclosure may include one or more bacteria associated with increased chances of cancer survival, for example, as disclosed in Figure 5. In certain embodiments, a pharmaceutical composition of the present disclosure may include one or more bacteria that include a gene associated with increased chances of cancer survival, for example, as disclosed in Figure 5.
[0167] In certain embodiments, a pharmaceutical composition of the present disclosure may include one or more bacteria associated with reduced CAR T cell therapy toxicity potential, for example, as disclosed in Figure 5. In certain embodiments, a pharmaceutical composition of the present disclosure may include one or more bacteria that include a gene associated with reduced CAR T cell therapy toxicity potential, for example, as disclosed in Figure 5.
[0168] In certain embodiments, pharmaceutical compositions of the present disclosure may include one or more therapeutic bacteria disclosed in Section III.
[0169] In certain embodiments, pharmaceutical compositions of the present disclosure may comprise one or more therapeutic bacteria or spores thereof, e.g., isolated and / or purified therapeutic bacteria or spores thereof, including Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Clostridium methoxybenzovorans, Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, Lactobacillus salivarius, Schaalia odontolytica, Ruminococcus bromii, Longicatena caecimuris, Bifidobacterium breve, Blautia luti, Faecalibacterium prausnitzii, or combinations thereof.In certain embodiments, the pharmaceutical compositions of the present disclosure comprise a 16S 16S bacterium selected from the group consisting of Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Clostridium methoxybenzovorans, Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, Lactobacillus salivarius, Schaalia odontolytica, Ruminococcus bromii, Longicatena caecimuris, Bifidobacterium breve, Blautia luti, and / or Faecalibacterium prausnitzii. The therapeutic bacteria may include one or more therapeutic bacteria or spores thereof comprising a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to an rRNA gene sequence.
[0170] In certain embodiments, a pharmaceutical composition for improving a subject's chances of cancer survival may comprise one or more therapeutic bacteria or spores thereof, e.g., isolated and / or purified therapeutic bacteria or spores thereof, of Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Clostridium methoxybenzovorans, Ruminococcus bromii, Longicatena caecimuris, Bifidobacterium breve, Blautia luti, Faecalibacterium prausnitzii, or combinations thereof. In certain embodiments, a pharmaceutical composition for improving a subject's chances of cancer survival may comprise one or more bacteria or spores thereof, such as isolated and / or purified therapeutic bacteria or spores thereof, comprising a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Clostridium methoxybenzovorans, Ruminococcus bromii, Longicatena caecimuris, Bifidobacterium breve, Blautia luti, and / or Faecalibacterium prausnitzii.
[0171] In certain embodiments, a pharmaceutical composition for reducing the likelihood of toxicity following CAR T cell therapy in a subject may comprise one or more therapeutic bacteria or spores thereof, e.g., isolated and / or purified therapeutic bacteria or spores thereof, of Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, Lactobacillus salivarius, Schaalia odontolytica, Blautia luti, Faecalibacterium prausnitzii, or combinations thereof. In certain embodiments, a pharmaceutical composition for reducing the likelihood of toxicity following CAR T cell therapy in a subject may comprise one or more therapeutic bacteria or spores thereof, such as isolated and / or purified therapeutic bacteria or spores thereof, comprising a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, Lactobacillus salivarius, Schaalia odontolytica, Blautia luti, and / or Faecalibacterium prausnitzii.
[0172] In certain embodiments, pharmaceutical compositions of the present disclosure may include a therapeutic bacterium, such as Ruminococcus gnavus, Streptococcus salivarius, Oscillibacter ruminantium, Ruminococcus bromii, Blautia luti, Faecalibacterium prausnitzii, or a combination thereof, or a bacterium having a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Ruminococcus gnavus, Streptococcus salivarius, Oscillibacter ruminantium, Ruminococcus bromii, Blautia luti and / or Faecalibacterium prausnitzii.
[0173] In certain embodiments, a pharmaceutical composition of the disclosure may comprise a therapeutic bacterium, such as Ruminococcus gnavus, Streptococcus oralis, Lutispora thermophila, Ruminococcus bromii, Blautia luti, Faecalibacterium prausnitzii, or a combination thereof, or a bacterium having a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Ruminococcus gnavus, Streptococcus oralis, Lutispora thermophila, Ruminococcus bromii, Blautia luti, and / or Faecalibacterium prausnitzii.
[0174] In certain embodiments, pharmaceutical compositions of the present disclosure may include a therapeutic bacterium, such as Ruminococcus bromii, Blautia luti, Faecalibacterium prausnitzii, or a combination thereof, or a bacterium having a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7%, or 99% sequence identity to the 16S rRNA gene sequence of Ruminococcus gnavus, Lactobacillus salivarius, Lutispora thermophila, Ruminococcus bromii, Blautia luti, and / or Faecalibacterium prausnitzii.
[0175] In certain embodiments, pharmaceutical compositions of the present disclosure may include a therapeutic bacterium, such as Blautia luti, Faecalibacterium prausnitzii, or a combination thereof, or a bacterium having a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Blautia luti, and / or Faecalibacterium prausnitzii.
[0176] In certain embodiments, pharmaceutical compositions of the present disclosure may include a therapeutic bacterium, such as Ruminococcus bromii, Blautia luti, Faecalibacterium prausnitzii, or a combination thereof, or a bacterium having a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Ruminococcus bromii, Blautia luti, and / or Faecalibacterium prausnitzii.
[0177] In certain embodiments, a pharmaceutical composition of the disclosure may comprise a therapeutic bacterium, such as Ruminococcus gnavus, Streptococcus oralis, Lutispora thermophila, or a combination thereof, or a bacterium having a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Ruminococcus gnavus, Streptococcus oralis, and / or Lutispora thermophila.
[0178] In certain embodiments, a pharmaceutical composition of the disclosure may comprise Ruminococcus gnavus, or a bacterium comprising a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Ruminococcus gnavus.
[0179] In certain embodiments, a pharmaceutical composition of the present disclosure may comprise Ruminococcus bromii or a bacterium comprising a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Ruminococcus bromii.
[0180] In certain embodiments, the pharmaceutical compositions of the present disclosure may comprise Blautia luti or a bacterium comprising a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Blautia luti.
[0181] In certain embodiments, a pharmaceutical composition of the disclosure may comprise Faecalibacterium prausnitzii or a bacterium comprising a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Faecalibacterium prausnitzii.
[0182] In certain embodiments, a pharmaceutical composition of the disclosure may comprise Streptococcus salivarius, or a bacterium comprising a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Streptococcus salivarius.
[0183] In certain embodiments, a pharmaceutical composition of the disclosure may comprise Oscillibacter ruminantium or a bacterium comprising a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Oscillibacter ruminantium.
[0184] In certain embodiments, a pharmaceutical composition of the disclosure may comprise Streptococcus oralis, or a bacterium comprising a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Streptococcus oralis.
[0185] In certain embodiments, the pharmaceutical compositions of the present disclosure may comprise Lutispora thermophila or a bacterium comprising a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Lutispora thermophila.
[0186] In certain embodiments, a pharmaceutical composition of the present disclosure may comprise Agathobaculum butyriciproducens or a bacterium comprising a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Agathobaculum butyriciproducens.
[0187] In certain embodiments, a pharmaceutical composition of the disclosure may comprise Lactobacillus salivarius, or a bacterium comprising a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Lactobacillus salivarius.
[0188] In certain embodiments, a pharmaceutical composition of the present disclosure may comprise Schaalia odontolytica or a bacterium comprising a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Schaalia odontolytica.
[0189] In certain embodiments, pharmaceutical compositions of the disclosure may include bacteria comprising a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Ruminococcus gnavus and Streptococcus salivarius, or Ruminococcus gnavus and / or Streptococcus salivarius. In certain embodiments, pharmaceutical compositions of the disclosure may include bacteria comprising a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Ruminococcus gnavus and / or Oscillibacter ruminantium, or Ruminococcus gnavus and / or Oscillibacter ruminantium.
[0190] In certain embodiments, pharmaceutical compositions of the present disclosure may include bacteria comprising Ruminococcus gnavus and Lactobacillus salivarius, or a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7%, or 99% sequence identity to the 16S rRNA gene sequence of Ruminococcus gnavus and / or Lactobacillus salivarius. In certain embodiments, pharmaceutical compositions of the present disclosure may include bacteria comprising Ruminococcus gnavus and Lutispora thermophila, or a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7%, or 99% sequence identity to the 16S rRNA gene sequence of Ruminococcus gnavus and / or Lutispora thermophila.
[0191] In certain embodiments, pharmaceutical compositions of the disclosure may include Streptococcus salivarius and Oscillibacter ruminantium, or bacteria comprising a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Streptococcus salivarius and / or Oscillibacter ruminantium.
[0192] In certain embodiments, pharmaceutical compositions of the disclosure may include Ruminococcus gnavus, Streptococcus salivarius, and Oscillibacter ruminantium, or a bacterium comprising a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7%, or 99% sequence identity to the 16S rRNA gene sequence of Ruminococcus gnavus, Streptococcus salivarius, and / or Oscillibacter ruminantium.
[0193] In certain embodiments, pharmaceutical compositions of the disclosure may include Ruminococcus gnavus, Lactobacillus salivarius, and Lutispora thermophila, or bacteria comprising a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7%, or 99% sequence identity to the 16S rRNA gene sequence of Ruminococcus gnavus, Lactobacillus salivarius, and / or Lutispora thermophila.
[0194] In certain embodiments, the pharmaceutical compositions of the present disclosure are intended to provide an agent or pathway that inhibits or inhibits purine nucleoside degradation (e.g., PWY1296), chorismate biosynthesis (e.g., ARO PWY), antigen building block biosynthesis (e.g., O Antigen Pathway), Calvin Benson Bassam cycle (e.g., Calvin PWY), peptidoglycan biosynthesis IV (e.g., PWY6471), adenine and adenosine salvage III (e.g., PWY6609), aromatic amino acid biosynthesis superpathway (e.g., COMPLETE ARO PWY), UDP N-acetylglucosamine biosynthesis (e.g., UDP NAGSYN PWY), chorismate biosynthesis from 3-dehydrogynate (e.g., PWY6163), L-methionine biosynthesis III (e.g., HSERMETANA PWY), or a combination thereof. PWY), peptidoglycan biosynthesis V beta-lactam resistance (e.g., PWY6470), and / or pyrimidine ribonucleoside salvage superpathway (e.g., PWY7196). In certain embodiments, pharmaceutical compositions of the disclosure may include bacteria that include one or more genes involved in aromatic amino acid biosynthesis (e.g., chorismate biosynthesis and aromatic amino acid biosynthesis superpathway (COMPLETE ARO PWY)), peptidoglycan biosynthesis (peptidoglycan biosynthesis IV (PWY6471), and / or peptidoglycan biosynthesis V beta-lactam resistance (PWY6470)) (e.g., peptidoglycan biosynthesis IV (PWY6471)). In certain embodiments, pharmaceutical compositions of the disclosure may include bacteria that include genes involved in peptidoglycan biosynthesis IV (e.g., PWY6471).
[0195] In certain embodiments, the pharmaceutical compositions of the present disclosure are directed to proteins that are involved in the synthesis of biotin biosynthesis II (e.g., PWY5005), CMP-regionaminate biosynthesis (e.g., PWY6749), chondroitin sulfate degradation I, bacteria (e.g., PWY6572), polyamine biosynthesis II superpathway (e.g., polyaminesin3PWY), TCA cycle, prokaryotes (e.g., TCA), pyrimidine deoxyribonucleotide de novo biosynthesis (e.g., PWY7184), and the like. , GDP-mannose biosynthesis (e.g., PWY5659), NAD salvage pathway II (e.g., NAD biosynthesis II), CMP3-deoxy-D-manno-octorsonate biosynthesis (e.g., PWY1269), pyrimidine nucleobase salvage superpathway (e.g., PWY7208), thiamine diphosphate biosynthesis II (e.g., PWY6895), polyisoprenoid biosynthesis, E. coli (e.g., polyisoprensyn PWY), thiamine diphosphate salvage II (e.g., PWY6897), superpathway of phospholipid biosynthesis I, bacteria (e.g., Phoslipsyn PWY), L-arginine biosynthesis III (via N-acetyl-L-citrulline) (e.g., PWY5154), superpathway of purine nucleotide de novo biosynthesis (e.g., PWY841), superpathway of L-aspartate and L-asparagine biosynthesis (e.g., ASPASN PWY), flavin biosynthesis III, fungi (e.g., PWY 6168), Pre Q0 biosynthesis (e.g., PWY6703), L-histidine degradation III (e.g., PWY6168), superpathway of thiamine diphosphate biosynthesis III, eukaryotic synthesis (e.g., THISYNARA PWY), L-ornithine biosynthesis (e.g., Arginine Syn4 PWY), 6-hydroxymethyl-dihydropterin diphosphate biosynthesis I (e.g., PWY6147), 6-hydroxymethyl-dihydropterin diphosphate biosynthesis III, Chlamydia (e.g., PWY7539), and / or bacteria containing one or more genes involved in dTDP-β-L-rhamnose biosynthesis (e.g., DTDPRHAMSYN PWY).
[0196] In certain embodiments, the pharmaceutical compositions of the present disclosure may further comprise a stabilizing compound or an additional therapeutic agent, for example, at least one other agent, such as a probiotic, a prebiotic, and / or a postbiotic.
[0197] In certain embodiments, the pharmaceutical composition may further comprise an antibiotic. In certain embodiments, the antibiotic present in the pharmaceutical composition does not target the bacteria present in the composition. In certain embodiments, the antibiotic is selected from clindamycin, cephalexin, tobramycin, cefpodoxime, atovaquone, ampicillin / sulbactam, cefuroxime and cefazolin, levofloxacin, cefepime, ciprofloxacin, and vancomycin. In certain embodiments, the antibiotic is not piperacillin-tazobactam, imipenem-cilastatin, and meropenem.
[0198] In certain embodiments, the pharmaceutical composition may be administered in any sterile biocompatible pharmaceutical carrier, including, but not limited to, saline, buffered saline, dextrose, glycerol, polyethylene glycol, and water. In certain embodiments, the pharmaceutical composition may be in liquid, lyophilized, or lyophilized form. In certain embodiments, the formulation includes a diluent having a suitable pH value and ionic strength (e.g., a buffer such as Tris, citrate, acetate, or phosphate buffer), a solubilizer such as polysorbate (e.g., Tween®), and a carrier such as human serum albumin or gelatin.
[0199] In certain embodiments, the pharmaceutical composition of the present disclosure may further comprise a preservative. In certain embodiments, the preservative does not affect the viability of the organism in the pharmaceutical composition. Non-limiting examples of preservatives include thimerosal, parabens, benzalkonium chloride or benzyl alcohol, antioxidants such as ascorbic acid or sodium metabisulfite, and other ingredients such as lysine or glycine. The selection of a particular composition may depend on many factors, including the condition being treated, the route of administration, and the pharmacokinetic parameters desired. A more extensive survey of ingredients suitable for pharmaceutical compositions can be found in Remington's Pharmaceutical Sciences, 18th ed. A R Gennaro, ed. Mack, Easton, PA (1980).
[0200] In certain embodiments, the pharmaceutical compositions of the present disclosure may be used to treat a subject having cancer, to increase the likelihood of cancer survival in a subject following CAR T cell therapy, to decrease the likelihood of CAR T cell-associated toxicity in a subject, or a combination thereof.
[0201] The final route of administration selected will depend on many factors and can be ascertained by those skilled in the art. In certain embodiments, the pharmaceutical compositions of the present disclosure can be formulated in dosages suitable for oral, nasogastric or rectal administration using pharma- ceutically acceptable carriers well known in the art. Such carriers allow the pharmaceutical compositions to be formulated as tablets, pills, capsules, liquids, gels, syrups, slurries, suspensions, etc., for oral, rectal, or nasal ingestion by the subject to be treated. In certain embodiments, the formulation comprises capsules or tablets, such as enteric-coated capsules or pills, that are formulated for gastrointestinal delivery.
[0202] In certain embodiments, the pharmaceutical compositions used in the present disclosure may include pharmaceutical compositions in which the active ingredient, e.g., therapeutic bacteria, is included in an effective amount to achieve the intended purpose. The amount will vary from individual to individual and will depend on several factors, including the gut microbiota of the subject, whether cells are collected from the patient for modification, whether modified T cells are administered to the patient, the type and dose of cancer treated by CAR T cell therapy, the results of any of the methods described herein for assessing the risk of a patient having a poor response to CAR T cell therapy or achieving a partial response versus a complete response to CAR T cell therapy, the likelihood that the patient will develop toxicity, including severe toxicity, and the overall physical condition of the patient.
[0203] In certain embodiments, the compositions of the present disclosure may be administered for therapeutic use, including prophylactic treatment. For example, but not limited to, the pharmaceutical compositions of the present disclosure may be administered in an amount sufficient to reduce the risk of poor response to CAR T cell therapy, increase response to CAR T cell therapy, and / or increase the chance of survival, e.g., chance of cancer survival, in a subject. In certain embodiments, the pharmaceutical compositions of the present disclosure may be administered in an amount sufficient to reduce the risk of CAR T cell therapy toxicity in a subject. The dosage for a patient depends on many factors, including the stage of the disease or condition, the severity of the disease or condition, the size, body surface area, age, the specific compound administered, sex, time and route of administration, general health, and interactions with other drugs administered simultaneously.
[0204] The therapeutic bacteria can be administered to a patient alone or in combination with CAR T cell therapies, including those designed to treat or reduce the risk of toxicity (including severe toxicity), and / or in combination with one or more other drugs, nucleotide sequences, lifestyle changes, etc., used in combination with pharmaceutical compositions when mixed with excipient(s) or other pharmaceutically acceptable carriers.
[0205] Single or multiple administrations of the formulations can be administered at a dosage and frequency as needed and tolerated by the patient. The formulations can provide a sufficient amount of active agent to increase the probability of survival after CAR T cell therapy or increase the chance of response to CAR T cell therapy.
[0206] V. Treatment method The present disclosure provides a method for treating a subject with cancer.In certain embodiments, the present disclosure provides a method for treating a subject with cancer, to increase the likelihood of cancer survival in the subject after CAR T cell therapy.In certain embodiments, the present disclosure provides a method for treating a subject with cancer, to reduce the likelihood of CAR T cell-related toxicity in the subject.
[0207] In certain embodiments, the methods disclosed herein comprise administering to a subject at least one of the disclosed therapeutic bacteria or spores thereof, or a pharmaceutical composition comprising same. In certain embodiments, the methods further comprise administering to the subject CAR T cell therapy. In certain embodiments, the therapeutic bacteria or spores thereof, or a pharmaceutical composition comprising same, are administered to the subject prior to or during CAR T cell therapy.
[0208] In certain embodiments, the disclosed methods may further include administration of an antibiotic. For example, but not limited to, the disclosed methods may include administration of an antibiotic followed by administration of a CAR T cell therapy. In certain embodiments, the antibiotic is not piperacillin-tazobactam, imipenem-cilastatin, or meropenem.
[0209] Patients in need of such treatment or composition include those undergoing, or being considered for, or who may undergo CAR T cell therapy. Such patients typically include those with certain cancers. Non-limiting examples of such cancers are disclosed herein. In certain embodiments, the cancer is selected from the group consisting of acute lymphoblastic leukemia, acute myeloid leukemia, biliary cancer, breast cancer, cervical cancer, chronic lymphocytic leukemia, chronic myeloid leukemia, colorectal cancer, endometrial cancer, esophageal, gastric, head and neck cancer, Hodgkin's lymphoma, lung cancer, medullary thyroid cancer, non-Hodgkin's lymphoma, multiple myeloma, kidney cancer, ovarian cancer, pancreatic cancer, glioma, melanoma, liver cancer, prostate cancer, and urinary bladder cancer, CD19 malignancies, and other B-cell related or hematological malignancies. In certain embodiments, the cancer is ovarian cancer, multiple myeloma, or B-cell malignancies, and any combination thereof. Non-limiting examples of B cell malignancies include acute lymphoblastic leukemia (ALL), chronic lymphoblastic leukemia (CLL), or non-Hodgkin's lymphoma (NHL). In certain embodiments, the cancer is ALL. In certain embodiments, the cancer is NHL. In certain embodiments, the patient is a human patient.
[0210] In certain embodiments, such subjects may include, inter alia, subjects identified using the diagnostic methods disclosed herein who have a decreased likelihood of cancer survival following CAR T cell therapy, or an increased likelihood of CAR T cell-associated toxicity, or a combination thereof. In certain embodiments, administration of a therapeutic bacterium or pharmaceutical composition thereof disclosed herein may increase the likelihood of cancer survival following CAR T cell therapy, or decrease the likelihood of CAR T cell-associated toxicity, or a combination thereof.
[0211] In certain embodiments, such subjects may include subjects identified using the diagnostic methods disclosed herein who have an increased likelihood of cancer survival following CAR T cell therapy, or a decreased likelihood of CAR T cell associated toxicity, or a combination thereof, in certain embodiments, administration of a therapeutic bacterium or pharmaceutical composition thereof disclosed herein may further increase the likelihood of cancer survival following CAR T cell therapy, or further decrease the likelihood of CAR T cell associated toxicity, or a combination thereof.
[0212] In certain embodiments, the present disclosure provides for increasing the likelihood of cancer survival following CAR T cell therapy or decreasing CAR T cell associated toxicity, or a combination thereof, by administering to a subject in need of such treatment an effective amount of at least one therapeutic bacterium or pharmaceutical composition thereof. Non-limiting examples of therapeutic bacteria that can be administered to a subject in need thereof are disclosed in Section III, and pharmaceutical compositions that can be administered to a subject in need thereof are disclosed in Section IV.
[0213] In certain embodiments, a method of treating a subject having cancer may include (a) identifying the subject as having an increased likelihood of cancer survival following CAR T cell therapy, e.g., as determined by any one of the methods disclosed herein, (b) administering an effective amount of a therapeutic bacteria or pharmaceutical composition thereof disclosed herein, and (c) administering CAR T cell therapy to the subject. Non-limiting examples of pharmaceutical compositions are disclosed in Section IV. In certain embodiments, the pharmaceutical composition may comprise one or more bacteria selected from Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Clostridium methoxybenzovorans, Ruminococcus bromii, Longicatena caecimuris, Bifidobacterium breve, Blautia luti, Faecalibacterium prausnitzii, or combinations thereof.In certain embodiments, a pharmaceutical composition may include one or more bacteria that include a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Clostridium methoxybenzovorans, Ruminococcus bromii, Longicatena caecimuris, Bifidobacterium breve, Blautia luti, and / or Faecalibacterium prausnitzii. In certain embodiments, the pharmaceutical composition may include Blautia luti and / or Faecalibacterium prausnitzii. In certain embodiments, the pharmaceutical composition may include Ruminococcus gnavus and / or Ruminococcus bromii.
[0214] In certain embodiments, a method of treating a subject with cancer may include (a) identifying the subject as having an increased likelihood of CAR T cell-associated toxicity, for example, as determined by any one of the methods disclosed herein; (b) administering a therapeutic bacterium or pharmaceutical composition thereof disclosed herein; and (c) administering a CAR T cell therapy to the subject. Non-limiting examples of pharmaceutical compositions are disclosed in Section IV. In certain embodiments, the pharmaceutical composition may include one or more bacteria selected from Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, Lactobacillus salivarius, Schaalia odontolytica, Blautia luti, Faecalibacterium prausnitzii, or a combination thereof. In certain embodiments, the pharmaceutical composition may include one or more bacteria that include a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7%, or 99% sequence identity to the 16S rRNA gene sequence of Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, Lactobacillus salivarius, Schaalia odontolytica, Blautia luti, and / or Faecalibacterium prausnitzii. In certain embodiments, the pharmaceutical composition may include Blautia luti and / or Faecalibacterium prausnitzii.
[0215] In certain embodiments, a method of treating a subject having cancer may include (a) identifying the subject as having an increased likelihood of cancer survival following CAR T cell therapy, e.g., as determined by any one of the methods disclosed herein, and (b) administering CAR T cell therapy to the subject. In certain embodiments, the method may further include administration of a therapeutic bacteria or pharmaceutical composition thereof disclosed herein prior to the CAR T cell therapy.
[0216] In certain embodiments, a method of treating a subject having cancer may include (a) identifying the subject as having a reduced likelihood of CAR T cell-associated toxicity, e.g., as determined by any one of the methods disclosed herein, and (b) administering a CAR T cell therapy to the subject. In certain embodiments, the method may further include administration of a therapeutic bacteria or a pharmaceutical composition thereof disclosed herein prior to the CAR T cell therapy.
[0217] In certain embodiments, the method of the present disclosure may further comprise administering an effective amount of prebiotics. In certain embodiments, the prebiotics may be administered separately from the therapeutic bacteria and may promote the growth, proliferation, and / or survival of at least one therapeutic bacteria. In certain embodiments, the prebiotics may comprise one or more agents, such as nutritional supplements, that increase the growth and survival of at least one therapeutic bacteria. The prebiotics may comprise one or more of poorly absorbed complex carbohydrates, oligosaccharides, inulin-type fructans, or arabinoxylans.
[0218] In certain embodiments, the methods of the present disclosure may further comprise administering an effective amount of a postbiotic. The postbiotic may be administered separately from the therapeutic bacteria.
[0219] The present disclosure provides for the use of a composition as described herein, comprising a therapeutic bacterium as described herein, for increasing the likelihood of cancer survival following CAR T cell therapy, or for decreasing CAR T cell-associated toxicity, or a combination thereof, in a subject. The use may be further characterized by the method aspects described above and elsewhere herein.
[0220] VI. Kit The presently disclosed subject matter provides kits for performing any of the methods disclosed herein or for providing any of the therapeutic bacteria disclosed herein or pharmaceutical compositions thereof.
[0221] In certain embodiments, the kits of the present disclosure are used to diagnose a subject's likelihood of cancer survival or likelihood of CAR T cell-associated toxicity following CAR T cell therapy. In certain embodiments, the kits of the present disclosure are used to treat a subject with cancer, for example, to increase the likelihood of cancer survival following CAR T cell therapy or to decrease CAR T cell-associated toxicity, or a combination thereof.
[0222] In certain embodiments, the kits of the present disclosure may include agents for determining whether a subject's sample (e.g., a fecal sample or a gut content sample) contains increased or decreased levels of bacteria or spores thereof, or bacterial genes compared to a reference level.
[0223] The increase or decrease in the level of the bacteria or its spores, or the bacterial gene is determined relative to a reference bacteria or its spore level, or a reference bacterial gene level. In certain embodiments, the level (e.g., the measured level and the reference level) may be based on the relative abundance in the gut microbiome. For example, the level may represent the proportion of the bacteria or its spores of all the bacteria or its spores in the gut microbiome. The level may also be an absolute number.
[0224] In certain embodiments, the agent is used to determine the level of bacteria in a sample from a subject, the bacteria being selected from the group consisting of Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Clostridium methoxybenzovorans, Hungatella effluvii, Coprobacillus cateniformis, Atopobium parvulum, Faecalicoccus acidiformans, Lactococcus lactis, Anaerobacterium chartisolvens, Atopobiaceae, Clostridium innocuum, Bacteroides thetaiotamicron, Streptococcus salivarius, Oscillibacter ruminantium, Eubacterium ramulus, Streptococcus gordonii, Caproiciproducens galactitolivorans, Clostridium hylemonae, Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, Lactobacillus salivarius, Schaalia odontolytica, Ruminococcus bromii, Bifidobacterium breve, Blautia luti, Longicatena caecimuris, Escherichia coli, Faecalibacterium prausnitzii, and any combination thereof.
[0225] In certain embodiments, the agent is used to determine bacterial genes in a sample of a subject, the bacterial genes being related to purine nucleoside degradation (e.g., PWY1296), chorismate biosynthesis (e.g., ARO PWY), antigen building block biosynthesis (e.g., O Antigen Pathway), Calvin Benson Bassam cycle (e.g., Calvin PWY), peptidoglycan biosynthesis IV Enterococcus faecium (e.g., PWY6471), adenine and adenosine salvage III (e.g., PWY6609), aromatic amino acid biosynthesis superpathway (e.g., COMPLETE ARO PWY), UDP N-acetylglucosamine biosynthesis (e.g., UDP NAGSYN PWY), chorismate biosynthesis from 3-dehydrogynate (e.g., PWY6163), L-methionine biosynthesis III (e.g., HSERMETANA PWY), peptidoglycan biosynthesis V beta-lactam resistance (e.g., PWY6470), pyrimidine ribonucleoside salvage superpathway (e.g., PWY7196), heterolactic acid fermentation (e.g., P122PWY), allantoin degradation glyoxylate II (e.g., PWY5692), anaerobic energy metabolism (e.g., PWY7384), allantoin degradation superpathway (e.g., URDEGR PWY), anaerobic energy metabolism (e.g., PWY7389), unsaturated fatty acid biosynthesis superpathway (e.g., PWY6284), enterobactin biosynthesis (e.g., ENTBACSYN PWY), NAD salvage pathway III (e.g., NAD Biosynthesis II), fatty acid biosynthesis superpathway (e.g., PWY6285), pyrimidine deoxyribonucleotide biosynthesis from CTP (e.g., PWY7210), mycolate biosynthesis superpathway (e.g., PWY 6113), NAD NADH phosphorylation and dephosphorylation (e.g., PWY 5083), palmitic acid biosynthesis II bacteria and plants (e.g., PWY5971), biotin biosynthesis I (e.g., BIOTIN BIOSYNTHESISPWY), CMP 3-deoxy-D-manno-octorsonate biosynthesis (e.g., PWY1269), lipid IVA biosynthesis (e.g., NAGLIPASYN, and / or peptidoglycan biosynthesis (peptidoglycan biosynthesis IV (PWY6471), and any combination thereof.
[0226] In certain embodiments, the agent is used to determine bacterial genes in a sample of a subject, the bacterial genes being related to the non-oxidative branch of the pentose phosphate pathway (e.g., nonoxypent PWY), L-isoleucine biosynthesis (e.g., PWY5104), pyruvate fermentation to acetate and lactate II (PWY5100), the superpathway of glycerol degradation to 1,3-propanediol (e.g., GOLPDLCAT PWY), formaldehyde assimilation III, the dihydroxyacetone cycle (e.g., PWY P185), pyrimidine deoxyribonucleotide de novo biosynthesis IV (e.g., PWY7198), acetyl-CoA fermentation to butanoic acid II (e.g., PWY5676), glycerol degradation to butanol (e.g., PWY7003), the superpathway of (R,R)-butanediol biosynthesis (e.g., PWY P125), biotin biosynthesis II (e.g., PWY5005), CMP-regionaminate biosynthesis (e.g., PWY6749), chondroitin sulfate degradation I, bacteria (e.g., PWY6572), polyamine biosynthesis II superpathway (e.g., polyaminesin3PWY), TCA cycle, prokaryotes (e.g., TCA), pyrimidine deoxyribonucleotide de novo biosynthesis (e.g., PWY71 84), GDP-mannose biosynthesis (e.g., PWY5659), NAD salvage pathway II (e.g., NAD biosynthesis II), CMP3-deoxy-D-manno-octorsonate biosynthesis (e.g., PWY1269), pyrimidine nucleobase salvage superpathway (e.g., PWY7208), thiamine diphosphate biosynthesis II (e.g., PWY6895), polyisoprenoid biosynthesis, E.coli (e.g., polyisoprensyn PWY), thiamine diphosphate salvage II (e.g., PWY6897), superpathway of phospholipid biosynthesis I, bacteria (e.g., Phoslipsyn PWY), L-arginine biosynthesis III (via N-acetyl-L-citrulline) (e.g., PWY5154), superpathway of purine nucleotide de novo biosynthesis (e.g., PWY841), superpathway of L-aspartate and L-asparagine biosynthesis (e.g., ASPASN PWY), flavin biosynthesis III, fungi (e.g., PWY 6168), Pre Q0 biosynthesis (e.g., PWY6703), L-histidine degradation III (e.g., PWY6168), superpathway of thiamine diphosphate biosynthesis III, eukaryotic synthesis (e.g., THISYNARA PWY), L-ornithine biosynthesis (e.g., Arginine Syn4 PWY), 6-hydroxymethyl-dihydropterin diphosphate biosynthesis I (e.g., PWY6147), 6-hydroxymethyl-dihydropterin diphosphate biosynthesis III (e.g., PWY7539), Chlamydia (e.g., PWY7539) and / or dTDP-β-L-rhamnose biosynthesis (e.g., DTDPRHAMSYN PWY), CMP-regionaminate biosynthesis (e.g., PWY6749), and / or Pre Q0 biosynthesis (e.g., PWY6703), and any combination thereof.
[0227] In certain embodiments, the agent may include a nucleic acid primer specific for the bacterium or gene of interest, such as a nucleic acid primer specific for 16S rRNA gene sequencing.
[0228] The subject matter of the present disclosure also provides kits for treating a subject who has undergone or may undergo CAR T cell therapy. For example, but not limited to, the kits of the present disclosure can be used to treat a subject identified as having a decreased likelihood of cancer survival and / or an increased likelihood of CAR T cell-associated toxicity. Such kits can include one or more therapeutic bacteria or pharmaceutical compositions described herein (e.g., as disclosed in Sections III and IV).
[0229] In certain embodiments, the kit may include instructions for administering the therapeutic bacteria or pharmaceutical composition thereof. The instructions may include information regarding the use of the therapeutic bacteria or pharmaceutical composition in conjunction with CAR T cell therapy. The instructions may include one or more of the following: description of the therapeutic bacteria or composition, dosing schedule and administration, cautions, warnings, indications, counter indications, overdosing information, adverse reactions, animal pharmacology, clinical trials, and / or references. The instructions may be printed directly on the container that holds the therapeutic bacteria or composition (if present), or as a label applied to the container, or as a separate sheet, pamphlet, card, or folder provided in or with the container.
[0230] In certain embodiments, the kits of the present disclosure may include both components for diagnosing whether a subject has an increased / decreased chance of cancer survival following CAR T cell therapy, or an increased / decreased chance of CAR T cell-associated toxicity undergoing or being considered for CAR T cell therapy, and components for treating a subject who has or may undergo CAR T cell therapy, such as one or more therapeutic agents. The kits may include instructions for administering the components for treating the subject based on the results obtained using the components for diagnosing the subject.
[0231] VII. Exemplary Embodiments A. The present disclosure provides a therapeutic agent comprising an effective amount of (a) a therapeutic bacterium or spore thereof selected from the group consisting of Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Clostridium methoxybenzovorans, Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, Lactobacillus salivarius, Schaalia odontolytica, Longicatena caecimuris, Bifidobacterium breve, Ruminococcus bromii, Blautia luti, Faecalibacterium prausnitzii, or combinations thereof, and / or (b) a therapeutic bacterium or spore thereof selected from the group consisting of Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Clostridium methoxybenzovorans, Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, Lactobacillus salivarius, Schaalia odontolytica, Longicatena caecimuris, Bifidobacterium breve, Ruminococcus bromii, Blautia luti, Faecalibacterium prausnitzii, or a combination thereof, and at least 94.The present invention provides a pharmaceutical composition comprising a bacterium or a spore thereof comprising a 16S rRNA gene sequence having 5%, 95%, 97%, 98%, 98.7% or 99% sequence identity.
[0232] A1. The pharmaceutical composition of A, further comprising a biocompatible pharmaceutical carrier.
[0233] A2. The pharmaceutical composition of A-A1, wherein the pharmaceutical composition is formulated for oral, nasogastric, rectal, transdermal or gavage administration.
[0234] A3. The pharmaceutical composition of any one of A-A2, further comprising a probiotic bacterium, a probiotic yeast, a prebiotic, a postbiotic, an antibiotic, or a combination thereof.
[0235] A4. The pharmaceutical composition according to any one of A-A3, wherein the pharmaceutical composition is in the form of a liquid, suspension, dry powder, tablet, capsule, food product, or a combination thereof.
[0236] A5. A pharmaceutical composition according to any one of A-A4, wherein the bacterium or spore thereof is a recombinant bacterium or a progeny thereof.
[0237] A6. (a) a therapeutic bacterium or a spore thereof selected from the group consisting of Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Clostridium methoxybenzovorans, Ruminococcus bromii, Longicatena caecimuris, Bifidobacterium breve, Blautia luti, Faecalibacterium prausnitzii, or a combination thereof, and / or (b) a therapeutic bacterium or a spore thereof selected from the group consisting of Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium The pharmaceutical composition of any one of claims A to A5, comprising a bacterium or a spore thereof comprising a 16S rRNA having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Bacillus celerecrescens, Anaeromassilibacillus senegalensis, Clostridium methoxybenzovorans, Ruminococcus bromii, Longicatena caecimuris, Bifidobacterium breve, Blautia luti, Faecalibacterium prausnitzii, or a combination thereof.
[0238] A7. (a) a therapeutic bacterium or a spore thereof selected from the group consisting of Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Clostridium methoxybenzovorans, or a combination thereof, and / or (b) a 16S antibody of Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Clostridium methoxybenzovorans, or a combination thereof A pharmaceutical composition according to A6, comprising a bacterium or a spore thereof comprising a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to an rRNA gene sequence.
[0239] A8. The pharmaceutical composition of A6 comprising (a) a therapeutic bacterium or a spore thereof selected from the group consisting of Ruminococcus bromii, Longicatena caecimuris, Bifidobacterium breve, Blautia luti, Faecalibacterium prausnitzii, or a combination thereof, and / or (b) a bacterium or a spore thereof comprising a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Ruminococcus bromii, Longicatena caecimuris, Bifidobacterium breve, Blautia luti, Faecalibacterium prausnitzii, or a combination thereof.
[0240] A9. A pharmaceutical composition according to any one of claims A-A6, comprising (a) a therapeutic bacterium or spore selected from the group consisting of Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, Lactobacillus salivarius, Blautia luti, Faecalibacterium prausnitzii, or a combination thereof, and / or (b) a bacterium or spore thereof comprising a 16S rRNA gene sequence having 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, Lactobacillus salivarius, Blautia luti, Faecalibacterium prausnitzii, or a combination thereof.
[0241] A10. The pharmaceutical composition of A9 comprising (a) a therapeutic bacterium or a spore thereof selected from the group consisting of Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, Lactobacillus salivarius, Schaalia odontolytica, or a combination thereof, and / or (b) a bacterium or a spore thereof comprising a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7%, or 99% sequence identity to the 16S rRNA gene sequence of Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, Lactobacillus salivarius, Schaalia odontolytica, or a combination thereof.
[0242] A11. The pharmaceutical composition of A9 comprising (a) a therapeutic bacterium or a spore thereof selected from the group consisting of Blautia luti, Faecalibacterium prausnitzii, or a combination thereof, and / or (b) a bacterium or a spore thereof comprising a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Blautia luti, Faecalibacterium prausnitzii, or a combination thereof.
[0243] A12. A pharmaceutical composition according to any one of A6 to A8, wherein an effective amount of the bacterium or its spores increases the chances of cancer survival in a subject to which the pharmaceutical composition is administered.
[0244] A13. A pharmaceutical composition according to any one of A9-A11, wherein an effective amount of the bacteria or spores reduces the likelihood of CAR T cell-associated toxicity in a subject administered the pharmaceutical composition.
[0245] B. The present disclosure provides a method for identifying a subject having cancer as having a decreased likelihood of cancer survival following CAR T cell therapy, comprising: (a) determining the level of bacteria or spores thereof in a sample of a subject; (b) comparing the level of the bacteria or spores thereof to a reference level of the bacteria or spores thereof, the reference level being the level of the bacteria or spores thereof in patients who did not demonstrate cancer survival; and (c) identifying the subject as having a decreased likelihood of cancer survival if the level of the diagnostic bacteria or spores thereof is higher than the reference level; The bacterium or spore thereof is selected from the group consisting of Hungatella effluvii, Coprobacillus cateniformis, Atopobium parvulum, Faecalicoccus acidiformans, Lactococcus lactis, Anaerobacterium chartisolvens, Atopobiaceae Clostridium innocuum, Bacteroides thetaiotaomicron, species of the family Veillonellaceae, and combinations thereof, or the bacterium or spore is selected from the group consisting of 16S of Hungatella effluvii, Coprobacillus cateniformis, Atopobium parvulum, Faecalicoccus acidiformans, Lactococcus lactis, Anaerobacterium chartisolvens, Atopobiaceae Clostridium innocuum, Bacteroides thetaiotaomicron, species of the family Veillonellaceae, and combinations thereof. The method includes the step of preparing a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to a 16S rRNA gene sequence.
[0246] B1. The bacterium or its spore is selected from the group consisting of Hungatella effluvii, Coprobacillus cateniformis, Atopobium parvulum, Faecalicoccus acidiformans, Lactococcus lactis, Anaerobacterium chartisolvens, Atopobiaceae Clostridium innocuum, Bacteroides thetaiotaomicron, and combinations thereof, or the bacterium or its spore is selected from the group consisting of 16S of Hungatella effluvii, Coprobacillus cateniformis, Atopobium parvulum, Faecalicoccus acidiformans, Lactococcus lactis, Anaerobacterium chartisolvens, Atopobiaceae Clostridium innocuum, Bacteroides thetaiotaomicron, or combinations thereof. The method of claim 2, comprising a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the rRNA gene sequence.
[0247] B2. The method according to B, wherein the bacterium or a spore thereof is a species of the family Veillonellaceae or comprises a 16S rRNA having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA of a species of the family Veillonellaceae.
[0248] B3. The method of any one of B-B2, further comprising treating a subject identified as having a likelihood of exhibiting decreased cancer survival with a pharmaceutical composition of any one of A-A8.
[0249] C. The present disclosure provides a method for identifying a subject having cancer as having an increased likelihood of cancer survival following CAR T cell therapy, comprising: (a) determining the level of bacteria or spores thereof in a sample of a subject; (b) comparing the level of the bacteria or spores thereof to a reference level of the bacteria or spores thereof, the reference level being the level of the bacteria or spores thereof in patients who have demonstrated cancer survival; and (c) identifying the subject as having an increased likelihood of cancer survival if the level of the diagnostic bacteria or spores thereof is higher than the reference level; The bacterium or spores thereof are selected from the group consisting of Ruminococcus gnavus, Blautia schinkii, ...
Claims
1. An effective amount of (a) Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium Saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Clostridium Methoxybenzovorans, Streptococcus oralis, Lutispora thermophila, Agathobaculum and / or (b) a therapeutic bacterium or a spore thereof selected from the group consisting of: Lactobacillus butyriciproducens, Lactobacillus salivarius, Schaalia odontolitica, Longicatena caecimuras, Bifidobacterium breve, Ruminococcus bromii, Blautia luti, Faecalibacterium prausnitzii, or a combination thereof; and / or (b) a therapeutic bacterium or a spore thereof selected from the group consisting of: Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Clostridium methoxybenzovorans, Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, Lactobacillus salivarius, Schaalia odontolytica, Longicatena caecimurais, Bifidobacterium breve, Ruminococcus bromii, Blautia luti, Faecalibacterium prausnitzii, or a combination thereof 16SA pharmaceutical composition comprising a bacterium or a spore thereof comprising a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to an rRNA gene sequence.
2. The pharmaceutical composition of claim 1 further comprising a biocompatible pharmaceutical carrier.
3. 3. The pharmaceutical composition of claim 1 or 2, wherein the pharmaceutical composition is formulated for oral, nasogastric, rectal, transdermal or gavage administration.
4. 4. The pharmaceutical composition of any one of claims 1 to 3, further comprising a probiotic bacteria, a probiotic yeast, a prebiotic, a postbiotic, an antibiotic, or a combination thereof.
5. The pharmaceutical composition according to any one of claims 1 to 4, wherein the pharmaceutical composition is in the form of a liquid, a suspension, a dry powder, a tablet, a capsule, a food product, or a combination thereof.
6. The pharmaceutical composition according to any one of claims 1 to 5, wherein the bacterium or a spore thereof is a recombinant bacterium or a progeny thereof.
7. (a) Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium Saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Clostridium Methoxybenzovorans, Ruminococcus bromii, Longicatena caecimuris, Bifidobacterium breve, Blautia luti, Faecalibacterium prausnitzii, or a combination thereof, and / or (b) a therapeutic bacterium or a spore thereof selected from the group consisting of Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Clostridium 7. The pharmaceutical composition of claim 1, comprising a bacterium or a spore thereof comprising a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Bacillus methoxybenzovorans, Ruminococcus bromii, Longicatena caecimuris, Bifidobacterium breve, Blautia luti, Faecalibacterium prausnitzii, or a combination thereof.
8. (a) a therapeutic bacterium or spore thereof selected from the group consisting of Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Clostridium methoxybenzovorans, or a combination thereof, and / or (b) a therapeutic bacterium or spore thereof selected from the group consisting of Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Clostridium methoxybenzovorans, or a combination thereof.
8. The pharmaceutical composition of claim 7, comprising a bacterium or spore thereof comprising a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Clostridium saccharolyticum, Clostridium cerecrescens, Anaeromassilibacillus senegalensis, Clostridium methoxybenzovorans, or a combination thereof.
9. (a) a therapeutic bacterium or a spore thereof selected from the group consisting of Ruminococcus bromii, Longicatena caecimurais, Bifidobacterium breve, Blautia luti, Faecalibacterium prausnitzii, or a combination thereof, and / or (b) a 16S bacterium or a spore thereof selected from the group consisting of Ruminococcus bromii, Longicatena caecimurais, Bifidobacterium breve, Blautia luti, Faecalibacterium prausnitzii, or a combination thereof.
8. The pharmaceutical composition of claim 7, comprising a bacterium or a spore thereof comprising a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the rRNA gene sequence.
10. (a) a therapeutic bacterium or a spore thereof selected from the group consisting of Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, Lactobacillus salivarius, Schaalia odontolitica, Blautia luti, Faecalibacterium prausnitzii, or a combination thereof, and / or (b) a therapeutic bacterium or a spore thereof selected from the group consisting of Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, Lactobacillus salivarius, Schaalia odontolitica, Blautia luti, Faecalibacterium prausnitzii, or a combination thereof.
7. The pharmaceutical composition of claim 1, comprising a bacterium or a spore thereof comprising a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Lactobacillus butyriciproducens, Lactobacillus salivarius, Schaalia odontolitica, Blautia luti, Faecalibacterium prausnitzii, or a combination thereof.
11. (a) a therapeutic bacterium or spore thereof selected from the group consisting of Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, Lactobacillus salivarius, Schaalia odontolitica, or a combination thereof, and / or (b) a 16S bacterium or spore thereof selected from the group consisting of Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, Lactobacillus salivarius, Schaalia odontolitica, or a combination thereof.
11. The pharmaceutical composition of claim 10, comprising a bacterium or a spore thereof comprising a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the rRNA gene sequence.
12. 11. The pharmaceutical composition of claim 10, comprising: (a) a therapeutic bacterium or a spore thereof selected from the group consisting of Blautia luti, Faecalibacterium prausnitzii, or a combination thereof; and / or (b) a bacterium or a spore thereof comprising a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Blautia luti, Faecalibacterium prausnitzii, or a combination thereof.
13. 10. The pharmaceutical composition of any one of claims 7 to 9, wherein the effective amount of the bacterium or spores thereof increases the chances of cancer survival in a subject administered the pharmaceutical composition.
14. 13. The pharmaceutical composition of any one of claims 10-12, wherein said effective amount of said bacteria or spores thereof reduces the likelihood of CAR T cell associated toxicity in a subject administered said pharmaceutical composition.
15. 1. A method for identifying a subject having cancer as having a decreased likelihood of cancer survival following CAR T cell therapy, comprising: (a) determining the level of bacteria or spores thereof in a sample from said subject; (b) comparing the level of the bacterium or spores thereof to a reference level of the bacterium or spores thereof, the reference level being the level of the bacterium or spores thereof in patients who did not exhibit cancer survival; and (c) identifying the subject as having a decreased likelihood of cancer survival if the level of the diagnostic bacteria or spores thereof is higher than the reference level; The bacterium or spores thereof are selected from the group consisting of Hungatell a effluvii, Coprobacillus cateniformis, Atopobium parvulum, Faecalicoccus acidiformans, Lactococcus lactis, Anaerobacterium chartisolvens, Atopobiaceae Clostridium innocuum, Bacteroides thetaiotaomicron, species of the family Veillonellaceae, and combinations thereof, or the bacterium or spores thereof are selected from the group consisting of Hungatell a effluvii, Coprobacillus cateniformis, Atopobium parvulum, Faecalicoccus acidiformans, Lactococcus lactis, Anaerobacterium chartisolvens, Atopobiaceae Clostridium innocuum, Bacteroides thetaiotaomicron, species of the family Veillonellaceae, and combinations thereof. effluvii, Coprobacillus cateniformis, Atopobium parvulum, Faecalicoccus acidiformans, Lactococcus lactis, Anaerobacterium chartisolvens, Atopobiaceae Clostridium innocuum, Bacteroides thetaiotaomicron, a species of the family Veillonellaceae, or a combination thereof.
16. The bacterium or spore thereof is selected from the group consisting of Hungatellla effluvii, Coprobacillus cateniformis, Atopobium parvulum, Faecalicoccus acidiformans, Lactococcus lactis, Anaerobacterium chartisolvens, Atopobiaceae Clostridium innocuum, Bacteroides thetaiotaomicron, and combinations thereof, or the bacterium or spore thereof is selected from the group consisting of Hungatellla effluvii, Coprobacillus cateniformis, Atopobium parvulum, Faecalicoccus acidiformans, Lactococcus lactis, Anaerobacterium chartisolvens, Atopobiaceae Clostridium innocuum, Bacteroides thetaiotaomicron, and combinations thereof.
16. The method of claim 15, comprising a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Lactobacillus cateniformis, Atopobium parvulum, Faecalicoccus acidiformans, Lactococcus lactis, Anaerobacterium chartisolvens, Atopobiaceae Clostridium innocuum, Bacteroides thetaiotaomicron, or a combination thereof.
17. 16. The method of claim 15, wherein the bacterium or a spore thereof is a species of the family Veillonellaceae or comprises a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of a species of the family Veillonellaceae.
18. 18. The method of any one of claims 15 to 17, further comprising treating the subject identified as having a decreased likelihood of cancer survival with a pharmaceutical composition of any one of claims 1 to 9.
19. 1. A method for identifying a subject having cancer as having an increased likelihood of cancer survival following CAR T cell therapy, comprising: (a) determining the level of bacteria or spores thereof in a sample from said subject; (b) comparing the level of the bacterium or spores thereof to a reference level of the bacterium or spores thereof, the reference level being the level of the bacterium or spores thereof in patients who have demonstrated cancer survival; and (c) identifying the subject as having an increased likelihood of cancer survival if the level of the diagnostic bacteria or spores thereof is higher than the reference level; The bacteria or spores thereof are selected from the group consisting of Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Longicatena caecimuras, Bifidobacterium breve, Escherichia coli, Clostridium or a combination thereof, or the bacterium or spore thereof is selected from the group consisting of Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium cerecrescens, Anaeromassilibacillus senegalensis, Longicatena caecimuris, Bifidobacterium breve, Escherichia coli, Clostridium methoxybenzovorans, Ruminococcus bromii, Blautia luti, Faecalibacterium prausnitzii, or a combination thereof.
20. The bacterium or spore thereof is selected from the group consisting of Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Clostridium methoxybenzovorans, and combinations thereof, or the bacterium or spore thereof is selected from the group consisting of Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Clostridium methoxybenzovorans, and combinations thereof.
20. The method of claim 19, comprising a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Clostridium schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Clostridium methoxybenzovorans, or a combination thereof.
21. The bacterium or spore thereof is selected from the group consisting of Longicatena caecimuras, Bifidobacterium breve, Escherichia coli, Ruminococcus bromii, Blautia luti, Faecalibacterium prausnitzii, and combinations thereof, or the bacterium or spore thereof is selected from the group consisting of Longicatena caecimuras, Bifidobacterium breve, Escherichia coli, Ruminococcus bromii, Blautia luti, Faecalibacterium prausnitzii, and combinations thereof.
20. The method of claim 19, comprising a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of I. prausnitzii, I. prausnitzii, or a combination thereof.
22. 1. A method for identifying a subject having cancer as having an increased likelihood of cancer survival, comprising: (a) determining the level of a bacterial gene in a sample from said subject; (b) comparing the level of the bacterial gene to a reference bacterial gene level, the reference level being the level of the bacterial gene in patients who have demonstrated cancer survival; and (c) identifying the subject as having an increased likelihood of cancer survival if the level of the bacterial gene is higher than the reference bacterial gene level; The method, wherein the bacterial gene is a gene involved in aromatic amino acid biosynthesis and / or peptidoglycan biosynthesis.
23. 23. The method of any one of claims 19-22, further comprising treating the subject with a CAR T cell therapy.
24. 24. The method of any one of claims 19-23, wherein cancer survival is survival of the subject at least about 100 days after CAR T cell therapy.
25. 1. A method for identifying a subject having cancer as having a likelihood of exhibiting increased CAR T cell associated toxicity, comprising: (a) determining the level of bacteria or spores thereof in a sample from said subject; (b) comparing said level of said bacteria or spores thereof to a reference level of said bacteria or spores thereof, said reference level being the level of said bacteria or spores thereof in a patient who has exhibited CAR T cell associated toxicity; and (c) identifying the subject as having a likelihood of exhibiting increased CAR T cell associated toxicity if the level of the bacteria or spores thereof is higher than the reference level; The bacterium or spore thereof is selected from the group consisting of Streptococcus salivarius, Oscillibacter ruminantium, Eubacterium ramulus, Streptococcus gordonii, Caproicproducens galactitolivorans, Clostridium hylemonae, and combinations thereof, or the bacterium or spore thereof is selected from the group consisting of Streptococcus salivarius, Oscillibacter ruminantium, Eubacterium ramulus, Streptococcus gordonii, Caproicproducens galactitolivorans, Clostridium hylemonae, and combinations thereof. gordonii, Caproicproducens galactitolivorans, Clostridium hylemonae, and combinations thereof, comprising a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Caproicproducens galactitolivorans, Clostridium hylemonae, and combinations thereof.
26. 26. The method of claim 25, further comprising treating said subject identified as having a likelihood of exhibiting increased CAR T cell associated toxicity with a pharmaceutical composition of any one of claims 1-6 and 10-12.
27. 27. The method of claim 25 or 26, further comprising treating the subject with a CAR T cell therapy.
28. 1. A method for identifying a subject having cancer as having a reduced likelihood of exhibiting CAR T cell associated toxicity, comprising: (a) determining the level of bacteria or spores thereof in a sample from said subject; (b) comparing said level of said bacteria or spores thereof to a reference level of said bacteria or spores thereof, said reference level being the level of said bacteria or spores thereof in a patient who did not exhibit CAR T cell associated toxicity; and (c) identifying the subject as having a likelihood of exhibiting reduced CAR T cell associated toxicity if the level of the bacteria or spores thereof is higher than the reference level; The bacterium or spore thereof is selected from the group consisting of Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, Lactobacillus salivarius, Schaalia odontolitica, Blautia luti, Faecalibacterium prausnitzii, and combinations thereof, or the bacterium or spore thereof is selected from the group consisting of Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, Lactobacillus salivarius, Schaalia odontolitica, Blautia luti, Faecalibacterium prausnitzii, and combinations thereof. The method includes the step of preparing a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Lactobacillus butyriciproducens, Lactobacillus salivarius, Schaalia odontolitica, Blautia luti, Faecalibacterium prausnitzii, and combinations thereof.
29. The bacterium or spore thereof is selected from the group consisting of Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, Lactobacillus salivarius, Schaalia odontolitica, and combinations thereof, or the bacterium or spore thereof is selected from the group consisting of 16S of Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, Lactobacillus salivarius, Schaalia odontolitica, and combinations thereof.
29. The method of claim 28, comprising a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the rRNA gene sequence.
30. 29. The method of claim 28, wherein the bacterium or spore thereof is selected from the group consisting of Blautia luti, Faecalibacterium prausnitzii, and combinations thereof, or the bacterium or spore thereof comprises a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Blautia luti, Faecalibacterium prausnitzii, and combinations thereof.
31. 1. A method for identifying a subject having cancer as having a likelihood of exhibiting decreased cancer survival and / or an increased likelihood of exhibiting CAR T cell associated toxicity, comprising: (a) determining whether the subject is receiving an antibiotic; and (b) identifying the subject as having an increased likelihood of CAR T cell associated toxicity and / or a decreased likelihood of cancer survival if the subject is administered piperacillin-tazobactam, imipenem-cilastatin, meropenem, or a combination thereof.
32. 32. The method of claim 31 , wherein the antibiotic is administered less than about 4 weeks prior to initiation of CAR T cell therapy.
33. 33. The method of any one of claims 25 to 32, wherein the CAR T cell associated toxicity is cytokine release syndrome (CRS) and / or immune effector cell-associated neurotoxicity syndrome (ICANS).
34. 1. A method for treating a subject having cancer with CAR T cell therapy, comprising: (a) determining the level of bacteria or spores thereof in a sample from said subject; (b) comparing the level of the bacterium or spores thereof to a reference level of the bacterium or spores thereof, the reference level being the level of the bacterium or spores thereof in a subject who has demonstrated cancer survival; and (c) identifying the subject as having an increased likelihood of cancer survival if the level of the bacterium or spores thereof is higher than the reference level; and (d) treating said subject identified as having an increased likelihood of cancer survival with a CAR T cell therapy; The bacteria or spores thereof are selected from the group consisting of Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Clostridium methoxybenzovorans, Ruminococcus bromii, Blautia luti, Longicatena or a combination thereof, or the bacterium or spore thereof is selected from the group consisting of Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Clostridium methoxybenzovorans, Ruminococcus bromii, Blautia luti, Longicatena caecimuris, Bifidobacterium breve, or Faecalibacterium prausnitzii, comprising a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Bacillus subtilis, Bacillus keloides ...
35. The bacterium or spore thereof is selected from the group consisting of Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Clostridium methoxybenzovorans, and combinations thereof, or the bacterium or spore thereof is selected from the group consisting of Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Clostridium methoxybenzovorans, and combinations thereof.
35. The method of claim 34, wherein the 16S rRNA gene sequence has at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Clostridium schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, or Clostridium methoxybenzovorans.
36. The bacterium or its spore is selected from the group consisting of Ruminococcus bromii, Blautia luti, Longicatena caecimuras, Bifidobacterium breve, Faecalibacterium prausnitzii, and combinations thereof, or the bacterium or its spore is selected from the group consisting of Ruminococcus bromii, Blautia luti, Longicatena caecimuras, Bifidobacterium breve, or Faecalibacterium prausnitzii 16S.
35. The method of claim 34, comprising a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the rRNA gene sequence.
37. 1. A method for treating a subject having cancer with CAR T cell therapy, comprising: (a) determining the level of bacteria or spores thereof in a sample from said subject; (b) comparing the level of the bacterium or spores thereof to a reference level of the bacterium or spores thereof, the reference level being the level of the bacterium or spores thereof in a subject who did not exhibit cancer survival; and (c) identifying the subject as having a decreased likelihood of cancer survival if the level of the bacterium or spores thereof is higher than the reference level; and (d) treating said subject identified as having a decreased chance of cancer survival with a pharmaceutical composition comprising one or more therapeutic bacteria and a CAR T cell therapy; The bacterium or spore thereof is selected from the group consisting of Hungatell aeffluvii, Coprobacillus cateniformis, Atopobium parvulum, Faecalicoccus acidiformans, Lactococcus lactis, Anaerobacterium chartisolvens, Clostridium innocuum, Bacteroides thetaiotaomicron, species of the family Veillonellaceae, and combinations thereof, or the bacterium or spore thereof is selected from the group consisting of Hungatell aeffluvii, Coprobacillus cateniformis, Atopobium parvulum, Faecalicoccus acidiformans, Lactococcus lactis, Anaerobacterium chartisolvens, Clostridium innocuum, Bacteroides thetaiotaomicron, species of the family Veillonellaceae, and combinations thereof. cateniformis, Atopobium parvulum, Faecalicoccus acidiformans, Lactococcus lactis, Anaerobacterium chartisolvens, Clostridium innocuum, Bacteroides thetaiotaomicron, species of the family Veillonellaceae, and combinations thereof, The therapeutic bacteria include Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium Saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Clostridium Methoxybenzovorans, Ruminococcus bromii, Longicatena caecimuris, Bifidobacterium breve, Blautia luti, and / or Faecalibacterium prausnitzii, or one or more of Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Clostridium methoxybenzovorans, Ruminococcus 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 109, 109, 109, 108, 109, 109, 109, 104, 105, 106, 107, 108, 109, 109, 109, 108, 109,
38. 38. The method of any one of claims 34-37, wherein cancer survival is survival of the subject at least about 100 days after CAR T cell therapy.
39. 1. A method for treating a subject having cancer with CAR T cell therapy, comprising: (a) determining the level of bacteria or spores thereof in a sample from said subject; (b) comparing said level of said bacterium or spores thereof to a reference level of said bacterium or spores thereof, said reference level being the level of said bacterium or spores thereof in a subject who did not exhibit CAR T cell associated toxicity; and (c) identifying the subject as having a likelihood of exhibiting reduced CAR T cell associated toxicity if the level of the bacteria or spores thereof is higher than the reference level; and (d) treating said subject identified as having a potential to exhibit reduced CAR T cell associated toxicity with a CAR T cell therapy; The bacterium or spore thereof is selected from the group consisting of Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, Lactobacillus salivarius, Blautia luti, Faecalibacterium prausnitzii, and combinations thereof, or the bacterium or spore thereof is selected from the group consisting of Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, Lactobacillus salivarius, Blautia luti, Faecalibacterium prausnitzii, and combinations thereof. salivarius, Blautia luti, and / or Faecalibacterium prausnitzii, comprising a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Bacillus subtilis, Bacillus salivarius, Blautia luti, and / or Faecalibacterium prausnitzii.
40. The bacterium or spore thereof is selected from the group consisting of Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, Lactobacillus salivarius, and combinations thereof, or the bacterium or spore thereof is selected from the group consisting of 16S of Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, and / or Lactobacillus salivarius.
40. The method of claim 39, comprising a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the rRNA gene sequence.
41. 40. The method of claim 39, wherein the cell or spore thereof is selected from the group consisting of Blautia luti, Faecalibacterium prausnitzii, and combinations thereof, or the bacterium or spore thereof comprises a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7% or 99% sequence identity to the 16S rRNA gene sequence of Blautia luti, and / or Faecalibacterium prausnitzii.
42. 1. A method for treating a subject having cancer with CAR T cell therapy, comprising: (a) determining the level of bacteria or spores thereof in a sample from said subject; (b) comparing the level of the bacterium or spores thereof to a reference level of the bacterium or spores thereof, wherein the reference level is the level of the bacterium or spores thereof in a subject that has exhibited CAR T cell associated toxicity; and (c) identifying the subject as having a likelihood of exhibiting increased CAR T cell associated toxicity if the level of the bacteria or spores thereof is higher than the reference level; and (d) treating said subject identified as having a likelihood of exhibiting increased CAR T cell associated toxicity with a pharmaceutical composition comprising one or more therapeutic bacteria and a CAR T cell therapy; The bacterium or spore thereof is selected from the group consisting of Streptococcus salivarius, Oscillibacter ruminantium, Eubacterium ramulus, Streptococcus gordonii, Caproicproducens galactitolivorans, Clostridium hylemonae, and combinations thereof, or the bacterium or spore thereof is selected from the group consisting of Streptococcus salivarius, Oscillibacter ruminantium, Eubacterium ramulus, Streptococcus gordonii, Caproicproducens galactitolivorans, Clostridium hylemonae, and combinations thereof. gordonii, Caproicproducens galactolivorans, Clostridium hylemonae, or a combination thereof, comprising a 16S rRNA gene sequence having at least 94.5%, 95%, 97%, 98%, 98.7%, or 99% sequence identity to the 16S rRNA gene sequence of The therapeutic bacteria is one or more of Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, Lactobacillus salivarius, Schaalia odontolitica, Blautia luti, Faecalibacterium prausnitzii, or Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, Lactobacillus salivarius, Schaalia odontolitica, Blautia luti, Faecalibacterium prausnitzii, or salivarius, Schaalia odontolitica, Blautia luti, Faecalibacterium prausnitzii, or a combination thereof.
43. 43. The method of any one of claims 38 to 42, wherein the CAR T cell associated toxicity is cytokine release syndrome (CRS) and / or immune effector cell associated neurotoxicity syndrome (ICANS).
44. The method of any one of claims 15 to 43, wherein the sample is a faecal sample or a bowel content sample of the subject.
45. 45. The method of any one of claims 15-44, further comprising administering to the subject chemotherapy, immunotherapy, stem cell therapy, cell therapy, probiotic bacteria, probiotic yeast, prebiotics, postbiotics, antibiotics, or combinations thereof.
46. 46. The method of any one of claims 15 to 45, wherein the cancer is selected from the group consisting of acute lymphoblastic leukemia (ALL), chronic lymphoblastic leukemia (CLL), or non-Hodgkin's lymphoma (NHL).
47. 47. The method of any one of claims 15-46, wherein the CAR T cell therapy comprises CAR T cells that target mucin 16 (MUC16), B-cell maturation antigen (BCMA), and / or CD19.
48. A kit comprising the pharmaceutical composition of any one of claims 1 to 14.
49. Ruminococcus gnavus, Blautia schinkii, Bacteroides finegoldii, Clostridium glycyrrhizinilyticum, Clostridium Saccharolyticum, Clostridium celerecrescens, Anaeromassilibacillus senegalensis, Clostridium Methoxybenzovorans, Hungatella effluvii, Coprobacillus cateniformis, Atopobium parvulum, Faecalicoccus acidiformans, Lactococcus lactis, Anaerobacterium chartisolvens, Atopobiaceae, Clostridium innocum, Bacteroides thetaiotamicron, Streptococcus salivarius, Oscillibacter ruminantium, Eubacterium ramulus, Streptococcus gordonii, Caprocicproducens galactitolivorans, Clostridium hylemonae, Streptococcus oralis, Lutispora thermophila, Agathobaculum butyriciproducens, Schaalia odontolytica, Lactobacillus salivarius, Ruminococcus bromii, Bifidobacterium breve, Longicatena caecimuris, Escherichia coli, Blautia luti, Faecalibacterium prausnitzii, and combinations thereof.
50. 50. The kit of claim 48 or 49, further comprising instructions for treating a subject with cancer.
51. The method further comprises the steps of: identifying the subject as having a likelihood of exhibiting increased cancer survival or a likelihood of exhibiting decreased cancer survival, the instructions comprising: (a) determining the level of said bacterium or spores thereof in a sample from said subject; (b) comparing the level of the bacterium or spores thereof to a reference level of the bacterium or spores thereof; (c) identifying the subject as having a likelihood of exhibiting increased cancer survival or a likelihood of exhibiting decreased cancer survival based on the comparison.
52. and instructions for identifying the subject as having an increased potential for CAR T cell associated toxicity or a decreased potential for CAR T cell associated toxicity, the instructions comprising: (a) determining the level of said bacterium or spores thereof in a sample from said subject; (b) comparing the level of the bacterium or spores thereof to a reference level of the bacterium or spores thereof; (c) identifying the subject as having an increased likelihood of CAR T cell associated toxicity or a decreased likelihood of CAR T cell associated toxicity based on said comparison.
53. Use of the pharmaceutical composition according to any one of claims 1 to 14 for treating a subject with cancer.
54. 54. The use of claim 53, wherein the cancer is being treated with or will be treated with CAR T cell therapy.
55. Use of the pharmaceutical composition according to any one of claims 7 to 9 for increasing the chances of cancer survival in a subject.
56. 56. The use of claim 55, wherein the subject is being treated with or will be treated with CAR T cell therapy.
57. Use of the pharmaceutical composition of any one of claims 10 to 12 to reduce the likelihood of CAR T cell-associated toxicity in a subject.
58. 58. The use of claim 57, wherein the subject is treated or will be treated with CAR T cell therapy.
